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Anti-angiogenesis represents a promising therapeutic strategy for the treatment of 
various malignancies. Although several proteins have been identified to inhibit 
angiogenesis, it is conceivable that many genes regulating angiogenesis in vivo have 
yet to be discovered. In this study, we aim to identify a novel endogenous 
angiogenesis inhibitor and characterize its function in in vivo angiogenesis.  
Isthmin (ISM) is a secreted 60 kDa protein containing a Thrombospondin Type 1 
Repeat (TSR) domain and an Adhesion-associated domain in MUC4 and Other 
Proteins (AMOP) domain with no known functions. The role of ISM is investigated in 
angiogenesis using in vitro angiogenesis cell assays, mouse tumor and embryonic 
zebrafish models.  
Recombinant mouse ISM inhibits endothelial cell (EC) capillary network formation 
on Matrigel. It also suppresses VEGF-bFGF induced in vivo angiogenesis in mouse. It 
mitigates various growth factors-stimulated EC proliferation without affecting EC 
migration. Furthermore, ISM induces EC apoptosis in the presence of VEGF through 
a Caspase -dependent pathway.  
Mechanism studies indicate that ISM binds to vβ5 integrin on the EC surface, 
interfering integrin αvβ5/focal adhesion complex/actin skeleton pathway downstream 
of VEGF to inhibit EC tube formation. Structure-functional analysis demonstrates the 
important role of the AMOP domain but not TSR domain in the anti-angiogenic 
function of ISM.  
xii 
 
Overexpression of ISM significantly suppresses B16 melanoma tumor growth via 
inhibition of tumor angiogenesis. In addition, ISM inhibits tumor angiogenesis by 
inhibiting TAM infiltration without affecting the expression level of VEGF in tumors. 
The expression and function of all three zebrafish ism family gene members during 
embryonic development are analyzed.  ism has maternal expression and is expressed 
dynamically whereas tail1a and tail1b starts to express at 24 hpf and is expressed 
persistently. Knockdown of ism in zebrafish embryos using MO leads to disorganized 
ISVs in the trunk. Furthermore, ism is required for the survival and development of 
zebrafish embryos. However, knocking down of tail1a or tail1b does not result in any 
significant gross morphological phenotypes during the zebrafish development. These 
results indicate distinct expression and function of the ism family genes.  
Therefore, our results demonstrate that ISM is a novel endogenous angiogenesis 
inhibitor with functions likely in physiological as well as pathological angiogenesis. 
This work expands the understanding of the regulatory mechanisms of angiogenesis 
in physiological and pathological conditions, and provides a novel therapeutic agent 
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Chapter One: Introduction 
1.1 Angiogenesis 
Angiogenesis, derived from the Greek word angêion meaning vase, and genesis 
meaning birth, is the name given to the outgrowth of new capillaries from the pre-
existing primary blood vessels (Folkman, et al., 1992). It comprises two different 
mechanisms: endothelial sprouting and non-sprouting with the former as the dominant 
form (Risau, 1997).  
During sprouting angiogenesis, vascular plexus progress by sprouting and remodeling 
into a highly organized vascular network. It is a complex process involving multiple 
steps including degradation of existing extracellular matrix (ECM), endothelial cell 
(EC) proliferation and migration, capillary tube formation and secretion of new ECM. 
The newly formed immature capillaries are stabilized by recruitment of supporting 
cells such as pericytes in smaller vessels and smooth muscle cells in larger vessels for 
functional perfusion (Fig. 1.1A) (Carmeliet, 2000).  
Non-sprouting angiogenesis is a process of dividing pre-existing vessels by formation 
and insertion of endothelial columns into the vessel lumen. It mainly has three phases 
including: 1) establishment of a contact zone within the two opposing capillary walls, 
2) reorganization of the EC junctions and the perforation of the vessel bilayer, 3) core 
formation between the two new vessels at the zone of contact (Fig. 1.1B) (Frontczak-
Baniewicz, et al., 2002). The subsequent growth and stabilization of these pillars 
result in partitioning of the vessel and remodeling of the local vascular network 
(Risau, 1997).  
 
  
Fig. 1.1 The process of angiogenesis. A) Sprouting angiogenesis: formation of blood 
vessels is a multi-step process, which includes (i) reception of angiogenic signals 
(yellow spot) from the surrounding by endothelial cells (EC); (ii) retraction of 
pericytes from the abluminal surface of capillary and secretion of protease from 
activated endothelial cells (aEC) and proteolytic degradation of extracellular 
membrane (green dash-line); (iii) chemotactic migration of EC under the induction of 
angiogenic stimulators; (iv) proliferation of EC and formation of lumen/canalisation 
by fusion of formed vessels with formation of tight junctions; (v) recruitment of 
pericytes and deposition of new basement membrane and initiation of blood flow. B) 
Non-sprouting angiogenesis – intussusceptive microvascular growth: it is initiated by 
(i) protrusion of opposing capillary walls towards the lumen; (ii) perforation of the EC 
bilayer and formation of many transcapillaries with interstitial core (red arrow); (iii) 
formation of the vascular tree from intussusceptive pillar formation and pillar fusion 
and elongation of capillaries (green arrows). (Adapted from Yue et al. Chinese 





 1.1.1 Angiogenesis in life, diseases and medicine  
Most angiogenesis occurs in the embryos to form vascular network to provide the 
growing organs with the necessary oxygen and nutrient. After birth, angiogenesis still 
contributes to organ growth but, during adulthood, most blood vessels remain 
quiescent and angiogenesis occurs only in specific physiological conditions such as 
female reproductive cycles, wound healing as well as in the placenta during 
pregnancy (Arnold, et al., 1991).  
When angiogenesis is dysregulated, it has a major impact on health and contributes to 
the pathologenesis of many disorders. Insufficient angiogenesis not only causes heart 
and brain ischemia, but can also lead to neurodegeneration, respiratory distress and 
gastric or oral ulcerations. On the other hand, many common disorders are caused by 
excessive angiogenesis including obesity, atherosclerosis, psoriasis, arthritis, 
blindness (Rupnick, et al., 2002) and cancer (Folkman, 1992).  
The essential role of angiogenesis in many pathogenic processes indicates the 
potential for developing new therapeutic strategies for all the diseases associated with 
pathological angiogenesis. Clinical trials have shown some promise in the patient with 
cardiovascular disease by stimulating angiogenesis (Ahn, et al., 2008,Al Sabti, 
2007,Simons, 2005) and patients with solid tumor (specially breast, colorectal and 
lung cancers) experienced benefits in overall survival when combining conventional 
chemotherapy and anti-angiogenic therapy (Jain, et al., 2006). Pro-angiogenic and 
anti-angiogenic are emerging as novel, promising and challenging therapies in the 
current medicine. Knowledge of molecular and cellular mechanism of angiogenesis 
will facilitate to fully exploit their therapeutic potential.  
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1.1.2 Tumor angiogenesis and tumor development 
The complex network of tumor blood microvessels guarantees adequate supply of 
tumor cells with nutrients and oxygen and provides efficient drainage of metabolites. 
Based on the knowledge that tumor cannot grow beyond 1-2 mm3 in an avascular 
state, the surgeon Judah Folkman was the first to hypothesize that targeting the blood 
vessels will lead to arrest of tumor growth or even shrinkage in the 1970s (Folkman, 
1971). This hypothesis was later confirmed experimentally by many studies (Folkman, 
1992,Folkman, et al., 1971,Norrby, 1997). Angiogenesis also facilitates tumor 
metastases by providing an efficient exit route for tumor cells to leave the primary site 
and enter the blood stream (Zhang, et al., 2009). Experimental and clinical studies 
have shown that primary tumors as well as metastases can remain dormant for years. 
However, most tumors escape dormancy once angiogenesis occurs (Narazaki, et al., 
2006,Naumov, et al., 2006,Tosetti, et al., 2002). In addition, the degree of tumor 
vascularization is correlated with tumor grade as well as aggressiveness, which serves 
as a significant clinical prognosis indicator (Sarbia, et al., 1996,Tanigawa, et al., 
1996).  
The angiogenic switch controlled by a net balance of positive and negative regulators, 
is the initiation of tumor angiogenesis(Hanahan, et al., 1996). The angiogenic cascade 
includes an activation and resolution phase. In the activation phase, tumors release 
diffusible activators of angiogenesis to the surrounding tissues and induce phenotypic 
changes in ECs as well as in other cell types. Proteases, heparanase and other 
digestive enzymes are released by endothelial and tumor cells to degrade capillary 
basement membrane. ECs in the surrounding tissues then migrate, proliferate and 
differentiate to form capillaries. In the subsequent resolution phase, maturation and 
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stabilization of the newly formed vessels were achieved by pericytes association, 
basement membrane construction and junction complex formation (Kurz, et al., 2002).  
However, tumor ECs are different from normal ECs in gene expression profile, 
behavior, as well as morphology (Hida, et al., 2008). Tumor ECs have relatively 
larger nuclei than normal ECs, indicating they have more DNA content. A certain 
percentage of tumor ECs are karyotypically aneuploid (e.g. 16% of liposarcoma ECs, 
34% of melanoma ECs, 54% of renal carcinoma ECs) whereas normal ECs are 
diploid. In addition, there is upregulation of adhesion molecules such as CD31 or 
ICAM-1 in lung carcinoma ECs compared to normal ECs (Hida, et al., 2008). 
Morphologically, tumor vessels are highly disorganized with irregular shape, uneven 
diameter and excessive branching and shunts whereas the normal vasculature shows a 
hierarchal branching pattern (McDonald, et al., 2003). The tumor vessel walls might 
be lined by cancer cells or a mosaic of cancer cells and ECs instead of single layer of 
ECs (Chang, et al., 2000). Tumor vessel basement membranes have structural 
abnormalities including loose associations with ECs, and varying thicknesses of type 
IV collagen layers (Kalluri, 2003). Tumor vessels are also leaky and hyperpremeable 
to circulating macromolecules (Feng, et al., 2000). Consequently, tumor blood flow is 
chaotic and variable, and leads to hypoxic (decreased O2) and acidic regions 
(increased CO2 ) inside tumors (Helmlinger, et al., 1997).  
In conclusion, tumor angiogenesis is necessary for the solid tumor progression and 
metastasis. However, different from physiological angiogenesis, tumor angiogenesis 
has its specific biological characteristic that might be considered in the development 




1.1.3 Anti-angiogenic cancer therapy 
Since tumor growth and metastasis are angiogenesis dependent, angiogenesis 
inhibition has attracted a lot of attention as a treatment method of cancer. Targeting 
ECs rather than cancer cells themselves, is a relatively new but particularly promising 
approach to cancer therapy because (1) the ECs are located in the most inner layer of 
blood vessels, therefore systemically administered drugs are easily accessible to ECs 
so that the problem of low penetration of the antitumoral drugs into solid tumors can 
be avoided (Gasparini, 1999); (2) a single vascular net may support the growth of 
more than one population of cells in tumor, thus, targeting ECs might be a much more 
effective strategy than targeting tumor cells (Kerbel, 1997); (3) the expression of 
specific markers by activated endothelium, such as integrin αvβ3, E-selectin, and 
vascular endothelium growth factor (VEGF) receptors, could be used to confer 
specificity to anti-angiogenic therapies and (4) tumor ECs are similar among most 
tumor types, an ideal anti-angiogenic drug could be useful in treating many cancers.  
During the past decades, intensive efforts have been undertaken to develop anti-
angiogenic therapy with more than 40,000 scientific papers published on this subject, 
and hundreds of molecules with anti-angiogenic activity in preclinical models have 
been reported and many have entered clinical testing in cancer treatment (Quesada, et 
al., 2006). In addition, numerous vascular endothelium-specific drug targeting 
strategies were developed including gene therapies (viral and non-viral approach), 
siRNAs, antisense oligodeoxynucleotides, as well as chemical inhibitors of signal 
transduction (Molema, 2005).  
To date, four anti-angiogenic drugs have been approved by the Food and Drug 
Administration (FDA) of USA for the clinical use for patients with solid tumors 
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because of their capacity to improve survival in Phase III clinical studies. There are 
Avastin (Genentech; bevacizumab), Torisel (Wyeth Corporation; temsirolimus), 
sunitinib (C.P. Pharmaceuticals International) and Sorafenib (Bayer; Nexavar). 
Avastin, a human recombinant antibody that neutralizes the biologically active forms 
of VEGF, had demonstrated significant prolongation of survival  in colorectal, breast 
and lung cancer patients when combined with conventional chemotherapy (Los, et al., 
2007). In 2006, Avastin received the FDA approval to be used in combination with 
carboplatin and paclitaxel chemotherapy as the first-line treatment for patients with 
non-small cell lung cancer (Sandler, et al., 2006).  
Angiogenesis inhibitors are likely to change the face of medicine in the next decade. 
However, Avastin only provides short-term overall survival benefit in cancer patients 
when combined with conventional chemotherapy. Furthermore, the use of anti-VEGF 
agents in advanced colorectal cancer has provided varied results. While avastin, in 
combination with chemotherapy, induced a significant increase in overall survival in 
patients with advanced colorectal cancer, vatalanib (selectively inhibits VEGF 
receptor-2) combined with chemotherapy, did not produce a survival benefit (Sessa, et 
al., 2008). In contrast, monotherapy with the multi-targeted receptor tyrosine kinase 
inhibitors Sorafenib, temsirolimus or sunitinib targets ECs as well as tumor cells, and 
probably also stromal and haematopoietic cells, demonstrated clinical benefits in 
certain cancers (Sessa, et al., 2008). These results indicate that in addition to anti-
angiogenic effects, these drugs may have direct effects on cancer cells that contribute 
to their antitumor activities, suggesting “one target-therapy” may be insufficient and 
additional inhibitors will be required. The limited clinical success using anti-
angiogenic monotherapies could be partially due to the high complexity of 
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angiogenesis regulation. Emerging evidence indicates that inhibition of a single target 
leads to upregulation of additional angiogenic factors (Folkman, 2006).  
Notably, in spite of complete tumor regressions in preclinical studies, only modest or 
even negative results emerged from the anti-angiogenic compounds entered in clinical 
trials. Some of the adverse effects of anti-VEGF therapy also appeared and mostly 
due to the requirement of threshold levels of VEGF for the survival and maintenance 
of quiescent vessels in healthy organs (Quesada, et al., 2007). Therefore, the safety of 
anti-angiogenic treatment appears to be a topic of emerging importance.  
The challenges or future directions of anti-angiogenic cancer therapy include 
combined treatment of anti-angiogenic agents with distinct complementary 
mechanisms of action, identification of novel class of target that only affects 
angiogenesis in diseases without affecting quiescent vessels in healthy organs 
(Carmeliet, 2005), combinations of angiogenesis inhibitors with conventional 
anticancer therapies and the use of low-dose metronomic chemotherapy (Quesada, et 
al., 2007), and development of suitable surrogate markers that can inform therapeutic 
efficacy (Kerbel, et al., 2002).  
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1.2 Angiogenesis regulators 
Angiogenesis is a tightly regulated process, influenced by the microenvironment and 
modulated by a multitude of pro- and anti-angiogenic factors. Pro- and anti-
angiogenic factors form a complex network made by multiple, complementary, 
overlapping and independent signaling pathways to regulate angiogenesis (Quesada, 
et al., 2007). Although angiogenic stimulators act on ECs to stimulate angiogenesis, 
angiogenic inhibitors tend to be pleiotropic in function (Sato, 2006). A thorough 
understanding of the function and molecular mechanisms of angiogenesis regulators 
might help to elucidate the process of angiogenesis.  
 
1.2.1 Pro-angiogenic factors  
Numerous molecules are identified as pro-angiogenic factors due to their significant 
role in stimulating angiogenesis (Table 1.1). These include members of the VEGF 
family and the fibroblast growth factor (FGF) family, angiogenin, transforming 
growth factor alpha and beta (TGF-α and -β), platelet-derived growth factor (PDGF), 
tumor necrosis factor alpha (TNF-α), interleukins, and angiopoietins. Ephrin-EphRs 
and Delta-Notch are also major regulators of angiogenesis (Shibuya, 2008). Among 
all these angiogenic factors, VEGF and FGF are the most potent and principal 




Table 1.1 List of Known Pro-angiogenic Factors 
Angiogenin
Angiopoietin-1
FGF: acidic FGF (aFGF) and basic FGF (bFGF)
Follistatin
Granulocyte colony-stimulating factor (G-CSF)




Placental growth factor (PLGF)
Platelet-derived endothelial cell growth factor (PD-ECGF)
Pleiotrophin (PTN)
Progranulin
Transforming growth factor (TGF)






1.2.1.1 Vascular endothelial growth factor (VEGF) family 
The VEGF gene family of angiogenic and lymphangiogenic growth factors comprises 
six secreted glycoproteins referred to as VEGF-A, -B, -C, -D, -E, and PIGF (Ferrara, 
2002). All members except VEGF-E are encoded in the mammalian genome (Shibuya, 
2008). The VEGF family proteins bind in a distinct pattern to three structurally related 





tyrosine kinase 1 [Flt-1]), -2 (also referred to as KDR, and the murine homologue, 
Flk-1) and -3 (also referred to as fms-like tyrosine kinase 4 [Flt-4]). In addition, 
neuropilin (NRP)-1 and NRP-2 serve as co-receptors for certain but not all VEGF 
proteins and increase binding affinity of these ligands to their respective receptors 
(Fig. 1.2) (Ferrara, 2002).  
VEGF-A (commonly referred to as VEGF), also known as vascular permeability 
factor (VPF), is a highly specific mitogen for vascular ECs and key player in 
vasculogenesis and angiogenesis. It exist as six different isoforms: VEGF121, 
VEGF145, VEGF165, VEGF183, VEGF189, and VEGF206, which differ in their 
biological properties (Cross, et al., 2003). VEGF165 is the most dominant isoform 
while VEGF145 and VEGF183 are less commonly expressed variants. VEGF165 is the 
dominant subtype among VEGF proteins and is most active. VEGF121 is freely 
secreted, whereas the largest isoform (VEGF189 and VEGF206) are sequestered in the 
ECM and require cleavage by proteases for their activation. VEGF165 exists in both a 
soluble and an ECM-bound form  (Li, et al., 2008).  
VEGF is expressed by numerous cell types including macrophages, T cells, smooth 
muscle cells, kidney cells, keratinocytes, astrocytes and osteoblasts (Ferrara, et al., 
1997). Moreover, VEGF is widely expressed by tumor cells and strongly upregulated 
in pathological angiogenesis. Hypoxia is the major upregulator of VEGF expression 
(Rosenbaum-Dekel, et al., 2005,Tuder, et al., 1995). Other regulators of VEGF 
transcription include epidermal growth factor (EGF), insulin-like growth factor-1 
(IGF-1), estrogen, TNF-α, TGF-α, and TGF-β (Neufeld, et al., 1999).  
Functional analysis demonstrated that not only homozygote but also heterozygote 
knockout of the VEGF gene in mice resulted in embryonic lethality with impaired 
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vasculogenesis and angiogenesis, indicating that the basal level of VEGF protein 
supplied from two alleles is essential for completion of the formation of a closed 
circulatory system (Carmeliet, et al., 1996,Ferrara, et al., 1996). Furthermore, 
inactivation of VEGF after birth has revealed that VEGF is required for vascular 
expansion during postnatal growth in various organs including kidney, bone, heart 
and retina (Eremina, et al., 2003,Maes, et al., 2002,Stalmans, et al., 2002).  
VEGF binds to VEGFR1 and VEGFR2, but mediates its biological functions mainly 
via stimulating VEGFR2 (Shibuya, 2008). As shown in Fig. 1.3, VEGF stimulate 
angiogenesis via activating several important intracellular signaling pathways. It 
induces EC proliferation through activation of Erk pathway, and inhibits EC apoptosis 
via Akt/PKB pathway. The Akt/PKB pathway regulates EC apoptosis by inhibiting 
pro-apoptotic molecules such as BAD and Caspase  9. The Akt/PKB pathway also 
activates endothelial nitric oxide synthase (eNOS), leading to the increase in vascular 
permeability and EC migration. Other molecules implicated in VEGF induced EC 
migration include p38 mitogen-activated protein kinase (MAPK) and focal adhesion 
kinase (FAK) as well as paxillin (Cross, et al., 2003). Aparting from these, VEGF 
also induces vasodilation through the release of eNOS and prostaglandins (Ferrara, et 
al., 2003). Recently, the effects of VEGF on the lymphatic vasculature have been 
reported. The lymphangiogenic activities of VEGF seem to be linked to the 
recruitment of inflammatory cells, such as macrophages, which secrete 
lymphanagiogenic factors (Cursiefen, et al., 2004).  
VEGF-B and PIGF bind and activate only VEGFR1. Since the tyrosine kinase activity 
of VEGFR1 is one order of magnitude weaker than that of VEGFR2, the angiogenic 
activity of VEGF-B and PIGF is about 10- fold weaker than that of VEGF (Carmeliet, 
et al., 2001).  In contrast, VEGF-C and -D are crucial regulators of 
lymphangiogenesis. Homozygotes and heterozygotes mice for the VEGF-C allele 
often die in the perinatal stage due to a dysfunction of lymph vessels (Shibuya, 2008). 
In conclusion, VEGF and VEGFR1-2 are crucial for vasculogenesis and angiogenesis 
whereas VEGF-C as well as VEGF-D and VEGFR3 are essential for lymphogenesis 
(Olsson, et al., 2006). Furthermore, VEGF is one of the most potent endothelial-
specific angiogenic growth factors, stimulating multiple aspects of physiological and 
pathological angiogenesis (Shibuya, 2008). 
  
 
Fig. 1.2 Binding specificity of various VEGF family members and their 
receptors. The VEGF family consists of seven ligands derived from distinct genes. In 
addition, specific family members, such as VEGF-A, expressed as isoforms due to 
mRNA alternative splicing. VEGF family members and isoforms have specific 
binding affinities to VEGFR-1, -2 and -3. NRP-1 and -2 are co-receptors for specific 




 Fig. 1.3 Schematic illustration of VEGFR-2 intracellular signaling. (Adopted from 





1.2.1.2 Fibroblast growth factor (FGF) family 
The FGF family of growth factors is small polypeptides of 155-268 amino acids and 
comprises 23 members to date. The FGFs selectively bind to 4 different types of FGF 
receptors and also bind to heparin and heparin sulfate proteoglycans with high affinity 
(Botta, et al., 2000). Unlike the VEGF family, FGFs are strong mitogens for many 
cell types, not being restricted to ECs or fibroblasts. They are major growth and 
differentiation factors in embryonic development as well as in adult playing a role in 
neuronal signaling, inflammatory processes, hematopoiesis, angiogenesis, tumor 
growth and invasion (Bouis, et al., 2006).   
FGF1 (acidic FGF, aFGF) and FGF2 (basic FGF, bFGF) are the two most extensively 
investigated among all FGF members. They were found to be structurally related and 
have high affinity for heparin and heparan sulfate. FGF1 stimulates EC proliferation 
and migration in vitro, and are among the most potent angiogenic proteins in vivo. 
FGF2 has four known alternative splice isoforms. It promotes angiogenesis through 
stimulating EC proliferation, migration and capillary network formation (Bouis, et al., 
2006). FGF2 also induces VEGF and VEGFR-2 upregulation in ECs and the 
angiogenic activity of FGF2 might partly be mediated by upregulation of VEGF 
(Seghezzi, et al., 1998). Animal studies suggested that gene therapy with bFGF could 
lead to more mature vessels than with VEGF (Masaki, et al., 2002). The expression of 
FGF2 are closely associated with various cancers in lung, breast, thyroid and ovary 
(Brattstrom, et al., 2004,Bremnes, et al., 2006,Pasieka, et al., 2003), indicating its 
prognostic impact in the tumor development.  
1.2.2 Endogenous inhibitors of angiogenesis 
Endogenous inhibitors of angiogenesis are defined as proteins or fragments of 
proteins that are formed in the body and can inhibit the formation of blood vessels. 
Currently, 27 endogenous molecules have been reported to inhibit angiogenesis 
(Nyberg, et al., 2005). These endogenous angiogenesis inhibitors can be classified 
into three major categories: gene products, natural proteolytic fragments and others 
including metabolites of hormones (Table. 1.2).  
With respect to proteolytic fragments, they are derived from parental proteins which 
have no obvious anti-angiogenic activity and their parental proteins can be divided 
into two subgroups: ECM proteins and non-ECM proteins (Sato, 2006). Although the 
generation of natural cleavage products could provide a precise mechanism for the 
regulation of angiogenesis, their physiological roles in the regulation of angiogenesis 
remain to be established (Watanabe, et al., 2004).  
Table 1.2 List of Known Endogenous Angiogenesis Inhibitors 
Gene Products Fragments Others
Matrix derived
Thrombospondin-1 and -2 Arresten 2-Methoxyestradiol
Pigment epithelium-derived factor Canstatin
Interleukin -12, -18 Endorepellin
Interferons Endostatin
Chondromodulin-I Tumstatin
Tissue inhibitors of metalloproteinases Fibulin
Platelet factor -4 Anastellin
Vasohibin Non-Matrix Derived
Vascular endothelial growth inhibitor Angiostatin
Soluble VEGF Receptor 1 Prolactin fragment








1.2.2.1 Gene Products 
Thrombospodins (TSPs) are large multifunctional ECM glycoproteins that regulate 
various biological events including cell adhesion, cell proliferation and survival, 
activation of TGF-β and protease, and angiogenesis inhibition (Tucker, 2004). Among 
the five members (TSP-1, -2, -3, -4 and -5) of the TSP family, TSP -1 and -2 are the 
most similar in structure and have potent anti-angiogenic activity (Tucker, 2004). 
Their structure includes a globular amino-terminal motif, followed by a pro-collagen 
homology region, three thrombospondin type 1 repeats, three EGF like domains, five 
calcium-binding and a globular carboxyl-terminal end.  
TSP-1 is an inhibitor of angiogenesis in vitro and in vivo and a potent suppressor of 
malignant growth (Chen, et al., 2000). Experiments in vitro performed by many 
laboratories have been shown that TSP-1 inhibits EC migration, proliferation and 
stimulates EC apoptosis (Iruela-Arispe, et al., 1991). Take advantage of the fact that 
the expression of Fas is low on quiescent ECs but enhanced when ECs are activated 
by pro-angiogenic factors, TSP-1 specifically targets pathologic neovascularization by 
upregulating FasL to stimulate Fas/FasL-mediated apoptosis on only proliferating 
ECs (Volpert, et al., 2002).  
In vivo, TSP-1 suppresses FGF2-mediated angiogenesis in the cornea pocket assay 
and inhibits growth of blood vessels in the chick chorioallantoic membrane (CAM) 
assay (Iruela-Arispe, et al., 2004). In TSP-1 null mice, tumors grow faster with the 
characteristics of increased vascular density, decreased rate of tumor cell apoptosis 
and increased rate of tumor cell proliferation (Lawler, et al., 2001). Overexpressing of 
TSP-1 in mice suppresses wound healing and tumorigenesis, whereas the lack of 
functional TSP-1 results in increased vascularization in tissues (Streit, et al., 1999). 
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TSP-1 is highly expressed in developing blood vessels and rapidly upregulated by 
injury or inflammatory mediators (Iruela-Arispe, et al., 2004). In addition, expression 
of TSP-1 has been shown to be inversely correlated with malignant progression in 
breast and lung carcinomas in human (Zabrenetzky, et al., 1994).  
Several receptors have been identified for TSP-1, such as the integrins (αvβ3, α3β1, 
α4β1, and α5β1), low-density lipoprotein-related receptor protein, CD36, and heparan 
sulfate proteoglycans. The anti-angiogenic activity of TSP-1 has been mapped to the 
type 1 repeats and within the NH2-terminal procollagen-like domain of the molecule 
(Miao, et al., 2001).  
TSP-2 is predominantly expressed in areas of chondrogenesis, osteogenesis, 
developing blood vessels, and in early connective tissues (Iruela-Arispe, et al., 1993) 
and its expression is regulated by growth factors and hormones (Streit, et al., 1999). 
In TSP-2-overexpressing tumors, extensive areas of necrosis are observed, and both 
the density and the size of blood vessels are significantly reduced. The anti-
angiogenic role of TSP-2 was further confirmed with systemic administration to mice. 
Daily injections of N-terminal 80 kDa recombinant fragment of human TSP-2 
significantly inhibited the growth of human squamouse cell carcinomas and reduced 
tumor vascularization in mice (Noh, et al., 2003). Some studies showed that inhibition 
of tumor growth by TSP-2 was even stronger than the inhibition by TSP-1. In addition, 
the combined overexpression of TSP-1 and TSP-2 mediated synergistic antitumor 
activity (Streit, et al., 1999). In contrast, TSP-2 deficiency dramatically enhanced 
susceptibility of skin carcinogenesis and resulted in accelerated and increase tumor 
angiogenesis. The possible mechanisms of the anti-angiogenic activity of TSP-2 are 
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inhibition of EC migration and tube formation as well as stimulation of EC-specific 
apoptosis (Noh, et al., 2003). 
Pigment epithelium-derived factor (PDEF) was isolated as a 50kDa protein 
secreted by cultured pigment epithelial cells of fetal human retina (Steele, et al., 1993). 
It is a non-inhibitory member of the serpin superfamily of serine/theronine kinases 
inhibitors, and possesses multiple functions, including neuronal cell differentiation, 
protection of neurons from various neurotoxic agents, and angiogenesis inhibition 
(Dawson, et al., 1999). PDEF is responsible for the avascularity of ocular 
compartments and therefore the most potent inhibitor of angiogenesis in mammalian 
eye (Bouck, 2002). Gene targeting of PDEF revealed that PDEF was also a key 
inhibitor of the growth of the stromal vasculature and epithelial tissue in 3-month-old 
mouse prostate and pancreas (Doll, et al., 2003). PEDF affects major signaling 
pathways including Akt/NKκB, MAPK, and Caspase s. Similar to TSP-1, PEDF 
stimulated EC apoptosis through the induction of FasL (Volpert, et al., 2002).  
Maspin is a unique member of the serpin family and also known as a class II tumor 
suppressor, as it has inhibitory effects on tumor growth, metastasis, and angiogenesis 
(Hendrix, 2000). Maspin is expressed in normal mammary epithelial cells and 
myoepithelial cells, and lost in mammary carcinoma lines (Domann, et al., 2000). 
Maspin is an effective angiogenesis inhibitor. It suppresses VEGF and bFGF induced 
EC migration, proliferation and tube formation in vitro and blocks neovascularization 
in in vivo cornea pocket assay. Overexpression of maspin in breast tumor cells inhibits 
their growth and metastasis in vivo, and dramatically reduced the density of tumor 
blood vessels (Zhang, et al., 2000).   
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Interleukins (ILs) are a family of leukocytes-derived proteins with broad-ranging 
physiological properties, including angiogenesis. IL-8 has a pro-angiogenic activity, 
whereas IL-12 and IL-18 show anti-angiogenic activity (Sato, 2006). Both IL-12 
treatment of tumor bearing mice and increased IL-12 delivery through gene transfer 
resulted in extensive tumor necrosis and decreased tumor growth (Morini, et al., 
2004,Yao, et al., 2000).  
Interferons (IFNs) are pleiotropic cytokines that regulate antiviral, antitumor, 
apoptotic, and cellular immune responses. Among three members of the IFNs family, 
IFN-α or IFN-β are identified to inhibit angiogenesis (Sidky, et al., 1987). Their anti-
angiogenic activity are mediated partially by down-regulating the expression of FGF2 
(Slaton, et al., 1999), VEGF (von Marschall, et al., 2003) and matrix metallopeptidase 
9 (MMP9) (Slaton, et al., 1999).   
Chondromodulin-I (ChM-I), a glycoprotein generated from a larger transmembrane 
ChM-I precursor, was originally isolated from bovine epiphyseal cartilage as a growth 
factor that stimulated chondrocytes growth and proteoglycan synthesis. However, 
ChM-I is also a tissue-specific inhibitor of angiogenesis (Sato, 2006). ChM-I is 
expressed and stored in the avascular zone of cartilage, and prevents EC invasion. The 
expression level of ChM-I is substantially decreased in chondrosarcomas or in other 
cartilage tumors (Hayami, et al., 1999). Similary, it is also expressed strongly in 
normal cardiac valves but significantly reduced in human valvular heart disease, 
suggesting that loss of ChM-I may lead to pathological conditions. ChM-I is a critical 
anti-angiogenic factor in cardiac valves and maintains their function by preventing 
angiogenesis (Yoshioka, et al., 2006). Treatment of ChM-I inhibits EC proliferation, 
migration and tube morphogenesis in vitro (Hiraki, et al., 1997). Loss of ChM-I had 
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no vascular phenotype in younger mice, but lead to augmented neovascularization in 
the cardiac valves in aged mice (Yoshioka, et al., 2006). Local administration of 
ChM-I inhibits tumor angiogenesis and growth of tumors, including human 
chondrosarcoma and mice colon adenocarcinoma, suggestive of a broad therapeutic 
potential (Hayami, et al., 1999).  
Troponin I (Tn I) is another cartilage-derived angiogenesis inhibitor. It is a subunit 
of the troponin complex, which along with tropomyosin regulate calcium-dependent 
striated muscle contraction (Sato, 2006). Tn I inhibits EC proliferation and in vivo 
angiogenesis (Moses, et al., 1999). It inhibits bFGF-stimulated EC proliferation by 
interaction with the bFGF receptor (Feldman, et al., 2002).  
Platelet factor-4 (PF-4) is a 8kDa protein released from platelet α-granules during 
platelet aggregation. PF-4 has been shown to have anti-angiogenic properties. It 
inhibits angiogenesis by associating directly with bFGF and the inhibitory activity of 
PF-4 is mapped partially in its heparin-binding region (Maione, et al., 1990).  
Vasohibin is the first identified angiogenesis inhibitor with the noteworthy 
characterics of negative feedback regulation of angiogenesis (Kerbel, 2004). It is 
selectively expressed in ECs and its expression is induced by angiogenic growth 
factors such as VEGF or bFGF. It is capable of inhibiting angiogenesis in vivo when 
tested using various assays including Matrigel implantation, mouse corneal 
micropocket assay and CAM assay. Similary, it inhibits several EC functions in vitro, 
such as migration, proliferation and tube formation. Furthermore, overexpression 
vasohibin suppresses tumor growth and tumor angiogenesis (Watanabe, et al., 2004). 
In contrast, knockdown of endogenous vasohibin augmented mouse retinal 
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neovascularization (Shen, et al., 2006). Moreover, the inhibitory effect of vasohibin is 
selective to ECs (Shimizu, et al., 2005).     
VEGI, a new member of the tumor necrosis factor family, is another endogenous 
negative regulator of angiogenesis (Metheny-Barlow, et al., 2006). It has three 
isoforms, including VEGI251, VEGI192 and VEGI174. VEGI is predominantly 
expressed in ECs and its mRNA levels are increased in proliferating rather than 
quiescent ECs. Recombinant VEGI251 is a potent inhibitor of EC proliferation, in vitro 
and in vivo capillary network formation, as well as tumor growth (Yu, et al., 2001).  
sVEGFR1 is a naturally existing soluble form of VEGF receptor 1 that can bind 
VEGF with high affinity but are unable to transducer signals due to its absence of the 
intracellular tyrosine kinase domain. sVEGFR1 functions as a decoy receptor by 
sequestering VEGF ligands and thereby only blocking VEGF-mediated angiogenesis 
(Kendall, et al., 1996). It has been shown that sVEGFR1 can serve as an antitumor 
agent by inhibiting VEGF (Belgore, et al., 2000). It is expressed in ECs and 
trophoblasts of placenta or in ECs during cutaneous wound healing. In human, the 
plasma level of VEGF is 75 pg/ml while sVEGFR1 is 23 ng/ml. The high level of 
sVEGFR1 may contribute to the lack of effect of VEGF in ischemia for vascular 
angiogenesis trials (Belgore, et al., 2000). 
In conclusion, most angiogenesis inhibitors of this category have pleiotropic effects. 
The expression of these proteins is not necessarily related to the regulation of 
angiogenesis. However, sVEGFR1, vascular VEGI and vasohibin are distinguished as 
they are rather selectively expressed in ECs and specifically inhibit angiogenesis 
(Watanabe, et al., 2004). Vasohibin is the first negative feedback regulator of 
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angiogenesis. Amongst them, TSP1 and PEDF are the best characterized ones that act 
under various physiological and pathological conditions.  
 
1.2.2.2 Natural protein fragments 
Vascular basement membrane components can modulate EC behavior in addition to 
providing structural and functional support (Darland, et al., 1999). A series of 
endogenous anti-angiogenic factors are fragments of naturally occurring ECM and 
basement membrane proteins, including arresten, canstatin, tumstatin, and endostatin 
(Nyberg, et al., 2005).    
The main component of vascular basement membranes is type IV collagen, forming a 
mesh-like structure with other macromolecules, such as laminin, fibronectin, and 
entactin (Costell, et al., 1996). Arresten, canstatin and tumstatin are derived from the 
α1, α2 and α3 chain of type IV collagen respectively (Colorado, et al., 
2000,Kamphaus, et al., 2000). They all display anti-angiogenic activities by inhibiting 
EC proliferation, migration and tube formation (Ribatti, 2009). Endostatin is an 
endogenous collagen XVIII-derived angiogenesis inhibitor efficiently blocking 
angiogenesis and suppressing tumor growth and metastasis in experimental animal 
models without any apparent side effects, toxicity or development of drug resistance 
(Boehm, et al., 1997,O'Reilly, et al., 1997).   
Other protein fragments that function as angiogenesis inhibitors are derived from 
blood coagulation factors, such as angiostatin (Ribatti, 2009).  Plasminogen contains 
five kringles and does not possess anti-angiogenic properties. However, when cleaved 
by protease, plasminogen generates anti-angiogenic peptide named angiostatin that 
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contains the first 4 triple-disulfide bridged kringle domains (Patterson, et al., 1997). 
Angiostatin specifically inhibits the proliferation of growing vascular ECs but have no 
effect on resting ECs (Ribatti, 2009).  
There are other protein fragments derived from non-matrix, such as Pex from MMP-2 
and the Prolactin fragment from prolactin. Pex inhibits angiogenesis and tumor 
growth (Ribatti, 2009). The 16kDa prolactin fragment blocks VEGF or FGF2 
stimulated-angiogenesis although its parental protein Prolactin is pro-angiogenic 
(D'Angelo, et al., 1995).  
 
1.2.2.3 Others 
2-Methoxyestradiol (2-ME), an endogenous estradiol metabolite derived from 
estrogen, is an inhibitor of angiogenesis. Its mechanisms of action is based on 2-ME-
mediated destabilization of microtubules which was associated with a block in nuclear 
accumulation and activity of hypoxia-inducible factor -1α, leading to significant 
reduction in the VEGF levels (Mabjeesh, et al., 2003). The physiological role of 2-Me 
as an inhibitor of angiogenesis is not yet understood.  
As mentioned above, many molecules exist in the body that functions to inhibit 
angiogenesis. However, how these endogenous angiogenesis inhibitors orchestrate to 
counteract the effects of angiogenesis stimulator remains unknown. The recent 
discovery of vasohibin and VEGI as negative feedback angiogenesis inhibitors may 
shed light on the inhibition of angiogenesis.    
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1.3 Angiogenesis and integrins 
Integrins, a family of heterodimeric transmembrane proteins formed by the 
noncovalent association of α and β subunits, mediates cell adhesion to the ECM. 
There are 18 α and 8 β subunits capable of forming 24 different functional but 
structurally related receptors for ECM proteins (Alghisi, et al., 2006). Each integrin 
subunit consists of an extracellular domain, a single transmembrane region and a short 
cytoplasmic tail. The cytoplasmic domain is essential for the regulation of integrin 
activity and function. Many integrins are expressed in ECs, including αvβ3, αvβ5, 
α1β1, α2β1 and α4β1 and have been shown to play important roles in angiogenesis 
(Silva, et al., 2008). 
The ligand specificity to integrins is largely determined, but not exclusively, by the 
composition of the heterodimer. Some integrins, such as α5β1, primarily recognize a 
single ligand, whereas others, such as αvβ3, can bind several ligands. Many integrins 
including αvβ3, α5β1, αvβ6, and α3β1, are the receptors for a wide variety of ECM 
ligands expressing the Arg-Gly-Asp (RGD) tripeptide motif, namely vitronectin, 
fibronectin, fibrinogen, thrombospondin and osteopontin (Plow, et al., 2000). Other 
integrins recognize alternative short peptide sequences, such as Glu-Ile-Leu-Asp-Val 
(EILDV) and Arg-Glu-Asp-Val (REDV) (Komoriya, et al., 1991).  
Integrin ligation promotes integrin clustering and subsequent integrin-mediated 
intracellular signal transduction. In addition to supporting physical adhesion, integrin 
ligation promotes cell spreading, migration, survival, proliferation, and differentiation 
(Giancotti, et al., 1999). Unlike growth factor receptors, integrins lack intrinsic 
tyrosine kinases activity and therefore activate complex signaling pathways by co-
clustering with kinases and adaptor proteins in focal adhesion complexes. There are 
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four main signaling pathways activated by integrins that are relevant to angiogenesis: 
Ras-mitogen-activated protein kinase (MARK), phosphatidylinositol 3 kinase (PI3K)/ 
protein kinase B (PKB), Rho-family GTPases, and nuclear factor- κB (NF-κB) (Fig. 
1.4) (Alghisi, et al., 2006,Eliceiri, et al., 2001,Martin, et al., 2002,Smyth, et al., 2002). 
The critical molecule in all these pathways is FAK. Phosphorylation of FAK in 
response to integrin ligation leads to the formation of phosphotyrosine sites for 
several classes of signaling molecule, which in turn activates a cascade of signaling 
pathways that lead to cell proliferation, migration, survival or differentiation.  
Many signaling pathways activated by integrins are also activated by growth factor 
stimulation, suggesting that integrin- and growth factor-mediated cellular responses 
may synergize and may function to coordinate biochemical responses in multiple cell 
types. For example, optimal cell stimulation with EGF, PDGF, insulin or VEGF 
depends on integrin-mediated cell adhesion to the appropriate ECM (Eliceiri, 2001). 
Furthermore, crosstalk between integrins and growth factor receptors provide 
specificity during angiogenesis (Eliceiri, 2001). The angiogenic pathway promoted by 
integrin αvβ5 is distinct from that regulated by αvβ3. In vivo angiogenesis assays 
showed that bFGF depends on αvβ3 to initiate angiogenesis, whereas αvβ5 is required 
for VEGF-mediated angiogenesis. These pathways are further distinguished by their 
sensitivity to an inhibitor of protein kinase C (PKC) which blocks αvβ5- but not αvβ3- 
mediated angiogenesis (Friedlander, et al., 1995).  
Numerous in vitro and in vivo data have demonstrated a number of EC integrins in the 
regulation of not only physiological but also pathological angiogenesis. These 
integrins include α1β1, α2β1, α4β1, α5β1, α6β1, α6β4, αvβ3, and αvβ5 (Table. 1.3) 
(Alghisi, et al., 2006). Particularly, integrin αvβ3 and αvβ5 are the major players in 
particular tumor angiogenesis. Integrin αvβ3 was the first found associated with tumor 
angiogenesis. It is highly expressed in angiogenic ECs and in malignant tumors and 
virtually absent from quiescent ECs. Inhibition of αvβ3 suppressed cornea 
vascularization (Friedlander, et al., 1995), hypoxia-induced retinal neovascularization 
(Hammes, et al., 1996), tumor angiogenesis, and tumor progression in various in vivo 
models (MacDonald, et al., 2001,Reinmuth, et al., 2003). Monoclonal antibody for 
αvβ5 inhibited VEGF-induced angiogenesis in the rabbit cornea as well as the chick 
chorioallantoic membrane model (Friedlander, et al., 1995), suggesting that vascular 
integrins are potentially relevant targets for anti-angiogenic therapies.   
Table 1.3 Vascular integrins in angiogenesis 
Integrin Major ECM ligands Gene deleted Mouse phenotype
α1β1 Collagen, laminin α1 Normal vascular development, reduced tumor 
angiogenesis
α2β1 Collagen, laminin α2 Normal vascular development
α4β1 Fibronectin α4 Lethal at E11-14, placental fusion defect and 
coronary arteries defect
α5β1 Fibronectin, fibrin α5 Lethal at E10, vasculogenesis but no angiogenesis
α6β1 Laminin, α6 Lethal at birth, no defects in vascular 
development
α9β1 Tenascin, fibronectin, 
collagen, laminin
α9 Lethal at birth, defects in large lymphatic vessels
αvβ1 Fibronectin,
vitronectin









β5 Normal development, reduced adult angiogenesis 
in response to certain angiogenic factors
αvβ8 Collagen, laminin, 
fibronectin
αv Lethal at E12, vascular defects in the placenta and 
brain, and intestine





 Fig. 1.4 Signaling pathways initiated by integrins at focal contacts. The four major 
signaling pathways activated by integrin engagement in adhesion complexes are 
shown. The key element in all these pathways is FAK, which becomes activated 
through autophosphorylation at Y397 and thereby allows binding of the Src and Fyn 







1.4 Angiogenesis and focal adhesions 
Focal adhesions (FAs) are large dynamic protein complexes where integrins link the 
outside ECM to intracellular cytoskeleton at the cell membrane. These protein 
assemblies play an important role in modulating cell adhesion as well as cell 
spreading (Tomar, et al., 2009). Moreover, FAs transduce various signaling pathways 
leading to migration, proliferation, survival and function of all cells. Four major 
factors influence the assembly rate, size, specific constituency, signaling repertoire, 
and functional impact of FAs. These are the biophysical and biochemical properties of 
the ECM, integrin activation and avidity, the contraction state of the cytoskeleton, and 
the specific cellular milieu in which these events occur (Romer, et al., 2006).  
FA complexes morphologically appear as tear shaped plaques at the ends of actin 
filament stress fiber (Craig, et al., 1996).  They are composed of diverse number of 
structural and signaling proteins, such as integrins, cytoskeleton proteins, protein 
kinases and phosphatases. Actin binding proteins that localize at FA sites include talin, 
tensin, paxillin, vinculin and α-actinin (Yam, et al., 2009).  
The assembly of FAs can be induced by growth factors, integrin ligation and 
lysophosphatidic acid (Craig, et al., 1996). In serum-starved Swiss 3T3 cells, FA 
plaques and stress fibers were stimulated within 15-30 min once EGF, PDGF or 
insulin was added (Barry, et al., 1994). Latex beads, coated with fibronectin or 
monoclonal antibody to the α5 subunit of integrin, bind to cultured fibroblasts and 
induce accumulation of FA proteins on the cytoplasmic surface of the bead-cell 
interface, whereas control beads coupled to polylysine bind to cells but do not induce 
FA protein assembly (Plopper, et al., 1995). 
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FAs play a very essential role in angiogenesis due to the fact that the ability of the 
ECs to respond to angiogenic stimuli is highly dependent on their interactions with 
the ECM. Moreover, adhesion of ECs to the ECM optimally promotes migration and 
other cellular processes at the specific stage of the angiogenic response (Eliceiri, et al., 
2001). One of the crucial upstream players in the assembly of FAs is FAK. Upon 
integrin-mediated cell adhesion, or growth factor receptor stimulation, FAK is rapidly 
phosphorylated at Tyr397. This creates a high-affinity binding sites for signaling 
molecules that contain SH2 domain and leads to the recruitment and activation of Src 
and other downstream signaling partners including PI 3-kinase and phospholipase C 
(PLC)- γ (Rizzo, 2004). 
Defective angiogenesis phenotypes were observed in the conditional FAK knockout 
mouse, includes abnormal angiogenesis in embryos, yolk sac, and placenta, impaired 
vasculature and associated hemorrhage. Furthermore, deletion of FAK in ECs isolated 
from the floxed FAK mice led to reduced tubulogenesis, cell survival, proliferation, 
and migration in vitro (Shen, et al., 2005). Overexpression of FAK in vascular ECs 
promotes pathophysiological angiogenesis in transgenic mice, such as wound healing 
and hindlimb ischemic, with minimal effect on embryonic vasculogenesis and 
angiogenesis under physiological conditions (Peng, et al., 2004). Moreover, high 
levels of FAK and FAK phosphorylation at Try397 were detected in microvascular 
ECs of malignant astrocytoma but not in ECs of normal brain, indicating the possible 




1.5 Tumor angiogenesis and macrophage as well as matrix metalloproteinases 
(MMPs) 
Tissue macrophage differentiate from its precursor monocyte when it migrates from 
the blood stream into tissue in the steady state or in response to inflammation (Mosser, 
et al., 2008). Macrophages are present in most of the tissues and demonstrate great 
phenotypic heterogeneity with their ability to engulf invading pathogens, cell debris 
or apoptotic cells. They also secret a wide array of immunomodulatory, and act as 
accessory cells in lymphocyte activation (Gordon, 2007). These cells play an 
important role in the emergence and resolution of inflammation and in the 
maintenance of tissue homeostasis. In all these processes, macrophages become 
activated by the combination of two signals: interferon(IFN)-γ and tumor-necrosis 
factor (TNF) (Mosser, et al., 2008).  
Tumor-associated macrophages (TAMs) are a major component of stroma cells in 
solid tumors (Coffelt, et al., 2009). The directional movement stimulated by 
chemokinesis is important in the recruitment and distribution of monocytes into 
tumors. The potent chemokinesis produced by tumors are monocyte chemotactic 
protein-1 (MCP-1), macrophage colony stimulating factor (M-CSF) and VEGF. 
Monocytes are then differentiated to the TAMs and accumulated in the hypoxic areas 
of tumor (Lewis, et al., 2005).  
TAMs are considered to have both anti-tumor and pro-tumor effects. At initial contact, 
they exhibit tumoricidal activity towards tumor cells by direct or indirect cytotoxicity 
and stimulate the anti-tumor functions of other cell types (Hock, et al., 1993). 
However, when they reside in the areas of hypoxia, they respond to the levels of 
hypoxia by upregulating transcriptional factors like hypoxia-inducible factor (HIF)-1 
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and HIF-2, which in turn activate a broad array of mitogenic, proinvasive, pro-
angiogenic, and prometastatic genes for promoting tumor progression and 
angiogenesis (Lewis, et al., 2005). Moreover, several studies have shown that the 
level of hypoxia in tumors was correlated with both TAM infiltration and high 
vascular density (Leek, et al., 1999,Shieh, et al., 2009).  
TAM has been demonstrated to have pro-angiogenic functions. Conditioned media 
derived from activated macrophages can induce angiogenesis (Polverini, et al., 1977). 
Depletion of macrophages in mice showed significant reduction in tumor 
vascularization and hence the delay of malignant transition (Evans, 1977). In contrast, 
enhanced recruitment of macrophages by overexpressing M-CSF in mammary 
epithelium of MMTV-PyMT mice increased tumor vascularization and progression to 
malignant progression (Lewis, et al., 2006). Many clinical data have indicated the 
correlation between macrophage infiltrating level and poor prognosis. Moreover, 
various human cancers, including breast, uterine cervical, prostate, liver, lung, bladder, 
kidney and brain have demonstrated a significant correlation between high number of 
TAMs and tumor angiogenesis (Coffelt, et al., 2009).  
Studies have shown that TAMs promoted tumor angiogenesis directly by releasing a 
broad spectrum of pro-angiogenic factors, such as growth factors (VEGF, bFGF, EGF 
and TGF-α), cytokines (IL-8, TNF-α, and IL-6) or indirectly by secreting MMPs 
(Lewis, et al., 2005).  
MMPs are tissue matrix-degrading enzymes. They are capable of degrading all kinds 
of ECM proteins that give structural support to cells and play an important role in cell 
adhesion, differentiation, proliferation and migration. MMP expression is normally 
low but is induced when ECM remodeling is required, such as in tissue 
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morphogenesis, repair and angiogenesis (Lewis, et al., 2005). A number of growth 
factors and cytokines secreted by cells are incorporated into the milieu of ECM, 
creating a functional microenvironment that assist various cell types in determining 
their responses to different signals (Lewis, et al., 2005).  
Among the members of MMP family, MMP-2 and MMP-9 are key players especially 
in tumor angiogenesis (eg, by relasing the matrix sequestered angiogenic factors, 
disrupting the tissue architecture to allow EC migration) and tumor progression (eg, 
degrade type IV collagen of basement membrane for tumor invasion). It has been 
reported that high expression of MMP-2 and MMP-9 in tumors is closely associated 
with low differentiation grade and high metastatic properties (Narazaki, et al., 
2006,Naumov, et al., 2006,Tosetti, et al., 2002) .  
Nevertheless, accumulating evidence has suggested that high TAM infiltration is 
advantageous to tumor progression and metastasis in certain cancers. One of the 
important molecular mechanisms that macrophages increase tumor angiogenesis and 
tumor cell migration is by producing and secreting MMPs, such as MMP-2 and 
MMP-9 (Lewis, et al., 2005).    
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1.6 In vitro angiogenesis assays and in vivo models of angiogenesis used in the 
study  
Angiogenesis assays are important tools for studying not only the potential 
angiogenesis modulators but also the mechanisms of angiogenesis. Numerous in vitro 
and in vivo angiogenesis models have been developed, such as in vitro capillary 
formation assay, the CAM assay, cornea pocket implantation assay, in vivo Matrigel 
plug assay, and the aortic ring assay (Shiba, et al., 2008). An optimal angiogenesis 
assay should provide a quantitative measure of the structure and functional 
characteristics of the new vasculature, avoid tissue damage (since it may lead to 
formation of new vessels), and be cost-effective, easy to use, reproducible and reliable 
(Auerbach, et al., 2000).  
 
1.6.1 In vitro angiogenesis assays 
During angiogenesis, ECs migrate away from the pre-existing vessel in response to 
angiogenic stimulus. Behind this migration front, ECs proliferation takes place to 
provide the necessary number of cells for making a new vessel. Subsequently, the 
new outgrowth of ECs reorganize, form a lumen and establish a patent three-
dimensionally tubulular structure.  Therefore, in vitro cellular assays presenting 
angiogenesis are EC migration, proliferation and tube formation (Auerbach, et al., 
2003), each reflecting one particular step involving ECs response to angiogenic 
stimulation. Moreover, many angiogenesis inhibitors inhibit angiogenesis by inducing 
ECs apoptosis, which can also be tested in vitro (Sulochana, et al., 2005). These 
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assays are usually performed with primary cultures of ECs rather than immortalized 
EC lines (Martinez, 2006).  
There are several devices to study cell migration, but most of them are based on the 
ability of ECs to pass through a porous membrane. Modified Boyden chamber assay 
is most frequently used to determine the migratory response of ECs to angiogenic 
factors. In this assay, mixture of ECs and a test reagent are placed on the upper layer 
of a cell-permeably filter and angiogenesis-stimulating factor is placed in the medium 
below the filter. As such, enumerating the cells that move preferentially toward a 
chemoattractant may well be the most reliable measure of a direct response of ECs to 
angiogenic factors (Auerbach, et al., 1991).  
The most specific test in vitro for angiogenesis is the measurement of the ability of 
ECs to form capillary-network formation. Initially, it was observed by Judah Folkman 
that ECs appeared able to form tubules spontaneously when EC cultures were 
maintained as confluent monolayers for prolonged periods of time without 
replenishment of nutrients (Folkman, et al., 1979). Tube formation can be enhanced by 
providing a variety of substrates, including collagen or fibrin clots (Auerbach, et al., 
2003). The Matrigel, a matrix-rich product derived from Engelbreth-Holm-Swarm 
(EHS) tumor cells, can evoke EC capillary-network formation within 24 hours 
(Kleinman, et al., 1986,Madri, et al., 1986). EC tube formation is a multi-step and 
dynamic process including cell attachment to matrix, cell migration, cell spreading, 
cell-cell adhesion, morphogenesis as well as apoptosis. After plating ECs onto 
Matrigel, cells first attach,  migrate and spread to Matrigel, and then elongate to form 
cell-cell alignment that appears as capillary tubes and finally the extensive cellular 
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network. Therefore, tube formation on Matrigel provides a more direct in vitro 
evidence of angiogenesis than migration or proliferation of ECs.  
Although individual in vitro angiogenesis assays focus on isolated EC functions and 
do not examine the coordination of cell functions required for a successful angiogenic 
response, they are valuable, easier to interpret, provide quantification, and present 
mechanisms of vessel formation. Moreover, in vitro tests are remarkably useful in 
screening for optimal compounds for specific functions, such as mitogen for ECs and 
reduction in cell motility, and identifying concentrations for efficacy (Auerbach, et al., 
2003).  
 
1.6.2 The Directed In vivo Angiogenesis Assay (DIVAA) 
In vivo angiogenesis assays examine the entire spectrum of molecular and cellular 
processes. Numerous in vivo angiogenesis assays have been developed, including the 
corneal pocket implantation assay, CAM assay, the Matrigel plug assay and chamber 
assays. Compared to these assays, DIVAA stands out by utilizing technically simple, 
reproducible methology that angiogenic response is objectively and easily quantified.  
DIVAA is an optimized version of the Matrigel plug assay. Matrigel has the property 
of being liquid at 4°C but semi-solid at 37°C. In the Matrigel plug assay, Matrigel 
containing test substances is injected subcutaneously into mice where it solidified to 
form a plug. This plug is recovered after 7-21 days in mice and assessment of 
angiogenesis is determined by measuring the extent of vessel growth into the Matrigel 
plug. However, it is difficult to generate identical three-dimensional plugs even 
though the total Matrigel volume is kept constant, leading to variability in the assay 
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(Auerbach, et al., 2000). DIVAA overcomes this shortcoming by utilizing semiclosed 
silicone cylinders (named angioreactors where gel solidified) and implant 
angioreactors into nude mice. The amount of angiogenesis in each angioreactor was 
quantified by measuring the number of ECs using fluorescently labelled EC-binding 
lectin, which have been shown to represent a true EC-mediated angiogenic response 
(Guedez, et al., 2003). Moreover, DIVAA is highly sensitive to effects of 
angiogenesis inhibitors and thus provides dose-response analysis, and identifies 
effective doses of angiogenesis-modulating factors (Guedez, et al., 2003).  
 
1.6.3 Tumor angiogenesis using syngenic mouse tumor model and stably 
modified tumor cell lines 
Overexpression of a gene of interest in tumor cells is an effective approach to 
investigate gene function in tumor angiogenesis. Overexpression of endogenous 
angiogenesis inhibitors (eg, endostatin, angiostatin, TSP-1 and -2 ) using viral and 
nonviral vectors have shown great promise for anti-tumor action in mouse model, 
indicating that these methods can successfully translate the effects of angiogenesis 
inhibitors into mouse tumor model (Chen, et al., 1999,Griscelli, et al., 1998).  
Plasmids containing the gene of interest can be delivered intra-tumorally or 
intravenously by adenoviruses. Competing technologies using nonviral delivery via 
liposome or “naked” DNA injection have also demonstrated efficacy. However, the 
problems associated with transfection efficiency compromises the feasibility and 
efficacy of the DNA-based method in studying tumor angiogenesis.  
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Alternatively, generating stable cell lines that overexpresses the protein of interest by 
tumor cells themselves has also been widely used because of the ability to 
continuously produce protein in tumor milieu. Tumor angiogenesis model can be 
generated by inoculating mouse with the tumor cells that overexpress the protein of 
interest.  
Stable cell lines are generated by transfecting with DNA vector and cultured under the 
selective antibiotics. The viability of stable cell lines is then analyzed before tumor 
inoculation. The volumn of tumor growth is highly correlated with tumor 
angiogenesis. To inoculate the tumor, tumor cells stably transfected are 
subcutaneously injected into the animal model. Tumor angiogenesis can be 
determined by assessing microvessel density through the quantification of expression 
level of ECs markers (e.g. CD31).   
 
1.6.4 Embryonic angiogenesis using zebrafish model 
The zebrafish, is an excellent model system for deciphering gene function as well as 
the cellular mechanisms underlying angiogenesis because of its genetic amenability, 
the experimental accessibility and the optical clarity (Vogel, et al., 2000). Transgenic 
zebrafish Tg (fli1: EGFP) which express green fluorescent protein (GFP) in vascular 
endothelium under the control of zebrafish fli1 promoter, permits in vivo time-lapse 
imaging of vascular endothelial cells and their angioblast precursors. The robust 
expression of GFP throughout the vasculature is a particularly powerful new tool for 
analyzing the dynamics of blood vessels formation (Childs, et al., 2002).  
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The anatomy of the developing trunk vasculature is both reproducible and 
characteristically conserved in vertebrates (Isogai, et al., 2001). In zebrafish, at 
approximately 1 day post-fertilization (dpf), trunk axia vessels composed of the dorsal 
aorta (DA) and posterior cardinal vein (PCV), are formed via vasculogenesis (Childs, 
et al., 2002).  
A conserved vascular network named intersegmental vessels (ISVs) consisting of 
intersegmental arteries and veins sprout from DA and PCV, and are patterned via 
angiogenesis (Childs, et al., 2002). At 1.5 dpf, ISVs sprout and elongate dorsally up 
and their tips anastamose longitudinally to form a right and left pair of dorsal 
longitudinal anastamotic vessels (DLAVs). ISVs connect ventrally to either the DA or 
PCV respectively, and run dorsally between and adjacent to the notochord-neural tube 
interface and the somites. By 3 dpf, nearly all ISVs are functioning, leading to the end 
of development of major trunk vessels (Isogai, et al., 2001). Because of their 
metameric arrangement and relative anatomical simplicity, ISVs are ideally suited to 
study the cues and mechanisms of the ordered formation of new blood vessels (Blum, 
et al., 2008).  
 
1.7 Thrombospondin type 1 repeat (TSR) domain 
TSRs are protein domains consisting of around 60 amino acids in length, and were 
first identified in the endogenous angiogenic inhibitor TSP-1 (Tucker, 2004). Crystal 
structure of TSRs of TSP-1 revealed three anti-parallel strands with two regular ß 
sheets and one ripped conformation (Tan, et al., 2002). Moreover, CWR-layered 
structure (comprised by the interdigitating side chain stacking of cysteine, tryptophan 
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and arginine in layers from three strands) and CSVTCG motif are important features 
of TSR. TSRs are present only in secreted proteins or extracellular regions of 
transmembrane proteins. The location of TSR implicates its involvements in cellular 
migration, communication, and tissue remodeling in complex tissues (Tucker, 2004).  
TSR domain have been identified in multiple protein families, such as 
thrombospondins, a disintegrin and metalloproteinase with thrombospondin motifs 
(ADAMTS) protein family, brain-specific angiogenesis inhibitor (BAI) as well as F-
spondin family and some semaphorins (Adams, et al., 2000). There are 41 TSR 
domain containing proteins in the human genome, including many predicted proteins 
with no known functions. 
The matrix metalloproteinases ADAMTS1 and 8, have been demonstrated to possess 
angioinhibitory properties (Iruela-Arispe, et al., 2003). Both TSP-1 and -2 also inhibit 
angiogenesis by inhibiting EC proliferation and inducing EC apoptosis (Tan, et al., 
2002). The studies of TSRs in TSP-1 and other anti-angiogenic proteins such as brain-
specific angiogenesis inhibitor 1 (BAI1), TSP-2 and ADAMTS1 sturdily indicate that 
TSRs play critical roles in the anti-angiogenic function (Tucker, 2004). Furthermore, 
the recent clinical trials of the anti-angiogenic peptides derived from the TSRs of 
thrombospondin-1 to treat cancer further demonstrated the importance of TSRs in 
anti-angiogenesis.  
Besides the anti-angiogenic function of TSR domain, many studies have also shown 
the possible role of TSR in neuronal development (Adams, et al., 2000). All 
thrombospondins except TSP-5 are expressed during development of the nervous 
system and TSP-1 plays important role in the regulation of neuronal differentiation 
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and neurite outgrowth (Tucker, et al., 1999). Semaphorin5A and B are found to play a 
role in neuroblast proliferation (Adams, et al., 2000).  
Biochemical interaction analysis revealed two types of adhesive receptors as cellular 
binding partners for TSRs: CD36 and glycoconjugates that are assumed to be linked 
to proteoglycans. CD36 expression has been documented to be expressed in ECs 
(Bongrazio, et al., 2006). In addition, point mutation study indicated the importance 
of the CSVTCG motif of TSRs in TSP-1’s anti-angiogenic activities (Crombie, et al., 
1998).     
In conclusion, the presence of TSRs in a wide variety of anti-angiogenic proteins 
suggests that the presence of the TSR domain may render the protein to be anti-
angiogenic.  
 
1.8 Adhesion-associated domain in MUC-4 and other proteins (AMOP) domain 
AMOP, representing adhesion-associated domain in MUC-4 and other proteins, was 
predicted to be a novel extracellular protein domain by Ciccarelli et al. in 2002 by 
bioinformatics due to its characteristic pattern of cysteine residues (Ciccarelli, et al., 
2002). It is a around 25kDa and contains eight invariant cystein residues.  Secondary 
structure prediction using the PHD programme indicates an initial region rich in α 
helix followed by four β strands in AMOP domain. However, no significant similarity 
of AMOP domain to a known protein folds were detected using protein structure 
prediction software 3D-PSSM and the THREADER (Ciccarelli, et al., 2002). 
Moreover, AMOP was found to precede von Willebrand type D (VWD) domain in 
many proteins that contain both AMOP and VWD domains.  
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AMOP domain is only found in proteins that contain extracellular domains such as 
MUC4, sushi domain containing (SUSD) 2, implying potential roles in cell adhesion 
for this domain. The MUC4 gene has at least 24 spliced isoforms and is expressed in 
epithelial tissues of different organs. It is noted that MUC4 is not expressed in normal 
pancreas but aberrantly overexpressed in diverse human carcinomas such as 
pancreatic adenocarcinomas (Van Klinken, et al., 1995), indicating a possible link of 
AMOP in cancer. 
 
1.9 Isthmin (ISM) 
Isthmin (ISM) is novel gene encoding a secreted protein of around 450 amino acids 
first identified in Xenopus with unknown function (Pera, et al., 2002). Orthologous 
Ism genes have also been found in other vertebrates, including human, mouse and 
zebrafish. Sequence analysis indicated that isthmin contains a N-terminal signal 
peptide, a centrally localized TSR and a C-terminal AMOP domain. Proteins of the 
ISM family share a highly conserved C-terminal region (containing TSR and AMOP), 
while their N-terminal extension is more variable and no known protein domains have 
been identified in this region (Rossi, et al., 2004).  
During neuronal stage, Xenopus Ism (xIsm) is highly expressed in the isthmus 
organizer, the signaling center located at the midbrain-hindbrain boundary (MHB). 
Additional expression was detected in the paraxial mesoderm and neural folds in 
tailbud stage as well as in notochord and neuronal stage (Pera, et al., 2002). Moreover, 
xIsm is co-expressed with xFgf-8 at multiple sites including the MHB, notochord, 
neural plate and neural crest. The overlapping expression domains between ism and 
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fgf-8 in Xenopus indicates that there are part of a synexpression group that may be 
involved in the same biological process (Niehrs, et al., 1999). In zebrafish, isthmin 
expression could be upregulated by overexpression of Wnt8 or downregulated by 
Wnt/β-Catenin inhibitor, indicating its involvement in Wnt signaling regulated 
processes during embryonic development (Weidinger, et al., 2005).  
 
1.10 Thrombospondin and AMOP containing isthmin-like (TAIL) 1 
TAIL1, representing thrombospondin and AMOP containing isthmin-like 1, is a 
isthmin-related human gene. It is designated as TAIL1 because it encodes a 571-
amino-acid protein that contains a TSR in the center and AMOP domain at C-terminal, 
similar to isthmin. The human TAIL1 gene is located on chromosome 14q24.3 within 
the arrhythmogenic right ventricular dysplasia/cardiomyopathy, type 1 (ARVD1) 
critical region. Sequence analysis revealed that the N-terminal region contains a 
hydrophobic signal peptide and 17 putative glycosylation sites. In the central TSR 
domain region, two binding motifs were found: WSXW heparin binding motif and a 
CSGNCS CD36 binding motif. In the promoter region of TAIL1, several putative 
consensus binding sites for the transcription factors Sp1 and MZF-1 were identified 
(Rossi, et al., 2004). The function of Tail1 is also unknown. 
In human, TAIL1 was expressed in various tissues, showing multiple splice variants. 
It is highly expressed in placenta and expressed at moderate to low level in pancreas, 
heart, liver, lung, kidney, brain and skeletal muscle (Rossi, et al., 2004). The 
expression pattern of TAIL1 might be different from that of hISM because the 5’ 
regulatory region of TAIL1 is quite different from that of ISM’s (Rossi, et al., 2004).  
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Taken together, the promoter organization and protein domain combination suggest 
that TAIL1 is a Ism related gene, but most likely with distinct functions.  
 
1.11 Aim of this study 
Although many proteins have been identified to inhibit angiogenesis and clinical 
translation of angiogenesis inhibitors has been established as a promising alternative 
approach in anti-cancer therapy, the molecular mechanisms and signaling pathways 
that are involved in angiogenesis are still unclear in many aspects. It is also 
conceivable that many genes regulating angiogenesis in vivo have not been discovered.  
To better understand the molecular mechanisms of physiological as well as 
pathological angiogenesis, the aim of this study is to identify novel endogenous 
protein angiogenesis inhibitor. Mainly based on the presence of TSR and AMOP 
domain, the novel secreted protein ISM, was predicted to function as an angiogenesis 
inhibitor. To validate our hypothesis, the role of ISM in angiogenesis will be 
investigated using mouse and zebrafish models in the following aspects:  
1. Characterizing the role of ISM in in vitro and in vivo angiogenesis 
2. Determining the role of ISM in tumor angiogenesis 
3. Examining the role of ISM in embryonic angiogenesis 





Chapter Two: Materials and Methods 
In general, all experiments were repeated at least three times, with duplicates or 
triplicates with each experiment. All protocols for handling animals were compliant to 
the National University of Singapore IACUC guideline (IACUC No. is 078/08).  
2.1 Cell Culture 
2.1.1 Isolation of Human Umbilical Vein Endothelial Cells (HUVECs)      
The source of human umbilical vein endothelial cells (HUVECs) is human umbilical 
cord vein  (Nachman, et al., 2004). The fresh cord was isolated from the placenta cord 
and immersed into sterile bottle filled with sterile phosphate buffered saline buffer 
(PBS, 8 g/l NaCl, 0.2 g/l KCl, 1.44 g/l Na2HPO4, 0.24 g/l KH2PO4, pH7.4). The cell 
isolation performance is preferably carried out immediately; otherwise, the cord can 
be kept in 4°C for 24 h before cell isolation. Briefly, the cord was wiped with sterile 
sponge and 1-2cm section at both ends removed to make a straight clean cut. Adapters 
were inserted into vein at each end of the cord and secured tightly with silk thread. 
The vein was flushed with sterile PBS to drain out any blood present. Sterile 
collagenase (Sigma, USA) with 0.2% was infused into vein, and both ends of cord 
were clamped shut with haemostat when the whole surface of vein was covered with 
collagenase.  After 15 min incubation at room temperature (RT), loose the secure and 
collect the released ECs together collagenase solution into 50 ml tube.  The cord was 
flushed with 20ml sterile PBS once more and the effluent was collected into the same 
tube. Spin down the cell suspension at 1,500 rpm for 5 min at RT. Resuspend cell 
pellet in 5 ml culture medium and culture cells in T-25 culture flask (NUNC, 
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Denmark) pre-coated with 0.2% gelatine (Sigma, USA) at incubator (SANYO, Japan) 
with 37°C and 5% CO2.  Replace cell medium 3 h later with fresh medium and the 
cells were cultured normally.   
 
2.1.2 Culture of cell lines and primary cell  
For HUVECs, cells were cultured in tissue culture flasks (NUNC, Denmark) pre-
coated with 0.2% gelatin (Sigma, USA) in a humidified incubator with 5% CO2 at 
37oC. The culture medium used was CSC complete medium (Cell Systems, USA) 
supplemented with 50 μg/ml Gentamycin (Sigma, USA) and the medium was 
replaced every two days or less. When cells reach 80%-90% confluence for 
subculture, the medium was discarded and the adherent cell monolayer was gently 
washed with warm sterile PBS. Appropriate amounts of 0.25% trypsin-EDTA (Life 
Technologies, USA) was added to the cell monolayer until most of the cells became 
detached. Cells were neutralized in complete medium and centrifuged for 3 mins at 
1,500 rpm. Then the supernatant were removed and the cell pellet was resuspended in 
medium and divided into new tissue culture wares with a ratio of 1:2.  
For cell lines culture, all cells were obtained from the American Type Cell Culture 
Collection (ATCC).  HepG2 or B16 tumor cells and Swiss 3T3 or NIH 3T3 fibroblast 
cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Life 
technologies, USA) supplemented with 10% heat-inactivated Fetal Bovine Serum 
(FBS) (Life technologies, USA), 0.1 mM MEM Non-Essential Amino Acids Solution 
(Life technologies, USA), 1 mM MEM Sodium Pyruvate Solution (Life technologies, 
USA), 2 mM L-Glutamine (Life technologies, USA) and 1% Penicillin-Streptomycin 
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(Life technologies, USA). All cells were grown in a humidified incubator with 5% 
CO2 at 37oC and were maintained through subcultures at a ratio of 1:3. Subculturing 
of cells was preformed as the method described above. 
 
2.1.3 Preservation of HUVECs and tumor cell lines 
All cells were preserved in liquid nitrogen. To cryo-preserve cells, cells were 
trypsinized and pelleted as description above. The resuspended cells were aliquoted 
into 2 ml plastic cryogenic vial (IWAKI, Japan) and tissue culture grade dimethyl 
sulphoxide (DMSO) (Sigma, USA) was added to a final concentration of 10%. The 
cryovials were put into a Cryo 1°C Freezing Container (Nalgene labware, USA) 
overnight at -80°C and transferred and stored in -150°C freezer (SANYO, Japan) the 
next day.  
 
2.1.4 Quantification of cell number 
Cells were counted by using NucleoCounter (Chemometec, Denmark). Briefly, 
appropriate volumn of diluted cell suspension was mixed well with equal volume of 
Reagent A (lysis buffer) and Reagent B (stabilizing buffer). Approximately 50 μl of 
the sample mixture was loaded into the NucleoCassette (Chemometec, Denmark). The 
NucleoCassette was then analysed in the NucleoCounter instrument. The value 
indicating cell concentration of the mixture was shown and multiple 3X of the value 




2.2 DNA cloning techniques 
Five different plasmid constructs were generated. Four different constructs containing 
full-length ISM and three truncated ISM fragments used pET-M vector for protein 
expression in E. coli. One plasmid construct containing full-length ISM used 
pSecTag2B vector for protein overexpression in mammalian cells.  
 
2.2.1 Polymerase chain reaction (PCR) 
Standard PCR was performed in a 50 µl reaction using the Perkin Elmer DNA 
thermal cycler Model 480 and 9600 (Perkin Elmer, USA), Peltier Thermal Cycler 
PTC200 (MJ Research, USA). Each reaction included 5 µl of 10X PCR buffer (0.5 M 
KCl, 0.1 M Tris-HCl, pH8.8, 15 mM MgCl2, 1% Triton X-100), 1 µl of 5 mM dNTP, 
1 µl of 10 pmol sense primer, 1 µl of 10 pmol antisense primer, 0.2 µl of 5U/µl Taq 
polymerase and 1 µl template DNA. A typical PCR reaction cycle consists of the 
following steps: denaturation at 94°C for 5 min, followed by 35 cycles of <94°C for 
30 sec, annealing at the required temperature for 1 min or its variable depending on 
the product size and 72°C for 1-2 min and final extension at 72°C for 10 min. 
 
2.2.2 DNA isolation 
Plasmid DNA isolation was carried out using High-speed plasmid mini kit (Geneaid, 
USA). Briefly, E.coli cells containing desired plasmid were cultured in antibiotics-
supplemented LB broth, shaked and incubated at 37°C, 250 rpm overnight. The next 
day, bacterial culture was transferred to 1.5 ml tube and spun down. PD1 buffer was 
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added to resuspend the bacterial pellet and PD2 buffer was added and mixed gently. 
Subsequently, PD3 buffer was added and mixed immediately. The mixture was 
transferred to PD Column and followed by centriguation, washing with W1 buffer and 
washing buffer. After spinning down the washing buffer, water was added and DNA 
was finally eluted by centrifugation.     
Isolation of DNA fragments (100bp-10kb) from agarose gel was performed using 
QIAquick Gel Extraction Kit (Qiagen, USA) according to manufacturer’s instructions. 
Briefly, the gel slide containing the DNA band of interest was cut from the gel and 
melted at 50°C in Buffer QG for 10 min. When the gel was completely melted, 1 
volume of isopropanel was added to mix. The column was then centrifuged at 14,000 
rpm for 1 min, washed by adding 0.75 ml of Buffer PE, and spun again. Sterile water 
of 20-50 µl was added to the top of the column and incubated at RT for 1 min. DNA 
fragment was then eluted into a 1.5-ml centrifuge tube by centrifugation at 14,000 
rpm for 1 min. 
 
2.2.3 DNA gel electrophoresis 
Typical DNA electrophoresis was performed in 1% agarose gel. The agarose powder 
was dissolved in 1XTAE (0.04 M Trisacetate; 0.001 M EDTA) by heating. After the 
solution was cooled to 60°C, a few drops of crystal violet were added to the run buffer 
to get an approximate concentration of 0.5 µg/ml. A voltage of 5 V/cm was applied 




2.2.4 DNA ligation 
DNA ligation reaction was carried out typically in 20 µl of volume, containing 2 µl of 
10X ligation buffer (0.3 M Tris-HCl, pH 7.8; 0.1 M MgCl2; 0.1 M DTT and 5 mM 
ATP), insert DNA (ISM, ISM-N, ISM-C or ISM-TSR), vector DNA (pET-M or 
pSecTag2B) and 1 unit T4 DNA ligase. The molar ratio of insert to vector DNA was 
between 3:1. Ligation reaction was incubated at 4°C for overnight.  
 
2.2.5 Restriction endonuclease digestion of plasmid DNA  
Restriction enzyme digestion was employed to screen recombinant clones, isolate 
specific DNA fragments and linearize the plasmid DNA for in vitro transcription. All 
the restriction enzymes (xhoΙ and EcoR I in pET-M, xhoI and BaHI in pSecTag2B) 
used in the study were purchased from New England Biolabs or Promega (USA). 
Digestions were performed at 37°C for overnight. Normally 2-4 units of enzyme were 
used to digest 1µg of plasmid DNA. Digested product can be purified by running 
agarose gel and gel extraction.  
 
2.2.6 Transformation 
Plasmid (pET-M-ISM, pET-M-ISM-N, pET-M-ISM-C or pET-M-ISM-TSR) was 
added into 50 µl of E.coli DH5α or E.coli BLR (DE3) competent cells. This 
transformation mixture was then incubated on ice for 30 mins. The mixture was 
heated at 42°C for 60 sec and cooled immediately on ice for 2 mins. LB of 900 µl 
medium was added to the mixture and incubated with shaking (200 rpm) at 37°C for 1 
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h. After incubation, 1/10 of the transformation reaction mixture was spread onto LB 
plate supplemented with 50 μg/ml penicillin and the plate was incubated at 37°C 
overnight. 
2.2.7 DNA sequence analysis 
Double-stranded template DNA was amplified using PCR with dye-labeled 
dideoxynucleotides using ABI PRISM™ terminator cycle sequencing ready reaction 
kit (Applied Biosystems Inc., USA) following the manufacturer’s instruction with 
modification. Half reaction was prepared containing 4 μl of terminator ready reaction 
mix (Applied Biosystems Inc., USA), 1.6 pmol of each sequencing primer and 100-
250 ng of plasmid. 
The program for sequencing reaction was 30 sec at 96°C, 15 sec at 50°C and 4 min at 
60°C for 25 cycles on the thermocycler. After the completion of cycles, the reaction 
mixtures were removed immediately to 4°C until ready to purify. The extension 
products were purified using the ethanol precipitation method. Briefly, the extension 
products were transferred to 1.5 ml tubes. 10 μl of H2O and 30 μl non-denatured pure 
ethanol was added to each tube. The solution was thoroughly mixed by vortexing 
before leaving for incubation at RT for 10 mins. This was followed by centrifuging at 
14,000 g for 20 min at 4°C and the supernatant was removed completely. The pellet 
was washed by adding 250 μl of 70% ethanol. The tubes were centrifuged at 14,000 g 
for 10 min before being dried. Prior to sequencing, 4 μl of automatic sequencing 
loading buffer was added to the DNA pellet. The sample was denatured by heating to 
90°C for 2 min and immediately chilled on ice. The mix was then used for sequencing 
on a 377 ABI PRISM automated DNA sequencer (Applied Biosystems Inc., USA).  
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2.2.8 Vectors used 
pGEM-T Easy vectors: The pGEM®-T Easy Vector System is convenient system 
for the cloning of PCR products (Fig. 2.1). The vector is prepared by cutting 
Promega’s pGEM®-T Easy Vector with EcoR V and adding a 3´ terminal thymidine 
to both ends. These single 3´-T overhangs at the insertion site greatly improve the 
efficiency of ligation of a PCR product into the plasmids by preventing 
recircularization of the vector and providing a compatible overhang for PCR products 
generated by certain thermostable polymerases. 
pET-M vector: The pET-32 series is designed for cloning and high-level expression 
of peptide sequences (Fig. 2.2). The pET-M expression vector is a derivative of the 
pET-32a vector with the thrombin cleavage site and Trx-tag removed. This vector 
allows the expression of the recombinant protein as N- and C- terminal His-tag fusion 
proteins.  
pSecTag2A, B, and C vector: the pSecTag2A, B, and C expression vector is 
designed for high-level stable and transient expression in mammalian hosts (Fig. 2.3). 
Proteins expressed from pSecTag2A, B, and C are fused at the N-terminus to the 
murine Ig κ-chain leader sequence for protein secretion and at the C-terminus to a 
peptide containing c-myc epitope and six tandem histidine residues for detection and 
purification. The Zeocin™ resistance gene allows selection in both E.coli and 





Fig. 2.1 pGEM®-T  easy vector map. (Reproduced from www.promega.com) 
 




 Fig. 2.3 pSecTag2A, B, C vector map. (Reproduced from www.invitrogen.com) 
 
2.3 RNA isolation  
Total RNA was isolated from zebrafish embryos, zebrafish and mouse tissues, culture 
cells and tumor tissues using Trizol solution (Invitrogen, USA) following the 
manufacturer’s instruction. All solutions used in RNA works were treated with 0.1% 
DEPC (Sigma, USA) and autoclaved to prevent RNA degradation.  
 
2.3.1 RNA extraction from tissues 
For zebrafish embryos, samples were washed with miliQ water and collected to 1.5 
ml RNase-free eppendorf tube. Trizol reagent (200 μl) was added to 50-100 embryos 
and embryos were homogenized using pestle. After homogenization, Trizol reagent 
was added to embryos till the total volume reached 1 ml. The homogenized samples 





mixed vigorously for 15 sec and incubated at RT for 5 min. After incubation, samples 
were spin at 12,000 x g for 10 min at 4°C, and the aqueous phase were transferred to a 
fresh tube containing 0.5 ml of isopropanol. Samples were incubated at RT for 30 min 
and spin at 12, 000 x g for 10 min at 4°C. Following centrifugation, RNA pellet was 
washed with 1 ml of 75% ethanol and air dried. After drying, RNA pellet was 
dissolved in miliQ water and stored at -80°C in aliquots.     
For adult zebrafish, 3-week old mouse tissues and tumor nodules, tissues were 
dissected out from connecting tissues completely. These tissues were quickly rinsed in 
ice-cold 0.9% NaCl before cutting into small pieces and flash freezing in liquid 
nitrogen and stored at -80°C. Before isolating RNA, tissues were grinded well in 
liquid nitrogen mixed with dry ice in a motar and pestle. Grinded samples were 
transferred to tubes and appropriate amount of Trizol reagent (1 ml per 100 mg tissue) 
was added. RNA extraction was then preceded using the method described above.  
 
2.3.2 RNA extraction from culture cells 
Cells grown for RNA extraction were cultured on flasks. Before RNA extraction, the 
medium was aspirated and the monolayer was rinsed with PBS. Ice-cold PBS (1ml) 
was then added to the monolayer and the cells were scraped using a disposable 
scraper and collected to tubes. The cells were spin by centrifugation at 12,000 x g for 
5 min at 4°C. The pellet was then resuspended thoroughly in 1 ml Trizol reagent and 




2.4 Reverse transcriptase-PCR 
The one-tube reverse transcription-PCR was carried out for the amplification of a 
specific target RNA using QIAGEN® one-step RT-PCR kit (Qiagen, USA) according 
to the manufacture’ instructions.  Briefly, 5 μl of 5X RT-PCR buffer, 1  μl of dNTP 
mix (10 mM each dNTP), 1.5 μl of each primer (10 μM), 1 μl of RT-PCR enzyme 
mix, 0.5 μl RNA template (1 μg/μl) and ERPC-treated H2O topped up to 25 μl total 
volume was mixed and reacted using the thermal cycler conditions as following: 30 
min at 50°C for 1 cycle, 15 min at 95°C for 1 cycle, 30 to 40 cycles of 30 sec at 94°C, 
45 sec at primer specific annealing temperature and 1 min at 72°C. This was followed 
by a 10 min extension at 72°C.  
In order to quantitiatively compare gene expression among different groups, cycle 
numbers of all RT-PCR reactions were performed between 20 to 28 cycles that were 
the exponential amplification phase to enable meaningful and realistic comparison of 
gene expression levels. The RT-PCR products were analyzed by DNA gel 
electrophoresis.  
 
2.5 Real-time RT-PCR 
Real-time RT-PCR was done by using QuantiTectTM SYBR® Gree RT-PCR kit 
(Qiagen, USA). Briefly, one half-reaction mix was prepared by adding 12.5 μl of 2X 
QuantiTect SYBR Green RT-PCR Master Mix (DNA polymerase, SYBR Green I dye, 
dNTP, ROX, MgCl2 and RT-PCR buffer), 1.25 μl of each primer, 0.25 μl of 
QuantiTect RT Mix containing reverse transcriptase, 0.5 μl RNA template (1 μg/μl) 
and RNase-free water. The master mix was mixed thoroughly and spun down briefly; 
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this followed by transferring to 0.2 ml low-profile while strip tubes (MJ Research, 
USA) and covered with optical flat strip caps (MJ Research, USA). The reaction was 
carried out in a DNA Engine Opticon 2 Continuous Florescence Detection System 
(MJ Research, USA) using cycling program outlined below; 30 min in 50°C and 15 
min in 95°C for 1 cycle; 15 sec in 94°C, 30 sec in 60°C, 30 sec at 72°C for 40 cycles 
and the plate read was taken after each 72°C extension; this was followed by 10 min 
at 72°C for final extension. NTCs were set up and β-actin was chosen as internal 
control.  
To avoid nonspecific binding of SYBR Green to any double strand DNA or primer 
dimmers, primers were carefully designed to a give a product around 200 bp base 
pairs and the disassociation analysis was performed for identification of the PCR 
product after completion of the amplification. Experimental reports including 
amplification analysis, melting curve analysis and threshold cycle number were 
provided automatically.   
 
2.6 Whole mount in situ hybridization on zebrafish embryos 
2.6.1 Linearization of plasmid DNA 
Plasmid DNA (10 µg) was linearized at the 5’ end of the cDNA insert by Ncol 
enzyme at 37°C for overnight. The digested mixture was loaded on the gel to separate 
and the desired product was then purified by Gel extraction Kit (Qiagen, USA) 




2.6.2 Probe synthesis and precipitation 
Linearized DNA of 1 µg was used to synthesize the DIG/Fluorescein labeled probe. 
The reaction was performed at 37°C for 4 h in a total volume of 20 µl containing 2 µl 
of 10X transcription buffer (Roche), 2 µl of DIG/Fluorescein-NTP mix [10mM ATP, 
10 mM CTP, 10 mM GTP, 6.5 mM UTP and 3.5 mM DIG/Fluorescein-UTP (Roche)], 
0.5 µl of RNase inhibitor (40U/µl) (Roche) and 2 µl of SP6 RNA polymerase (50 
U/µl) (Roche). Following the reaction, 1 µl of 0.5 M EDTA (pH 8.0) was used to stop 
the restriction digestion. Subsequently, 2.5 µl of 4 M LiCl and 75 µl of cold pure 
ethanol were added to precipitate the RNA. After washing with 75% ethanol, the 
RNA probe was resuspended in 50 µl of DEPC treated water. 
 
2.6.3 Quantification of labeled probe 
The labeled probe was quantified visually by Gel Electrophoresis and quantitated 
using spectrophotometric analysis at OD260/280 nm. 
 
2.6.4 Preparation of zebrafish embryos 
All zebrafish embryos used in this study were staged according to the Zebrafish Book 
and indicated as hours post fertilization (hpf) at 28.5°C. Staged embryos were fixed in 
4% paraformaldehyde (PFA)/PBS for 24 h at 4°C. Embryos younger than 16 hpf were 
fixed before dechorionization and the chorion was removed afterwards. Embryos 
older than 16 hpf were dechorionated before fixation. Older embryos with tails were 
hibernated on ice before fixation to prevent the curling of tails. After fixation, the 
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embryos were washed in PBST (0.1% Tween20 in PBS) twice for 1 minute each, 
followed by four times for 20 minutes each on a nutator (ClAY ADAMS® Brand, 
USA) at RT. After changing PBST to methanol, the embryos were kept at -20°C for 
several months. Before they were used for in situ hybridization, the embryos were 
rehydrated in PBS in two or three times by changing half volume of solution each 
time. 
 
2.6.5 Proteinase K treatment 
This step is especially necessary for embryos older than 14 somites (>16hpf). 
Embryos were treated with 10 µg/ml of proteinase K in PBST at RT. The time of 
exposure depended upon embryos age as the followings: 16-24 hpf 3-4 min, 24-32 hpf 
5-6 min, 32-50 hpf 10-20 min. To stop the reaction, the proteinase K solution was 
removed completely, and the embryos were fixed again in 4% PFA for 20 min at RT. 
Embryos were first washed in PBST twice for 1 min and then 4-5 times for 15-20 min 
each. 
 
2.6.6 Prehybridization  
Prehybridization was performed by changing half the volume of washing solution 
with hybridization buffer (50% formamide, 5X SSC, 50 µg/ml Heparine, 500 µg/ml 
tRNA, 0.1% Tween20, pH6.0) and incubated at RT for 1 h. This solution was 





DIG-labelled probe of 1 μl was diluted in 200µl of hybridization buffer. The probe 
was denatured by heating at 80°C for 5 min followed by 2 min of ice bath. Embryos 
were selected and placed in the tube and the original buffer was replaced with the 
probe solutions. Hybridization was performed at 68°C in a circulating water bath 
overnight with shaking. 
 
2.6.8 Post-hybridization 
The next day, the probe solution was removed and replaced with pre-warmed 100% 
hybridization wash solution (hybridization buffer without tRNA and heparine) for 15 
min. The embryos were then washed in the following order of wash solutions: 75% 
hybridization wash solution mixed with 25% 2X SSCT (SSC with 0.1% Tween20); 
50% hybridization wash solution mixed with 50% 2X SSCT; 25% hybridization wash 
solution mixed with 75% 2X SSCT for 15-20 min each. This was followed by 2X 
SSCT wash twice for 30-45 min each and 0.2X SSCT wash twice for 30-45 min each. 
Subsequently, the embryos were washed twice with PBST (PBS with 0.1% Tween20) 
at RT for 5 min each. 
 
2.6.9 Preparation of pre-absorbed DIG 
Commercial DIG-AP antibodies (Boehringer) should be preincubated with biological 
tissues, preferably of the same origin as the sample used for hybridization, in order to 
decrease the staining background and increase signal-to-noise ratio. Anti-DIG and 
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Fluorescein-AP was diluted to 1:500 and 1:50 in Maleic Acid buffer (0.15M Maleic 
acid, 0.1M Nacl; pH 7.5)/10% FCS (Fetal calf serum, Gibco BRL) respectively and 
incubated with 50 zebrafish embryos of any stages on a nutator at 4°C overnight. 
After that, the antibodies solution was transferred to a new tube and diluted to 1:5000 
and 1:500 with Maleic Acid buffer/10% FCS. 10µl of 0.5M EDTA (pH8.0) and 5µl of 
10% sodium azide were added to prevent bacterial growth. The pre-absorbed antibody 
was stored at 4°C and can be reused. 
 
2.6.10 Incubation with pre-absorbed antibodies 
The embryos after hybridization and post-hybridization washes were incubated in 
Maleic Acid buffer/10% FCS for 2 h at room temperature to block non-specific 
binding sites for antibody. After removing the blocking solution, the embryos were 
incubated with pre-absorbed anti-DIG-AP antibody at 4°C for overnight. 
 
2.6.11 Color development 
Embryos were washed in PBST on a nutator at RT followed by washing in buffer 9.5 
(0.1 M Tris-HCl, pH9.5, 50 mM MgCl2, 10 mM NaCl and 0.1% Tween20) once for 
30 sec and twice for 10 min each. NBT of 4.5 µl (Nitroblue tetrazolium, Boehringer 
Mannheim, 50mg/ml in 70% dimethyl formamide) and 3.5 µl of BCIP (5-bromo, 4-
chloro, 3-indodyl phosphate salt, Boehringer Mannheim, Germany; 50mg/ml in H2O) 
was added into 1 ml of buffer to embryos and mixed thoroughly. Embryos were 
incubated with staining solution in dark at RT until the staining can be observed under 
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a Leica MZ12 microscope (Leica, Germany). Embryos were then washed in PBST 
and preserved in 4% PFA at 4°C. 
 
2.6 12 Mounting and photography 
Selected embryos were washed with PBST and transferred to 50% glycerol, 
equilibrated at RT for several hours. For whole mounts, a single chamber was made 
by placing stacks of 3-5 small cover glasses on both side of a 25.4X76.2 mm 
microscope slide. Small cover glasses in the stacks will be perfectly solid 1 h after 
placing a drop of Permount between them. Selected embryo was transferred to the 
chamber in a small drop of 50% glycerol and oriented by a needle. A 22X44 mm 
cover glass with a small drop of the same buffer was superimposed onto the embryo. 
The orientation of the embryo can be adjusted by gently moving the cover glass. For 
flat specimen, the yolk of selected embryo was removed completely by needles. The 
embryo without yolk was then placed onto a slide with a small drop of 50% glycerol 
and adjusted to a proper orientation by removing excess of liquid and with the help of 
needles. A small fragment of cover glass (a bit larger than the specimen) was covered 
onto the embryo. Care was taken to avoid bubbles and a drop of 50% glycerol was 
added to fill the space under the cover glass. This specimen was sealed with nail 
polish along the edge of the cover glass to prevent it from drying. Photographs were 
taken using a camera mounted to an Olympus AX-70 microscope (Olympus, Japan). 





2.7 Protein isolation 
Proteins were isolated from cytoplasm, cell membrane, conditioned medium or tumor 
tissues to serve different experimental purposes. Extraction of cell cytoplasm proteins 
after ISM treatment was to study the molecular mechanism of the action of ISM. 
Extraction of cell membrane proteins was to identify ISM receptor. Concentration of 
proteins from conditioned medium was to detect ISM overexpression in stable cell 
lines. Extraction of proteins from tumor tissues was to study the molecular 
mechanism of ISM in tumor angiogenesis.  
 
2.7.1 Protein isolation from cell lysate 
Culture cells were harvested by scrapping with a disposable scrapper. Briefly, the 
monolayer cells were rinsed with PBS, and 1 ml of M-PER® Mammalian Protein 
Extraction Reagent (Pierce, USA) with EDTA-free protease inhibitor cocktail (Roche, 
Germany) was added, followed by harvesting the cells by scrapping. Cells were 
transferred to tube and incubated on ice for 30 min. The supernatant was transferred 
to a clean tube after centrifugation at 13,000 g at 4°C and stored at -80°C until used. 
Protein concentration was determined before storage.  
For FAK phosphorylation analysis, cells were cultured on 6-well plate to 90% 
confluence. Cells were starved for 2-4 h with 2% FBS/CSC medium and then 
incubated with 15 ng/ml of VEGF, different concentrations of ISM in the presence of 
VEGF for 30 min. For active-Caspase  3 detection, the treatment period is 6-8 h. After 
treatment, total cytoplamisc proteins were isolated using the method above.  
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2.7.2 Protein isolation from tumor tissues 
Snap frozen tumor tissues were weighted and every 1 gram tumor tissue were 
homogenized using a polytron homogenizer in 5 ml ice-cold RIRA buffer (50 mM 
Tris.Cl pH 7.6, 150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS) with 
0.2 mM sodium orthovanadate, 2 mM PMSF, 5 μg.ml Leupeptin, 5 μg/ml pepstatin 
and 20 μg/ml aprotinin on ice. The mixture was incubated at 4°C for 1 h using a 
culture tube rotator (Stuart Scientific, UK). Then the lysate was cleared by 
centrifugation at 17,000 g for 30 min at 4°C. The supernatant was collected and stored 
at -80°C. 
 
2.7.3 Collection of conditioned medium 
B16 stable cells were cultured in DMEM medium without serum but containing 
approximate concentration of zeocin for 2 days. The conditioned media(CM) were 
then collected and filtered through a 0.45 μm filter (Millipore, USA) and further 
concentrated with Centricon® Plus-20 (Millipore, USA) following the manufacturer’s 
recommendation. Briefly, CM were transferred into the sample filter cup and sealed 
with supplied cap. The filter unit was centrifuged for 30 min at 3000 g at 4°C in a 
swinging-bucket rotor (Beckman, USA). After the centrifugation step, the 
concentrated sample was transferred to a suitable container and the sample filter cup 
was inverted and inserted into a retentate cup and spun for 2 min at 1000 g to collect 





2.8 Expression and purification of recombinant ISM proteins 
2.8.1 IPTG induction and recombinant protein expression 
The recombinant ISM proteins were induced by isopropyl-beta-D-thiogalactoside 
(IPTG). Briefly, inoculate 5 ml LB medium containing 25 μg/ml ampicilin and grow 
the cultures overnight at 37°C with shaking. The next day, inoculate 1L of pre-
warmed media with 2 ml of the overnight cultures and grow at 37°C until the OD600 is 
0.4-0.6. Then protein expression was induced by adding IPTG to a final concentration 
of 1mM. After an additional 6 h medium culturing, bacterial were harvested by 
centrifugation at 4000x g for 20min.   
 
2.8.2 Protein purification 
The bacterial pellets were resuspended in 10 ml lysis buffer and sonicated with 10 s 
pause at 200-300 W. Lysate were kept on ice at all times. After sonication, lysate 
were spin down and pellets were resuspended in 10 ml bacterial pellet wash buffer to 
remove endotoxin. After three times wash, lysate was spin down and pellet was 
dissolved in 10 ml extraction buffer. Supernatant was applied in Ni2+ columns 
(QIAGEN, USA) and the column was washed with wash buffer. Proteins were then 
eluted by elution buffer and further purified by RP-HPLC on a phenomenex Jupiter 
300 Å 5 μ C18 semipreparative column. The purity of protein was examined by 





2.8.3 Determination of protein concentration 
Protein concentration was measured using Bradford method (Bradford, 1976).  Four 
dilutions of a protein standard were prepared using BSA. BSA was added to dye 
reagent to generate the linear range concentration from 0.2 to 0.8 mg/ml. Protein 
samples were added to dye reagent and incubated at RT for 5 min. Protein 
concentration was measured at absorbance 595 nm using 96-well plate spectrometer 
reader.  
 
2.8.4 Detection of protein endotoxin 
Endotoxin of recombinant proteins was measured using E-toxate detection kit (Sigma, 
USA) according to the manufacture’s instructions. Standard endotoxin was prepared 
by reconstituting endotoxin with LAL reagent water to a concentration of from 0.015 
EU/ml to 4 EU/ml. E-toxate working solutions were added to endotoxin standard or 
purified proteins in endotoxin-free glass tube. The samples were mixed gently and 
incubated at 37°C for exactly 1 h. The glass tubes were inverted slowly for gel 
observation. A positive result is characterized by the formation of a firm gel that 








2.9 In vitro cell assays 
2.9.1 Acute cytotoxicity assay 
Cell acute cytotoxicity was measured with EZ4U nonradioactive cell proliferation and 
cytotoxicity assay kit (Biomedica, Austria) according to the manufacturer’s 
instructions. Cells (3000) were seeded in 96-well plate and cultured with 200 μl 
complete medium for overnight at tissue culture incubator. The next day, the complete 
medium was removed and incomplete medium with different concentrations of ISM 
proteins were added to the wells. After 4 h of incubation, 25 μl of the dye substrate 
was added and incubated at 37°C for 2h. Optical density was measured by the 
microplate spectrophotometer at absorbance wavelength 450 nm.   
 
2.9.2 EC In vitro capillary network formation 
Capillary network formation was preformed by using In Vitro Angiogenesis Assay 
Kit (Chemicon, USA). Thaw ECMatrix solution and the dilution buffer on ice. Add 
100 μl of 10X dilution buffer to 900 μl of ECMatrix solution in a sterile microfuge 
tube. Mix well slowly, transfer 50 μl to each well of a 96-well plate and incubate at 
370 C for one hour to allow the matrix solution to solidify. ECs (20000) were starved 
with CSC incomplete medium (Cell System, USA) containing 2% FBS, then 
harvested and suspended in 2% FBS media containing different concentrations of 
ISM proteins for 30 min. Cell suspension was added onto the surface of the 
polymerized ECmatrix and incubate at 37°C for 6-8 hours in a tissue-culture incubator. 
Capillary network structures were documented using an inverted microscope (Zeiss 
Axiovert 200). Tube-like structure length was quantified by measuring the length of 
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branches from representative fields using NIH Image J 1.32 software. For time-course 
analysis, ISM proteins were added into 2% FBS media at time points of 0, 2, 4 h after 
seeding ECs onto polymerized ECmatrix.  
 
2.9.3 EC migration assay 
Migration assay was done using Modified Boyden Chambers containing polyethylene 
membranes (8.0 μm pore size; BD Falcon, USA). The inserts were placed into BD 
Falcon cell culture insert companion 24 well plates (Becton Dickinson, USA) and 
coated with 0.2% gelatine solution. ECs were starved for 4h in CSC incomplete 
medium containing 2% FBS. VEGF at 15 ng/ml (R&D Systems, USA) with CSC 
incomplete medium supplemented with 2% FBS were placed on the lower chamber. 
ISM proteins at concentrations of 100 nM, 500 nM and 1 μM with 20000 cells were 
seeded on gelatine-coated cell culture insert. After 8 h incubation, cells on the upper 
surface of the insert were removed with a cotton swab. Migrated cells on the lower 
surface of inserts were fixed, and stained with Giemsa (Sigma, USA). The migrated 
cells were counted and quantified using light microscopy. Similar experiments were 
also performed in the presence of 15 ng/ml bFGF or 10% FBS.  
 
2.9.4 EC attachment and spreading assay 
96-well plate was coated with 0.2% gelatine, 50 ug/ml fibronectin (Sigma, USA) or 
250X diluted Matrigel for 2h at 370 C. ECs were pre-incubated with different 
concentrations of ISMs for 30 min. The treated cells were seeded onto the plate for 
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15min, 30min, 1h and 2h at 370 C. Attached cells were then fixed and stained with 
Giema (Sigma, USA). The number of cells attached was counted under light 
microscopy.  
 
2.9.5 EC proliferation assay 
Cell proliferation was evaluated by BrdU incorporation method. ECs (20000 per well) 
were cultured overnight in a coated 96-well plate in CSC complete medium at 370 C. 
Cells were starved the following day for 3 h in CSC basal medium and ISM proteins 
were then added to the medium together with 15 ng/ml VEGF. After 24 h of 
incubation, EC proliferation was determined using BrdU cell proliferation kit 
(Chemicon, USA) according to manufacture’s instructions. BrdU reagent was added 
into the culture media and incubated for 2 h. ECs were then fixed with fixation 
solution for 30 min at RT. After three times of PBS wash, anti-BrdU monoclonal 
antibody was added and incubated with the samples for 1 h at RT. Secondary 
antibody was incubated for 30 min and then TMB Peroxidase substrate was added. 
The reaction was stopped by adding the acid stop solution and read the plate using a 
spectrophotometer microplate reader set at wavelength of 450 nm.  
For non-ECs (Swiss 3T3, NIH 3T3, B16, or HepG2), 10000 cells were cultured 
overnight in 96-well plate in DMEM supplemented with 10% FBS at 370 C. Cells 
were then starved for 24 h with DMEM. Subsequently, ISM was added to culture 
medium with or without 10% FBS. After additional 24 h incubation, cell proliferation 
was determined using the same method described above.  
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For stable cell lines, the growth kinetics of the selected stable lines was examined 
after confirmation of the stably expression of the transgenes. Cells were grown in 
tissue culture flasks in complete selection medium. After confluence, the cells were 
trypsinized, resuspended, counted and plated into 6-well plate. Each clone was plated 
at a density of 20000 cells per well in 2 ml culture medium containing 400 μg/ml 
zeocin (Invitrogen, USA). Two wells for each clone were counted every day. The 
media were replaced every 2 days throughout the experimental period. The growth 
kinetics was monitored for 5 consecutive days.  
 
2.9.6 EC apoptosis assay 
Apoptosis was determined by measuring cytosolic oligonucleosome-bound DNA 
using a Cell Death ELISA kit (Roche, USA). 300000 ECs per well were cultured in 
0.2% gelatine-coated 6-well plate in CSC complete medium overnight at 37°C. Cells 
were then starved with 2% FBS medium. ISM proteins (100 nM to 1 μM), 15 ng/ml 
VEGF and 10 μM z-VAD-fmk (Calbiochem Inc. UK) were added to the culture 
medium and incubated for 24 h before cell harvesting.  Spin down the cells at 200X g 
for 5 min and resuspended the cell pellet with 500 incubation buffer and incubate for 
30 min at RT. Spin down the lysate at 20000 X g for 10 min and transfer the 
supernatant to anti-human histone antibody coated plate. After 90 min incubation, 
removed the solution, added secondary anti-DNA antibody coupled to peroxidise and 
incubated for 90 min. Substrate was then added and the readings was measured at 
wavelength 405 nm.  
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For non-ECs cells (Swiss 3T3, NIH 3T3, B16 or HepG2 cells), 200000 cells per well 
were cultured in 6-well plate in DMEM supplemented with 10% FBS at 37°C 
overnight. Cells then starved in DMEM for 24 h. Subsequently, ISM were added to 
the culture medium and incubated for an additional 24 h prior to apoptosis detection.  
For stable cell lines, 200000 cells per well were seeded and cultured in 6-well plate in 
complete selection medium. The following days, cells were harvested for apoptosis 
detection using the same method descried above.  
 
2.9.7 Binding assay 
96-well plate was coated with ISM proteins at concentrations of 100 nM, 500 nM and 
1 μM at 37°C for 2 h. Excess ISM proteins then were removed and the wells were 
blocked with 3% BSA for 2h. Cells were seeded on the wells and incubated for 2 h at 
37°C. The attached cells were photographed under light microscopy.  
 
2.10 Western Blotting 
Western blotting was used for desired protein detection. Crude total protein samples 
are prepared by the methods described in Protein Isolation chapter. Different normal 






2.10.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
The SDS-PAGE gel was carried out using a Mini-PROTEAN 3 Electrophoresis 
System (Bio-rad, USA). The gels were prepared dependent on different gel 
concentrations in order to detect proteins of various molecular weights. Briefly, 
separating gels were prepared by mixing appropriate amount of 40% 
acrylamide/bisacrylamid solution (37.5:1, acrylamide/bis; Bio-rad, USA) with 2.5 ml 
of 1.5M Tris.Cl (pH 8.8), 100 μl of 10% SDS, 100 μl of 10% fresh ammonium 
persulfate (APS) (Bio-rad, USA) and H2O to a total volumn of 10 ml. The volume can 
be scaled according. 5 μl of TEMED (Bio-rad, USA) was added just prior to pouring 
gel. 100% ethanol was covered on top of the separating gel. After polymerization, 
overlay was decanted and a 5% stacking gel was poured. 5 ml of 4% stacking gel was 
prepared by mixing 0.5 ml of 40% acrylamide/bisacrylamid solution with 0.5 ml 1M 
Tris.Cl (pH 6.8), 50 μl of 10% SDS, 50 μl of 10% fresh APS, 5 μl TEMED and H2O. 
Comb was inserted correctly and allowed to ploymerize completely before running.  
The protein samples were mixed with 1x loading buffer (62.5 mM Tris.Cl pH6.8, 
10% glycerol, 2% SDS, 0.05% bromophenol blue), and 100 mM dithiothreitol (DTT) 
(Sigma, USA) was added just before boiling in 100°C heat blocker for 5 min. Samples 
were then loaded and the gel was run under constant 60 volts till the dye reached the 
resolving gel and thereafter at 100 V till satisfactory protein separation was observed. 
Dual color Procision Plus protein standards (Bio-rad, USA) was run as a protein 





2.10.2 Gel transfer 
The separated proteins were electrophorectically transferred onto Hybond-C Extra 
nitrocellulose membrane (Amershan-Pharmacia, UK). The polyacrylamide gel was 
rinsed in water, placed in-between layers of Whatman paper and membrane of the 
same size of the gel, inserted into the plastic holder with spone filters soaked in 
transfer buffer (0.3% Tris, 1.45% glycine and 20% methanol). The air bubbles were 
removed by rolling with a glass pipet. Membrane was facing the anode. The transfer 
was performed in transfer buffer at 250-400 mA for 1 h at 4°C. The blotted membrane 
was marked and washed with 1x Tris-buffered saline (TBS) (20mM Tris-Cl pH 7.4, 
150 mM NaCl) buffer and stored at 4°C if not used immediately.  
 
2.10.3 Immunoprobing and detection 
The immunoprobing was carried out following the standard protocol. Briefly, the 
membrane was blocked with 3% BSA in 0.1% TBST (0.1% Tween-20 in 1 x TBST) 
for 2 h at RT. After blocking, Membrane was then incubated with 1/500 diluted 
mouse anti-His (C-Term) antibody (Invitrogen, USA), 1/1000 with mouse anti-
phospho-FAK (Y397) (Chemicon, USA), 1/500 diluted anti-human Caspase  3 Active 
antibody (R&D Systems, USA), 1/1000 diulted PCNA(FL-261) antibody (Santa Cruz, 
USA), 1/100 diluted rabbit anti-ISM antibody ( Biogenes GmbH, Germany), 1/500 
rabbit anti-mouse VEGF (R&D Systems, USA) in 3% BSA in 0.1% TBST, 1/1000 
mouse anti-human β1 integrin antibody (Chemicon, USA), 1/1000 mouse anti-human 
β3 integrin antibody (Chemicon, USA) and 1/1000 rabbit anti-β5 integrin antibody 
(Chemicon, USA) overnight at 4°C. The next day, after washing three times with 
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TBST for 10 min each, the membrane was incubated with corresponding 1/2000 
diluted anti-mouse or anti-rabbit IgG HRP-conjugated secondary antibody (Sigma, 
USA) in 0.1% TBST for 1.5 h at RT. The membrane was then washed for three times 
as above before incubating with the SuperSignal West Pico Substrate solution (Pierce, 
USA) by mixing equal volumes of the two reagents for 3 min and exposed to 
Hyperfilm X-ray films (Kodak, USA) at various desired time lengths in the dark room.  
 
2.10.4 Stripping and re-probe 
The membrane was stripped after chemilumiescent detection for reprobing with other 
antibodies. Briefly, the membrane was washed in TBST for 5 min and incubated in 
Restore Western Blot Stripping Buffer (Pierce, USA) at 37°C for 10 min. The 
membrane was washed in TBST again and ready for immunoprobing with the 
methods described above.   
 
2.11 Immunocytochemistry  
5000 ECs were cultured on 96-well-plate in complete medium for overnight. The next 
day, they were starved for 3h and incubated with 10ng/ml VEGF, different 
concentrations of ISM in the presence of VEGF in 2%FBS/CSC medium for 1h. 
Following three washes with PBS, the cells were fixed with 4% formaldehyde and 
blocked with 3% BSA/PBS. After blocking, cells were incubated with TRITC-
conjugated phalloidin (Molecular Probes, USA) for 1h at RT and anti-paxillin 
antibody (1:250 dilution) (Upstate Technology, USA) for overnight at 4°C. After 
three times of PBS washing, cells were incubated with 500 diluted secondary FITC-
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y was ready for IP.  
conjugated anti-mouse IgG (Santa Cruz, USA) for paxillin detection. The nuclei were 
stained blue with Dapi solution (Molecular Probes, USA) at RT for 30 min. All 
images were acquired using Zeiss Axiovert-200 fluorescent microscope.    
 
2.12 Immunoprecipitation(IP) 
2.12.1 Antibody conjugation 
Antibodies were immobilized on a protein A/G plus agarose beads before 
immunoprocipitation. 10 μl of antibody, such as mouse anti-vβ3 or anti-vβ5 (Santa 
Cruz, USA) was mixed with 30 μl of Protein A/G PLUS-agarose beads (Santa Cruz, 
USA) in 0.5 ml ice-cold PBS in a 1.5 ml tube. The tube was tumbled end over in a 
tube rotator for 2 h at 4°C. After the incubation, the tube was centrifuged 15 sec at 
15,000 g at 4°C. The supernatant was aspirated carefully and 1 ml lysis buffer (20 
mM Tris/HCl, 2mM EDTA, 137 mM NaCl, 1mM NaVO4, 1mM 
phenylmethylsufonyl fluoride, 10% glycerol and 1% Triton X-100) was added to 
wash the pellet. This was followed by spinning down at 15,000 x g for 30 sec at 4°C 
and washing with non-denaturing buffer once more. After centrifugation, the agarose-
bound antibod
Control IgG and protein A/G Sepharose beads (25 μl, Santa Cruz, USA) were added 
into the co-immunoprecipitation reaction, and incubated for a further 2 h at 4°C. The 
precipitated proteins were resolved by SDS-PAGE, and blotted with anti-His antibody. 
Also, the anti-ISM antibody, control IgG and protein A/G Sepharose beads were 
added into the co-immunoprecipitation reaction and incubated for 2 h at 4°C. The 
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precipitated proteins were resolved by SDS-PAGE and blotted with anti-v, β1, β3 and 
β5 antibody respectively.  
 
2.12.2 Lysate preclear and IP 
HUVECs membrane extract were precleared with 30 μl Protein A/G PLUS-agarose 
(Santa Cruz, USA) by tumbling for 1 h at 4°C in a tube rotator. The agarose-conjugate 
antibody was mixed with the precleared protein sample. The mixture was centrifuged 
for 30 sec at 15,000 x g at 4°C after incubation at 4°C in a tube rotator for overnight. 
This was followed by centrifugation at 15,000 x g for 30 sec at 4°C. The beads were 
washed with cold PBS and boiled together with protein loading dye and β-
mercaptoethanol. After centrifugation, the supernatant was loaded for SDS-PAGE. 
 
2.13 Transfection 
2.13.1 Determination of zeocin sensitivity of tumor cells 
B16 cells were seeded in 6-well tissue culture plates (Becton Dickson, USA) with 
DMEM supplemented with 10% FBS in duplicate. Zeocin (100mg/ml, Invitrogen, 
USA) was added to the wells at increasing concentrations ranging from 100 μg/ml to 
1000 μg/ml. Medium was changed every 2 days and the cells were monitored under 
microscope. After 2 weeks, zeocin sensitivity concentration was determined at the 
concentration which there was no cell survival, but viable cells were seen in the 




2.13.2 Lipid transfection 
The transfection was carried out using Mirus Bio’s using TransIT-LT1 Reagent 
(Mirus, USA) as described by the manufacturer. Briefly, cells with 50-70% 
subconfluency were grown in 6-well plate.  Before transfection, cells were refed with 
fresh culture medium. Plasmid DNA (2.5 μg) construct or expression vector alone 
together with 7.5 μl of TransIT-LT1 Reagent were added to 250 μl DMEM medium 
and incubated for 20 min. The mixture solution was then added dropwise to the cells 
and incubated with cells together for 24 h.  
 
2.13.3 Selection of stable expression clones 
The cells were refed with fresh medium containing appropriate concentration of 
zeocin the following day and changed every two days. Resistant colonies were formed 
in approximately 14 days. These resistant colonies were inspected under microscope 
and those well separated from adjacent ones were selected and cloned using sterile 
culture inserts. The inserts were made by cutting the top end of blue pipette tips about 
1cm in length and autoclaved. The insert was placed and fixed upside down on the 
selected colony using Vaseline (Unilever, USA). Trypsin/EDTA (100 μl) was added 
inside the insert and cells suspension was transferred to 24-well plate once they were 
detached.  Complete medium plus appropriate concentration of zeocin was added to 
each well and cells were continuingly grown at tissue culture incubator.  
The medium was replaced every 2 days till the clones reached confluence, and were 
then expanded to 6-well plate and T25 culture flasks in selection medium. Several 
stocks were made for each single colony stored at -1500 C freezer.    
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2.14 In vivo pathological angiogenesis models 
2.14.1 Animals  
Female Balb/c nude, and C57BL/6J mice (7-8 weeks old) (Centre for Animal 
Resources, Singapore) were used. Animal work was carried out in the Animal 
Holding Unit of the National University of Singapore. Mice care was in agreement 
with institution animal welfare guidelines. Maximal 5 mice were kept in one cage and 
put in the isolator provided with sterile deionized water and autoclaved chow. At the 
end of the study, mice were sacrificed by CO2 asphyxiation.  
 
2.14.2 Directed In Vivo Angiogenesis Assay 
The role of ISM in in vivo angiogenesis in Matrigel plug was determined using the 
directed in vivo angiogenesis assay kit (Trevigen. Inc, USA) according to manufacturer’s 
instructions (Guedez, et al., 2003). Briefly, the angioreactors were either filled with 
basement membrane extracts (BME) alone, in combination with VEGF or with VEGF 
supplemented with 500 nM or 1 μM ISM proteins and incubated at 37°C for 1 h to allow 
gelling. The angioreactors were then implanted into the dorsal flank of nude mice. After 2 
weeks of incubation, the angioreactors were harvested. The invaded ECs were isolated, 
and labeled with FITC-lectin at 4°C overnight. The fluorescence was measured in 96-
well plates using a SPECTRAmax microplate spectrofluorometer (excitation 485 nm, 





2.14.3 Subcutaneous tumor model 
B16/ISM B16 cells or B16/Vec B16 cells (1 million) in 1X PBS were injected 
subcutaneously into to study the effects of ISM on tumor growth. The mice were 
weighed and 10 mice were radonmized into each group. Thoroughly mixed cell 
suspendsions less than 150 μl were injected using a 24-gauge needle (Becton 
Dickinson, USA) in the dorsal midline area of each mouse. The growth of the tumor 
was monitored over 2 weeks and tumor volume was recorded by carefully measuring 
the two perpendicular diameters of the tumors every two days. The tumor volume was 
calculated following the formula: 0.52x A2 x B where A is the shortest axis and B is 
the longest axis. At the end of the study, the mice were terminated and the tumors 
were dissected, weighed and washed in ice-cold PBS. One half of the tumor was fixed 
in neutralized formalin. The other half was immediately minced and snaps frozen.  
 
2.15 Immunohistochemistry  
2.15.1 Fixation 
Half of the tumors excised from mice were immediately submerged in 10% formalin 
with a few changes to remove remaining blood and kept in the fixative from 24 h to 
maxium 72 h depending on the size of specimens. 
 
2.15.2 Embedding 
The fixed tumors were transferred to 70% ethanol for 24 h at 4°C, followed by 
dehydration in 90% and 95% ethanol for 1 h each. The specimens were passed 
80 
 
through 2 changes of 100% ethanol for 1 h each, followed by kept in a 1:1 100% 
ethanol and histoclear mixture solution for 30 min and 100% histoclear for overnight. 
Then, the cleared tumors were transferred into fresh histoclear for 2 h before being 
immersed in 2 changes of paraffin wax at 56°C for 1 h each. The paraffin-infiltrated 
tumors were placed into an embedding boat and oriented into desired position before 
adding fresh paraffin to fill the dish. Bubbles were carefully avoided.  
 
2.15.3 Sectioning 
The paraffin blocks were trimmed so as to have a 2-3 mm margin of paraffin around 
the edges of the tissue and mounted by paraffin onto a wooden block. Before 
sectioning, the tissue blocks were put into -20°C for 10 min and cut into 5 mm thick 
serial sections using a microtome (Reichert-Jung, Germany). The sections were 
transferred to a 40°C water bath after floated briefly with 30% ethanol. The intact and 
stretched sections were selected individually laid on the pre-coated glass slides. The 
sections were labelled, dried in a 37°C incubator overnight and stored until used.  
 
2.15.4 Dewax and rehydration  
The sections were dewaxed by plunged into three xylene solutions for 5 min each. 
Rehydration was conducted by passing through 3 min each of 3 100% ethanol, 2 95% 





2.15.5 Antigen retrieval 
Slides were immersed into boiling 10% citrate acid buffer for 5 min and transferred to 
other boiling 10% citrate acid buffer for 20 min. After cooling to RT, slides were then 
rinsed with running tap water and put into PBS for subsequent procedures.   
 
2.15.6 Immunohistochemistry 
All immunostainings were carried out by using fluorescence-conjugated secondary 
antibody detection system. Briefly, after pretreatment and PBS wash, blocking 
solution (Dako, USA) was applied to cover the section. After 1 h incubation at RT, 
the slides were washed twice with PBS for 5 min each. 1/500 rabbit anti-VEGF 
antibody (abcam, USA), 1/100 F4/80 antibody (sc-26642) (Santa Cruz, USA), 1/500 
PCNA antibody (sc-7907) (Santa Cruz, USA), or 1/500 PECAM-1 (sc-1506) (Santa 
Cruz, USA) was dropped onto the section and incubated at 4°C for overnight. The 
next day, the section was incubated with corresponding secondary FITC or Alexfluo-
conjugated antibodies at RT for 2 h after server times of washing. The nuclei were 
counterstained with DAPI at RT for 30 min. The section was then washed again and 
observed under a confocal laser microscopy system (Zeiss LSM 510, Germany).  
 
2.15.7 TUNEL 
Tumor apoptosis was assessed using the ApoAlert DNA Fragmentation Assay Kit 
(Clonetech, USA) based on the widely used terminal deoxynucleotidyl transferase 
(TgT)-mediated dUTP nick-end labelling (TUNEL)(Gavrieli, et al., 1992). Briefly, 
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after dewax and rehydration, the sections were incubated in 0.85% NaCl for 5 
min.Before fixed in 4% freshly prepared formaldehyde/PBS (PFA) for 15 min, the 
sections were washed twice in PBS for 5 min each. This was followed by digestion in 
20 μg/ml Proteinase K for 10 min at RT after twice PBS washings. After another 
twice immersion in PBS for 5 min each, the sections were fixed again in 4% PFA for 
5 min. Following washing in PBS for 5 min, the sections were equilibrated in 100 μl 
of evenly distributed equilibration buffer for 10 min at RT. After removing the excess 
liquid by tapping, the TdT incubation buffer (45 μl of equilibration buffer, 0.25 μl of 
1mM Alexa 488 dUTP, 0.5 of 1mM dATP, 4.25 μl of TE and 1 μl of TdT terminal 
transferase for 1 section) was added and put in a dark, humidified chamber at 37°C for 
1 h before being stopped by incubation in 2 X SSC for 15 min at dark. This was 
followed by three washes of PBS for 5 min each. The sections were counterstained in 
DAPI for 30 min. The apoptotic cells were counted under fluorescent microscopy. 
The average number of apoptotic cells per microscopic filed was determined by 
analysing three microscopic fields per tumor section, three tumor sections per tumor 
and three tumors in each experimental group.  
 
2.15.8 Microvessel density (MVD) 
The sections stained with CD31 were examined carefully under microscope. The 
vessels in the selected field of tumor tissue were counted using method described by 
Weidner et al (Weidner, et al., 1991). For vessel quantification, the average number 
of vessels per microscopic filed, from three microscopic fields per tumor section, 




2.16 In vivo physiological angiogenesis model 
2.16.1 Zebrafish maintenance 
A local line of wild-type zebrafish and a Tg(fli-1:EGFP) fish line was used. The 
transgenic Tg line has GFP expression in endothelial cells. The fish were maintained 
basically according to the methods in The Zebrafish Book (Westerfield, et al., 1999). 
For breeding, two to three pairs of fish were transferred to the breeding tank with RO 
water. The males and females were separated using a divider to avoid spawn. The 
next morning, separator was removed and embryos were collected. Embryos were 
then washed with RO water and transferred to petridish containing egg water. All 
embryos were monitored under the microscope for staging according to the 
morphological features.  
2.16.2 Microinjection of morpholino oligonucleotide (MO) into embryos 
The samples for injection were prepared to different concentrations in sterile water. 
The needles used for the microinjection were prepared using Sutter Micropipette 
puller P-97 (Sutter Instruments Co, USA). The optimized conditions of heat and pull 
time was set at pressure-500, heat-500/550, pull-150/150, velocity-100/100 and time-
150/150. 1-2 cell stage of zebrafish embryos were placed under a dissection 
microscopy (Olympus SZX12, Japan) and even amount of MOs were injected into the 
cytoplasm of embryos using Picoinjetor PLI-100 (Medical Systems Co, USA). The 





2.16.3 Design of MO 
Anti-sense oligos or morpholino (MO) have become an attractive method to 
specifically block gene function (Nasevicius, et al., 2000,Summerton, et al., 1997). 
Design of an efficient antisense Morpholino required the carful consideration of 
certain criteria. For translation blocking MO, approximately 25bp antisense 
oligonucleotides sequences were designed to bind to the 5’ UTR to 3’ translation start 
site. For splicing interfering MO, the target sequence, approximately 25 bp for MO 
should be located in the pre-mRNA exon-intron junction. Different from translation 
blocking MO, splicing interfering MO modifies the mRNA splicing process and alters 
the nucleotide sequence structure of mRNA. Therefore, the knockdown efficacy by 
splicing MO can be detected by examining the knockdown product using RT-PCR. 
To minimize the possibility of non-specific effects, we designed at least two MOs 
(Gene Tools Inc, USA) for each gene.   
2.17 Statistical analysis  
The data were presented in the form of mean ± M.E. Two-tailed, unpaired student’s t 
test was used for comparing experimental data from different groups. A p-value of 
less than 0.05 was considered significant in all cases (* p<0.05; **p<0.01).  
 
2.18 Lists of primers and morpholino oligos 
Primers 
secISMf                    5’AAAGGATCCGGAGCCTCCGACCGG3’ 
secISMr                    5’AAACTCGAGATGGGCAGTTTGGACGG3’ 
IsmF1EcoRI:            5’CGCGCGGAATTCAGGATGGTGCGCCTGGCTGC3’  
IsmR1XhoI:              5’CGCGCGCTCGAGGTACTCTCTGGCTTCTTGGAACTG3’  
IsmAMOPF1EcoRI: 5’ CGCGCGGAATTCGAAGTGAGTCTGCTTGCGGG3’  
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IsmTSRR1XhoI:       5’CGCGCGCTCGAGCCCGCAAGCAGACTCACTTC3’ 
mISMRTf                 5’GGAGCCTCCGACCGGCAGGACGC3’ 
mISMRTr                 5’GTCCCATCCTCTAGGAACACTGA3’ 
zisminsituf                5’TGGCGGCGGAGCTGCTGCTGCTTT3’ 
zisminsitur                5’GTTTATAGTAGTCCTCATCCTGAGGG3’ 
mβ-actinf                  5’GTATGCCTCGGTCGTACCA3’ 
mβ-actinr                  5’CTTCTGCATCCTGTCAGCAA3’ 
zβ-actinf                   5’GAGAGAGGCTACAGCTTCAC3’ 
zβ-actinr                   5’ACTCCTGCTTGCTAATCCAC3’ 
zismrtf                      5’CAGACTGAATACGACTACTAAGACGGGG3’ 
zismrtr                      5’ACTTTGTATGGTAGGTCAGCGGAGAAC3’ 
ztail1artf                   5’GCGTCTACGTTGAAAATCAGGGTCC3’ 
ztail1artr                   5’TTATGAGTCCAGTCGCCATCTGTCTTG3’ 
ztail1brtf                   5’CCCAAACATTCAAGTGACCATTGAGGTTG3’ 
ztail1brtr                   5’GCAGAACCTGGCGGAGGGCTTGTAGAT3’ 
ismmof                     5’GACAATATTCTTCCATTGTTTAGGTC3’ 
ismmor                     5’CCCCGTCTATGTAGTCGTATTCAGTC3’ 
tail1amof                  5’GGCTCCAGCATCACTCTACAGGTGTCC3’ 
tail1amor                  5’TCACTCTTACAGTTCAACCACTTCTCA3’ 
tail1bmof                  5’ATTCAGGGTCAAAACCAACTAAGGA3’ 




ISM-ATG              5’CTCCGCCGCCAGACGCACCATCCTC3’ 
ISM-ATGmis        5’CTGCGCCCCCAGAGGCACGATCGTC3’ 
ISM-spl1              5’TGTGAGCATATACCTGTATATTGGG3’ 
ISM-spl1mis        5’TGTCAGGATCTACCTCTATTTTCGG3’ 
ISM-spl2              5’ CTATGGTGACCTAAACAATGGAAGA3’ 
ISM-spl2mis        5’CTTTCGTGACGTAAAGAATCGAAGA3’ 
Tail1a-ATG           5’CCTTTACGCGCTCTCAGCATTTTGC3’ 
Tail1a-spl             5’CTTCGATGGTCACCTGTAACAAAGA3’ 





Chapter Three: Results Part I 
 
3. Characterization of the role of ISM EC cell angiogenesis 
 
3.1 Generation of recombinant mouse ISM and its truncated proteins 
 
3.1.1 Comparison of ISM Proteins in vertebrates 
To study the function of ISM, we cloned the full-length mouse and zebrafish ISM 
cDNAs and compared the deduced amino acid sequences with human and Xenopus 
ISM available from Genbank. As shown in Table 3.1 and Fig. 3.1A, the TSR domains 
are highly conserved with 98% identity between mouse and human; 87%-88% 
identity between mouse and zebrafish, or mouse  and Xenopus. The C-terminal 
AMOP domains are also highly conserved with 99% identity between mouse and 
human; 91% identity between mouse and Xenopus and 85% identity between mouse 
and zebrafish. The signal peptide was highly conserved among all four species as well. 
In comparison, the region N-terminal to the TSR is relatively more divergent with 
85% identity between mouse and human and 62% between mouse and Xenopus 
respectively. No known protein domains were identified in the N-terminal region. 
However, within the C-terminal AMOP domain, a “KGD” motif was found to be 
conserved in all four species. “KGD” has been implicated as an alternative integrin 
binding motif in some proteins (Minoux, et al., 2000).   
 
3.1.2 Cloning, expression and purification of recombinant mouse ISM and its 
truncated fragments in E.coli  
To examine the function of isthmin protein in angiogenesis, we expressed and 
purified His-Tagged full-length mouse isthmin protein (ISM) in E.coli. To identify the 
functional domain of ISM, three truncated forms (ISM-TSR, ISM-C and ISM-N) 
containing TSR, AMOP and TSR respectively plus N-terminal region (Fig. 3.1B) 
were also produced in E.coli and purified. The recombinant proteins were purified by 
Ni-NTA affinity chromatography under denaturing conditions followed by reverse-
phase HPLC purification. The molecular weight of recombinant ISM, ISM-N, ISM-C 
and ISM-TSR were determined to be 60 kDa, 40 kDa, 25 kDa and 10 kDa 
respectively, consistent with their amino acid composition. All of the purified 
recombinant proteins were presented as a single band by SDS-PAGE analysis with 
coomassie blue staining (Fig. 3.1 C), indicating the high purity of the purified proteins.  
 
Table 3.1 Summary of the aimono acid identities of TSR and AMOP domains of 
ISM among different vertebrate species 
TSR hISM mISM xISM zISM
hISM ‐ 98% 89% 88%
mISM 90% ‐ 88% 87%
xISM 89% 88% ‐ 93%
zISM 88% 87% 93% ‐
AMOP hISM mISM xISM zISM
hISM ‐ 99% 93% 92%
mISM 99% ‐ 91% 85%
xISM 93% 91% ‐ 96%








     hISM   MVRLAAELLLLLGLLLLTLHITVLRGSGAADGPDAAAGNASQAQLQNNLNVGSDT---TSETSFSLSKEA 
     mISM   MVRLAAELLLLLGLLLLTLHITVLRGSGASDRQDAAAG-------NNNLNLESDS---TSETSFPLSKEA 
     xISM   MLRLAAELLLLLGLLLLTLHITVLRGS---PDSSSN----------SSHSLIQNE---PSSDSFSFNPSD 
     zISM   MVRLAAELLLLLGLLLLTLHITVLRSSPLQHGNDTVS-------LEQDSRVAENNVNADSSSSVQLGPGD 
                                                                               
     hISM   PREHLDHQAAHQPFPRPRFRQETGHPSLQRDFPRSFLLDLPNFPDLSKADINGQNPNIQVTIEVVDGPDS 
     mISM   P---EEHQVVHQPFPRQRFPPETGHPSLQRDGPRSFLLDLPNFPDLSKADINGQNPNIQVTIEVVDGPDS 
     xISM   R-QEYLDEATRRAFPKHRLMTS-GHTSLQRDGTGSFLLDLPNFPDLSKVDINGQNPNIQVTIEVVDGPDS 
     zISM   R----QTRVAHIPASQPWAQSPGTGGSLQRDGPGAFLLDLQNFPDLSKADINGQNPNIQVTIEVVDSLEG 
                                                                                  
     hISM   -EADKDQHPENKPSWSVPSPDWRAWWQRSLSLAR------ANSGDQDYKYDSTSDDSNFLNPPRGWDHTA 
     mISM   -EAEKDQHPENKPSWSLPAPDWRAWWQRSLSLAR------TNSGDQDDKYDSTSDDSNFLSVPRGWDRPA 
     xISM   -EPENEMQKENMPSWPVPSPDWRSWWQRSATLPR------MNYGDQDYKYDSTTEDSNFLNPLGGRNRQV 
     zISM   SEPEKGMRKEN--KPGWAAPNWRNWWQRSSSSSSSSVSTPKGPEEQDYPYESNTEDSNFLKPLGDWERRV 
                                                                            
     hISM   PGHRTFETKDQPEYDSTDGEGDWSLWSVCSVTCGNGNQKRTRSCGYACTATESRTCDRPNCPGIEDTFRT 
     mISM   PGHRTFETKEQPEYDSTDGEGDWSLWSVCSVTCGNGNQKRTRSCGYACIATESRTCDRPNCPGIEDTFRT 
     xISM   PSHRTFDTKEQPEYDYVDGEGDWSSWSVCSVTCGSGNQKRTRTCGYACTATESRTCDMPNCPGIEDTFRT 
     zISM   KSEAGAGSRTQTEYDYIDGEGDWSAWSPCSVSCGNGNQKRTRSCGYACTATESRTCDMPSCPGIEDAFKT 
                                                                            
     hISM   AATEVSLLAGSEEFNATKLFEVDTDSCERWMSCKSEFLKKYMHKVMNDLPSCPCSYPTEVAYSTADIFDR 
     mISM   AATEVSLLAGSEEFNATKLFEVDMDSCERWMSCKSEFLKKYMHKVINDLPSCPCSYPTEVAYSTADIFDR 
     xISM   AATEVSLLAGNEDFNATKLFGVDTDSCERWMNCKSEFLKKYMHKVANDLPSCPCSYPTEVAYSTAEIYDR 
     zISM   AATEVSLLAGTEEFNATELFGVDTDSCERWMNCKSEFLKKYMSKVATDLPSCPCFYPTEVAYSTADVHDA 
                                                                             
     hISM   IKRKDFRWKDASGPKEKLEIYKPTARYCIRSMLSLESTTLAAQHCCYGDNMQLITRGKGAGTPNLISTEF 
     mISM   IKRKDFRWKDASGPKEKLEIYKPTARYCIRSMLSLESTTLAAQHCCYGDNMQLITRGKGAGTPNLISTEF 
     xISM   IKRKDFRWKDASGPKEKLEIYKPTARYCIRSMLSLESTTLAAQHCCFDDSMQLITRGKGAGTPNLISVEF 
     zISM   NTKRNFRWKDASGPKEKLEIYKPTARYCIRSMLTLESTTLAAQHCCYDDSMKLITRGKGAGTPNLISTEF 
                                                           
     hISM   SAELHYKVDVLPWIICKGDWSRYNEARPPNNGQKCTESPSDEDYIKQFQEAREY 
     mISM   SAELHYKVDVLPWIICKGDWSRYNEARPPNNGQKCTESPSDEDYIKQFQEAREY 
     xISM   SAELHYKVDILPWIMCKGDWSRYNEVRPPNNGQKCTENPSEDDYLKQFQEAREF 
     zISM   SADLHYKVDILPWIICKGDWSRYNHARPPNNGQKCAENPQDEDYYKQFEEAREF 
 













Fig. 3.1 Sequence comparison, expression and purification of recombinant mouse 
ISM and its truncated fragments. A. Amino acid alignment of ISM from mouse, 
human, Xenopus and zebrafish. Identical amino acid residues were highlighted either 
in yellow (identical in all four sequences) or in blue (identical in three sequences). 
The tentative signal peptide at N-terminus is underlined. TSR domain in the centre is 
framed by red rectangle and AMOP domain at C-terminus is underlined. “KGD” 
motif is framed by black rectangle. B. Diagrams illustrating the domain organization 
of native ISM and its recombinant forms. Dark green oval represents signal peptide; 
yellow rectangle represents N-terminal portion of ISM; black oval represents TSR 
domain; blue rectangle represents AMOP domain; red rectangle represents His-Tag. C. 
SDS-PAGE gel showing purified recombinant ISM and its truncated fragments. 





3.1.3 Determination of endotoxin level in recombinant ISM proteins 
Endotoxins are lipopolysaccharides (LPSs) present in the cell wall of most gram-
negative bacteria. Recombinant proteins derived from E.coli can be contaminated 
with endotoxins leading to adverse reactions (Morrison, et al., 1978). Therefore, it is 
essential to remove them during purification and monitor their level after purification. 
Endotoxin was removed by Triton X-114 phase separation since it had been proven to 
be an effective method in reducing the amount of endotoxin present in protein 
preparations from E.coli (Liu, et al., 1997). Further removal of endotoxin was 
achieved by HPLC. Approximately 11 mg of ISM, 10 mg of ISM-N, 14 mg of ISM-C 
and 14 mg of ISM-TSR were purified from 1L of bacterial culture after HPLC (Table 
3.2). Endotoxin levels of the recombinant proteins were measured using Limulus 
Amebocyte Lysate (LAL) gel-clot method, which could even detect very minute 
quantities (Liu, et al., 1997). All proteins tested had insignificant endotoxin level of 
less than 0.25 EU/mg (Table 3.2), which has minimal or undetectable effect on 
mammalian cell growth, functions and biochemical events (Epstein, et al., 1990).    
 










































3.1.4 Determination of acute cytotoxicity of the recombinant ISM proteins 
Since recombinant ISM proteins are to be used in cell culture assays, it is important to 
determine the maximum concentration of recombinant proteins that has no acute 
cytotoxicity to cells. Only concentrations that do not induce cell acute cytotoxicity 
can be applied in cell culture assays.  
Acute cytotoxicity assay was performed as previously described (Sulochana, et al., 
2005). Briefly, ECs were treated with different concentrations (100 nM, 500 nM and 1 
μM) of ISM proteins for 4 hours. Next, to examine whether the protein treatment 
induces acute cytotoxicity, tetrazolium salts were added into the cell culture medium 
and incubated for 2 hours. This method is based on the fact that only living cells with 
functional mitochondria are capable of reducing uncoloured tetrazolium salts into 
intensely coloured formazan derivative, which can be measured at the wavelength of 
450 nm. Therefore, tetrazolium salts were used to indicate cell viability and a 
decreased absorbance would indicate cell death.  
As shown in Fig. 3.2, control is the ECs without any treatment. The mean absorbance 
value of ECs under treatment with different concentrations of ISM and ISM truncated 
proteins is comparable to those of control, indicating that neither ISM nor its three 
truncated proteins were cytotoxic to ECs when tested from 100 nM to 1 μM.   
Taken all together, as shown in Table 3.1, the purified recombinant ISM and ISM 
truncated proteins showed 99% purity (indicated by SDS-PAGE) with decent amount 
of yield (more than 10 mg/L) and hardly detectable endotoxin level (less than 0.25 





















































ISM ISM-N ISM-C ISM-TSR  
Fig. 3.2 Acute cytotoxicity of recombinant ISM and its truncated proteins to 
ECs. Control is ECs without ISMs treatment. There is no significant difference on the 
absorbance value between ECs treated with recombinant ISMs and control, indicating 






3.2 ISM inhibited various aspects of angiogenesis in vitro 
Angiogenesis is a multistep and dynamic process. Initiation of angiogenesis coincides 
with the degradation of the basement membrane and exposure of ECs to extracellular 
matrix. ECs then sprout into new capillary network through migration, attachment and 
spreading, proliferation and morphogenesis (Davis, et al., 2005). Disruption in any of 
the steps could inhibit angiogenesis. Therefore, EC migration, attachment and 
spreading to ECM, proliferation, apoptosis and capillary network formation are 
various aspects investigated for angiogenesis in vitro. In this study, these in vitro 
angiogenesis assays were used to analyze the function of ISM protein.  
 
 
3.2.1 ISM inhibited in vitro capillary network formation in a time-dependent 
manner 
ECs rapidly aligned and formed hollow tubular structures within 6-8 hours when 
cultured on Matrigel (Madri, et al., 1986). Premixed EC suspensions with different 
concentrations of recombinant ISM were plated onto a pre-formed Matrigel and the 
extent of capillary network formations were monitored. The capillary network 
formation was documented at 6 h after ECs were plated onto Matrigel. As shown in 
Fig. 3.3A and B, ISM significantly inhibited EC tube formation in a dose-dependent 
manner. This result suggests that ISM has anti-angiogenic activity.  
The in vitro formation of EC capillary network is a multi-step and dynamic process 
including cell attachment to matrix, cell migration, cell spreading, cell-cell adhesion, 
morphogenesis as well as apoptosis (Davis, et al., 2006). After plating ECs onto 
Matrigel, we observed that cells attached to Matrigel and migrated during the 0-1 h 
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period; cells then spread and elongated to form cell-cell alignment during 1-2 h; 
between 2-3 h, some short cell-cell connections were formed; capillary tubes appeared 
by 4 h and finally extensive cellular network was fully formed by 6 h (data not shown).  
To investigate at which stage that ISM would interfer with in vitro capillary network 
formation, recombinant ISM (at 1 μM) was added to the assay culture media at 0 h, 1 h, 
2 h and 4 h respectively, after ECs were plated onto Matrigel. As shown in Fig. 3.3 C, 
when ISM was added together with ECs to Matrigel (0 h), hardly any tubular network 
was formed at the end of the experiment (6 h post EC plating onto Matrigel). There 
was a gradual loss of angiogenesis inhibition observed at 6 h when ISM was added 
into the angiogenesis assay at the later time points. After 2 h of EC plating onto 
Matrigel, ISM could no longer disrupt capillary network formation. These results 
indicate that ISM inhibited EC capillary network formation mainly by interfering with 
the early stages of in vitro angiogenesis on Matrigel. Possibly, cell-matrix attachment, 




































Control ISM 0h ISM 1h ISM 2h ISM 4h  
Fig. 3.3 ISM inhibited EC capillary network formation in both dose-dependent 
and time-dependent manners. A. ISM inhibited EC tube formation. Scale bar 
presents 200 μm. B. Quantification of capillary length in different concentrations of 
ISM. ISM inhibited EC capillary network formation dose-dependently. C. ISM is 
required to be present from the early stages of in vitro angiogenesis (0 h) in order to 
prevent capillary network formation. ISM was added to the culture media at various 
time intervals after ECs had been plated onto Matrigel as shown. There was a gradual 





3.2.2 ISM had no effect on VEGF, bFGF or serum stimulated EC migration  
Since the previous results indicated that ISM inhibited the early cellular events (e.g. 
cell migration, attachment and spreading to matrix) of EC capillary network formation, 
the effects of ISM on ECs migration was then investigated. There are four different 
types of ECs migration, namely chemotaxis, the directional migration towards a 
gradient of soluble chemoattractants; chemokinesis, the random migration in the 
absence of any gradient generated by chemoattractants; haptotaxis, the directional 
migration toward a gradient of extracellular matrix (ECM); and mechanotaxis, the 
directional migration generated by mechanical forces (Lamalice, et al., 2007). 
Chemotaxis stimulated by angiogenic growth factors is as an important mode of EC 
migration in angiogenesis. A recent report has shown that while VEGF stimulates EC 
chemotaxis, it reduces EC chemokinesis (Barkefors, et al., 2008). However, the role 
of haptotaxis in angiogenesis is still not very clear. In addition, it is unlikely that ISM 
inhibited EC capillary network formation through influencing EC mechanotaxis 
because there were no mechanical forces involved in our experimental conditions. 
Therefore, to study the effects of ISM on EC migration, we analyzed the EC 
chemotaxis and chemokinesis. 
EC chemotaxis migration assay was performed using 8 μm  Falcon cell culture inserts. 
Recombinant ISM protein at different concentrations with cells were seeded on cell 
culture insert while either chemoattractant with medium or 2% FBS were placed on 
the lower chamber. After incubation, cells on the upper surface of the insert were 
removed and the ones on the lower surface were counted as migrated cells. Since EC 
chemotaxis in angiogenesis is mainly mediated by VEGF, bFGF and serum, all those 
three angiogenic factors were used as chemoattractant. As shown in Fig. 3.4, in 
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agreement with the previous report (Sulochana, et al., 2005), there were almost 50% 
more migration in the presence of VEGF, bFGF or serum compared to basal level of 
2% FBS. In addition, no significant difference of migration was detected between 
ISM treated cells and cells without treatment. This result indicated that ISM does not 
affect EC chemotaxis toward secreted angiogenic stimulators such as VEGF, bFGF or 
serum.  
In chemokinesis cell migration assay, all the procedures were the same as chemotaxis 
described above except that the chemoattractant was either absent or present in both 
the bottom and upper wells at the same concentration. As shown in Fig. 3.5, the 
relative EC migration was not influenced in the presence of ISM compared to control, 
indicating that ISM did not affect EC chemokinesis as well.  
Taken together, ISM affected neither EC chemotaxis nor chemokinesis. Whereas the 
role of ISM on EC haptotaxis needs to be further determined, it is unlikely that ISM 
has significant effect on EC migration because it has been shown that the main mode 
of EC migration in angiogenesis is angiogenic factors stimulated EC chemotaxis but 
not haptotaxis or chemokinesis. Therefore, inhibition of cell migration is not the 
critical cellular mechanism by which ISM inhibits EC capillary network formation.  
 





































































2% FBS Serum 100 nM 500 nM 1 µM
+Serum +ISM  
Fig 3.4 ISM did not influence VEGF, bFGF or serum stimulated EC chemotaxis. 
A. ISM had no effect on VEGF-stimulated EC migration up to 1 μM. VEGF at 15 
ng/ml was used as chemoattractant. B. ISM had no effect on bFGF-stimulated EC 
migration up to 1 μM. bFGF at 15 ng/ml was used as chemoattractant. C. ISM had no 






















































Fig 3.5 ISM did not influence EC chemokinesis in the absence or presence of 
VEGF. A. There were no differences of migration between ISM and control in the 
absence of VEGF. B. There were no differences of migration between ISM and 







3.2.3 ISM did not interfere with EC attachment and spreading onto ECM 
EC attachment and spreading onto ECM is another early and essential process of in 
vitro angiogenesis. The adhesion of EC to attach and spread upon surfaces coated 
with various ECMs, including fibronectin, collagen, and laminin, plays an important 
role in several biological activities such as cell proliferation, differentiation and 
apoptosis  (Madri, et al., 1986). Since fibronectin and collagen are the main ECM 
components playing essential roles in angiogenesis (Nicosia, et al., 1993), these 
materials were tested in EC attachment. It has been reported that EC attached and 
spread on both native or denatured collagen I without significant differences 
(Macarak, et al., 1983), gelatin (denatured type I collagen) therefore was used to 
substitute collage I. In addition, to mimic the experimental condition of cell adhesion 
during EC capillary network formation, we also examined the EC attachment to 
diluted Matrigel which is composed of a complex mixture of laminin, collage type IV, 
heparan sulfate proteoglycans, entactin and nidogen (Kleinman, et al., 1986).  
We carried out EC attachment assay using dose of 10 μg/ml of gelatin or fibronectin 
for coating. These doses had been used by a number of laboratories for cell 
attachment or spreading in published reports (Macarak, et al., 1983). ECs were added 
in the wells coated with different ECM, and incubated for 30 min in the presence of 
ISM. Subsequently, the unattached cells were washed away with PBS and the number 
of attached cells was counted. Surprisingly, aalthough ISM suppressed the early 
stages of EC capillary network formation on Matrigel (Fig. 3.3), ISM had no effect on 
EC attachment to gelatin, fibronectin or diluted Matrigel (Fig. 3.6).  
EC attachment is followed by cell spreading, which is also pivotal during the early 
stages of angiogenesis. To thoroughly understand the whole process of EC spreading 
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on ECM, time course analysis of EC adhesion on gelatine was conducted. Equal 
number of cells was added to the gelatin-coated wells in the absence or presence of 
ISM and incubated for 15 min, 30 min, 1 h and 2 h respectively.  
As shown in Fig. 3.7, in control samples, very few cells were attached at 15 mins after 
being plated onto the gelatin-coated surface; the attached cells were significantly 
increased by 30 mins but without any spreading; limited cell spreading occurred by 1 
h as the cells somewhat flattened with no apparent directionality; by 2 h, complete 
spreading was observed with cells well-spread in a radial fashion and stretched on the 
surface. Consistent with the previous EC attachment results, the number of attached 
cells in the presence of ISM was similar to control, further confirm that ISM had no 
effect on EC attachment to gelatin. Furthermore, there was no difference on the 
degree of EC spreading between ISM-treated cells and control cells without treatment, 
suggesting that ISM did not influence EC spreading to gelatin as well.  
Taken together, ISM did not affect EC attachment or spreading onto ECM-coated 
surface. These results suggest that ISM is likely to inhibit EC capillary network 
formation through influencing other cellular mechanisms, such as cell-cell adhesion 
and EC morphogenesis.  
                     


























Control 100 nM 500 nM 1 μM
ISM  


























































Fig. 3.6 ISM did not interfere with EC attachment to gelatin, fibronectin or 
diluted Matrigel. A. ISM had no effect on EC attachment to gelatin. B.ISM had no 
effect on EC attachment to fibronectin. C. ISM had no effect on EC attachment to 






















Fig. 3.7 ISM did not influence EC spreading on gelatin-coated surface. Time 
course of EC spreading in the absence or presence of various concentrations of ISM. 
Experiments were terminated after 15 min, 30 min, 1 h or 2 h after plating cells onto 
gelatin-coated surface. ECs attached and spread normally onto gelatin-coated surface 














3.2.4 ISM inhibited VEGF, bFGF or serum-stimulated EC proliferation 
Vigorous EC proliferation is indispensible during the process of angiogenesis, which 
can be stimulated by VEGF, bFGF or serum (Semenza, 2007). To test if ISM 
influences EC proliferation, bromodeoxyuridine (BrdU) labeling method was used. 
BrdU is an analogue of thymidine. It can substitute for thymidine during DNA 
replication and incorporates into newly synthesized DNA strands of actively 
proliferating cells (Cappella, et al., 2008). The incorporated BrdU can then be 
detected by anti-BrdU antibody, thus indicating cells that are specifically in 
proliferative status.  
In our EC proliferation experiment, equal number of cells was incubated for 24 h with 
VEGF or VEGF plus recombinant ISM protein at different concentrations, prior to 
BrdU detection. Control cells were incubated with basal medium (2% FBS) without 
VEGF. As shown in Fig. 3.8A, VEGF significantly stimulated EC proliferation 
compared to control. In addition, ISM inhibited VEGF-stimulated EC proliferation in 
a does-dependent manner. The proliferation of EC treated with 1 μM of ISM is 
significantly lower compared to the control.  
Furthermore, ISM was able to inhibit bFGF or serum-stimulated EC proliferation in a 
similar fashion (Fig. 3.8B and C). These results indicate that ISM is similar to many 
other angiogenesis inhibitors (Sato, 2006), that can inhibit EC proliferation stimulated 
by multiple angiogenic factors.   
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Fig. 3.8 ISM inhibited multiple growth factors-stimulated EC proliferation in a 
dose-dependent manner. Control cells were incubated in the absence of growth 
factors.  A. ISM inhibited VEGF-stimulated EC proliferation. VEGF added was 15 
ng/ml. B. ISM inhibited bFGF-stimulated EC proliferation. bFGF used was 15 ng/ml. 





3.2.5 ISM stimulated EC apoptosis in the presence of VEGF, bFGF or serum 
Induction of EC apoptosis is one of the mechanisms utilized by anti-angiogenic 
molecules to inhibit angiogenesis (Sulochana, et al., 2005). For example, endostatin 
mediates angiogenesis through inducing EC apoptosis by increasing the activity of the 
intracellular protease Caspase  3 (Dhanabal, et al., 1999). Another example is TSP-2, 
which increase EC specific apoptosis through the N-terminal region of the molecule 
(Noh, et al., 2003).  
To examine if ISM has the ability to induce apoptosis in ECs in the presence of 
angiogenic factors, EC apoptosis assay were performed by incubating cells for 24 h 
with angiogenic factors or angiogenic factors in the presence of recombinant ISM 
protein. After ISM treatment, the degree of cell apoptosis was analyzed by detection 
of DNA fragmentations.  
As shown in Fig. 3.9, in agreement with previous reports (Sulochana, et al., 2005), 
angiogenic factors (VEGF, bFGF and serum) prevents ECs from undergoing 
apoptosis. However, when ISM was added to the medium supplemented with 
different angiogenic growth factors, including VEGF, bFGF and serum, the EC 
apoptotic value was significantly increased. These results indicate that ISM induced 
EC apoptosis even in the presence of angiogenic growth factors. Furthermore, it is 
noted that the level of EC apoptosis induced by ISM in the presence of VEGF, bFGF 
and serum is comparable, demonstrating that its efficacy is not dependent on the 
angiogenic stimulus.   
Taken together, ISM can potently induce EC apoptosis in the presence of various 
angiogenic factors.     
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Fig. 3.9 ISM induced EC apoptosis in the presence of VEGF, bFGF or serum. 
Control cells were incubated with only 2% FBS without angiogenic factors. A. ISM 
potently induced EC apoptosis in the presence of 15 ng/ml VEGF. B. ISM induced 
EC apoptosis in the presence of 15 ng/ml bFGF. C. ISM induced EC apoptosis in the 





3.3 Different anti-angiogenic activities of ISM require different functional 
domain 
To identify the protein domain(s) within ISM that are responsible for its anti-
angiogenic activity, truncated ISM fragments ISM-N, ISM-C and ISM-TSR 
representing the N-terminal portion plus TSR domain, TSR domain alone and C-
terminal AMOP domain alone were generated from E. coli expression (Fig. 3.1B and 
C). Their anti-angiogenic functions were examined by in vitro angiogenesis assays.  
 
3.3.1 Only ISM-C inhibited in vitro capillary network formation in a time-
dependent manner 
Since ISM potently inhibited EC capillary network formation (Fig. 3.3), we firstly 
investigated which domain or region within ISM inhibits EC tube formation. As 
shown in Fig. 3.10A, ISM-C inhibited EC capillary network formation dose-
dependently. In contrast, ISM-N and ISM-TSR had no such effects. Moreover, the 
median effective dose ED50 of ISM (318±16 nM) (Fig. 3.3B) is comparable to the 
ED50 of ISM-C (334±65 nM) (Fig. 3.10B), suggesting that the anti-capillary network 
formation function of ISM was largely mediated through its C-terminal AMOP 
domain.  
Time course analysis of EC capillary network formation showed that similar to ISM, 
ISM-C was required at the early stages of the in vitro angiogenesis process to prevent 
ECs tube formation (Fig. 3.10C). This suggested that ISM-C could affect the same 
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ISM-N ISM-C ISM-TSR  
C
Control ISM-C 0h ISM-C 1h ISM-C 2h ISM-C 4h  
Fig. 3.10 ISM-C but not other ISM truncated forms inhibited in vitro capillary 
network formation. A. ISM-C inhibited capillary network formation in a dose-
dependent manner while ISM-N and ISM-TSR had no such activity. B. Quantification 
of capillary length in different concentrations of ISM truncates. C. ISM-C (1 μM) was 
required to be present from the early stages of in vitro angiogenesis (0 h) in order to 
prevent capillary network formation. Scale bar present 200 µM.  
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3.3.2 Truncated ISM proteins did not influence EC migration 
Although the earlier results have been shown that ISM did not affect VEGF, bFGF or 
serum-stimulated EC migration (Fig. 3.4 and 3.5), we wanted to determine if ISM 
fragments can influence EC migration. EC chemotaxis in the presence of different 
recombinant ISM truncates was investigated. The representative angiogenic growth 
factor VEGF was used as the chemoattractant under similar experimental condition 
for ISM.  
Consistent with ISM (Fig. 3.4), none of the ISM truncated proteins influenced VEGF-
stimulated EC chemotaxis up to 1 μM (Fig. 3.11). These results suggest that not only 
































































Fig. 3.11 ISM truncates had no effect on VEGF-stimulated EC chemotaxis. 
Control is cell migration in the absence of VEGF. Cell migration was increased in the 
presence of 15 ng/ml VEGF. The migration of cells treated with ISM-N, ISM-C or 
ISM-TSR in the presence of VEGF was comparable to that of cells without protein 
treatment.   
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3.3.3 ISM truncates had no effect on EC attachment to matrix 
Next, we investigated the effects of ISM truncates on EC attachment to matrix using 
gelatin as coating reagent. Cells were plated to gelatin-coated wells in the presence or 
absence of recombinant ISM truncated proteins and incubated for 30 mins. As shown 
in Fig. 3.12, the number of cells attached to gelatin in the treatment of ISM-N, ISM-C 
or ISM-TSR has no significant difference compared to control. These results indicate 































































ISM-N ISM-C ISM-TSR  
Fig. 3.12 ISM truncates had no effect on EC attachment to gelatin. The number of 
cells attached to gelatin-coated surface in the presence of ISM-N, ISM-C or ISM-TSR 
was not significantly different compared to control. There was no protein treatment in 





3.3.4 ISM-N and ISM-C mildly inhibited VEGF-stimulated EC proliferation 
To find out the region of ISM that is responsible for its inhibitory activity on EC 
proliferation, EC proliferations under VEGF-stimulated condition using ISM-N, ISM-
C and ISM-TSR were studied. As shown in Fig. 3.13, both ISM-N and ISM-C 
proterins inhibited VEGF-stimulated EC proliferation at 1 μM. However, ISM-TSR 
had no such activity. Furthermore 1 μM of ISM inhibited 90~100% of VEGF-
stimulated EC proliferation while ISM-N and ISM-C inhibited only 40~55% (Fig. 
3.8A and 3.13), suggesting that both ISM-N and ISM-C contributed to the anti-
proliferative activity of full length ISM.  
Taken together, these results demonstrate that ISM-N and ISM-C but not ISM-TSR 
might contribute to the inhibitory activity of ISM in angiogenic factor induced EC 

































































Fig. 3.13 ISM-N and ISM-C mildly inhibited VEGF-stimulated EC proliferation. 
Control cells were incubated under the 2% FBS basal medium without VEGF. VEGF 
used was 15 ng/ml. ISM-N and ISM-C mildly inhibited VEGF-stimulated EC 
proliferation at 1 μM. ISM-TSR did not exhibit an inhibitory effect on EC 





3.3.5 None of ISM truncates induced EC apoptosis 
We last examined which region of ISM contributes to its ability to induce EC 
apoptosis in the presence of angiogenic factors.  
Surprisingly, although ISM potently induces EC apoptosis in the presence of VEGF 
(Fig. 3.9A), none of the ISM truncated forms have such activity (Fig. 3.14). This 
result suggests that the pro-apoptotic activity of ISM requires the context of the full-
length ISM protein, possibly its three-dimensional structure.  
The lack of pro-apoptotic activity of ISM-N and ISM-C might explain their weak 
anti-proliferation effect because the anti-proliferation activity measured by BrdU 
incorporation (cells in active DNA synthesis) is the combined effect of both 
proliferation inhibition and apoptosis induction. This also indicates that the results of 
EC proliferation and apoptosis in the treatment of different truncated ISMs are 
consistent with each other.   
By binding to the “RGD” motif of ECM molecules, integrin signalling affects and 
influences the growth factor mediated-cellular events including cell proliferation and 
apoptosis (Fujio, et al., 1999). On the other hand, anchorage disruption between the 
integrin and “RGD” motif by RGD antagonist could induce EC apoptosis (Meerovitch, 
et al., 2003). Since R in “RGD” motif is a non-essential amino acid during cell-matrix 
adhesion and can be substituted by other amino acid such as K (Lu, et al., 2006), 
“KGD” motif may play an important role similar to the “RGD” motif in cell-matrix 
adhesion, and hence influence cell apoptosis. Although ISM has one “KGD” sequence 
located at the C-terminal AMOP domain (ISM-C), it is unlikely that “KGD” was 
involved in mediating the pro-apoptotic activity of ISM since ISM-C did not affect 





























































Fig. 3.14 None of the ISM truncates induced EC apoptosis. Control cells were 
incubated under basal condition with 2% FBS without VEGF. Compared to control, 
EC apoptosis was apparently reduced in the presence of VEGF. The treatment with 
ISM truncated proteins were conducted in the presence of VEGF. The apoptotic value 
of samples with different concentrations of ISM-N, ISM-C or ISM-TSR showed no 










3.4 The effect of ISM on other cell types  
Many angiogenic inhibitors tend to be pleiotropic in function and their physiological 
roles are divergent. PEDF, the most potent inhibitor of angiogenesis in mammalian 
eye diseases, induces neuronal differentiation of cultured Y79 retinoblastoma cells 
(Steele, et al., 1993). TSP-1, the first protein to be recognized as a naturally occurring 
angiogenesis inhibitor, also increases neutrophil adhesion and migration (Vallejo, et 
al., 2000). Therefore, to find out whether ISM only specifically affects ECs, the 
effects of ISM on different types of cell are investigated.  
 
3.4.1 ISM mildly inhibited serum-stimulated fibroblast proliferation 
It has been shown earlier that ISM potently inhibited serum-stimulated EC 
proliferation (Fig. 3.8C), the effect of ISM on serum-stimulated proliferation of non-
ECs, such as fibroblast, was then examined. Two mouse fibroblast cell lines were 
tested, Swiss 3T3 and NIH 3T3. Different from primary HUVECs, Swiss 3T3 and 
NIH 3T3 are immortalized cell lines originally established from the primary mouse 
embryonic fibroblast cells (Todaro, et al., 1963).  
As shown in Fig. 3.15A, ISM mildly inhibited serum-stimulated Swiss 3T3 cell 
proliferation. Similarly, ISM also inhibited serum-stimulated NIH 3T3 cell 
proliferation (Fig. 3.15B). However, the inhibitory efficacy of ISM on proliferation of 
fibroblast cells was different from ECs. The effect of ISM on the proliferation of EC 
was present at lower concentration of 100 nM, and ISM inhibited EC proliferation by 
90~100% at 1 μM. In contrast, ISM only inhibited serum-stimulated proliferation of 
fibroblast cells by 20~30% at 1 μM.  
The angiogenesis inhibitor endostatin was identified to specifically inhibit EC 
proliferation by only inhibiting ECs but not smooth muscle cells, epithelial cells, 3T3 
fibroblast cells or Lewis Lung carcinoma cells even when endostatin was tested at 
doses up to 1 log-fold higher than those used to inhibit ECs (O'Reilly, et al., 1997). 
Although ISM inhibited EC proliferation more potently than fibroblast cells, the 
statistically significant inhibition of fibroblast proliferation by ISM suggests that it 
has inhibitory effects on proliferation of both EC and fibroblast.  





























































Fig. 3.15 ISM mildly but significantly inhibited fibroblast cells proliferation. A. 
ISM inhibited serum-stimulated Swiss 3T3 proliferation at 1 μM while ISM did not 
affect such effect at 100 nM or 500 nM. No FBS added in the control. Serum refers to 
10% FBS used. B. ISM only inhibited serum-stimulated NIH 3T3 proliferation at 1 
μM. No FBS added in the control. 10% FBS was used as serum. 
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3.4.2 ISM did not influence serum-stimulated tumor cell proliferation 
Since ISM influenced the proliferation of both ECs and fibroblast cells, it is of interest 
to investigate whether ISM has any influence on tumor cells. B16 melanoma (mouse) 
and HepG2 (human hepatocellular carcinoma) cells were tested.  
As shown in Fig. 3.16, tumor cells in the presence of serum had a higher proliferation 
rate than control where serum is absent. However, ISM did not show any effect on 
serum-stimulated proliferation of both B16 and HepG2 tumor cells up to 1 μM. These 
results indicate that ISM preferentially inhibits the proliferation of certain type of cell 




















































Fig. 3.16 ISM did not affect serum-stimulated tumor cell proliferation. A. ISM 
did not inhibit serum-stimulated B16 tumor cells proliferation up to 1 μM. No FBS 
added in the control. 10% FBS was used as serum.  B. ISM did not inhibit serum-
stimulated HepG2 tumor cells proliferation up to 1 μM. No FBS added in the control. 





3.4.3 ISM marginally induced fibroblast apoptosis 
Since ISM potently induced EC apoptosis in the presence of serum (Fig. 3.9C), 
whether ISM can induce apoptosis of fibroblast was also investigated. Fibroblast 
apoptosis assay were performed in the presence of serum (10% FBS). Cells were 
treated with different concentrations of ISM for 24 hours prior to DNA fragmentation 
detection.  
As shown in Fig. 3.17, ISM was able to induce apoptosis of Swiss 3T3 and NIH 3T3 
in the presence of serum. However, this activity was very weak although it is 
statistically significant. Under the same experimental condition, the induction of 
apoptosis of ECs was first observed at concentration of 100 nM (Fig. 3.9). On the 
other hand, the induction of fibroblast apoptosis was only observed at 1 μM which 
was the maximal concentration tested in this experiment. 
The characteristic of ISM in marginally inducing fibroblast apoptosis at 1 μM but not 
100 nM or 500 nM is also shown in its inhibitory activity in serum-stimulated 
proliferation of fibroblast that ISM only inhibited fibroblast proliferation at 1 μM (Fig. 
3.15). This also suggests that results of the above proliferation and apoptosis of 
fibroblast cells were consistent with each other because the anti-proliferation activity 
measured by BrdU incorporation is the combined effect of both proliferation 
inhibition and apoptosis induction.  
Similar to EC, ISM can inhibit serum-stimulated fibroblast proliferation and induce 
fibroblast apoptosis in the presence of serum. However, its activities on proliferation 
inhibition and apoptosis induction of fibroblast are weaker compared to that of EC.  
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Fig. 3.17 ISM marginally induced fibroblast cells apoptosis. A. ISM slightly but 
significantly induced Swiss 3T3 cells apoptosis at 1 μM but not 100 nM or 500 nM in 
the presence of serum. B. ISM slightly but significantly induced NIH 3T3 cells 
apoptosis at 1μM in the presence of serum. ISM had no influence on NIH 3T3 cells 





3.4.4 ISM did not affect tumor cell apoptosis 
Next, we investigated the effect of ISM on tumor cell apoptosis. Apoptosis of tumor 
cell assay was conducted in the presence of serum (10% FBS) using the same method 
described above.  
As shown in Fig. 3.18A, the apoptotic value of B16 in ISM-treated samples had no 
difference to that of serum sample without treatment, indicating that ISM did not 
induce apoptosis of B16 in the presence of serum. Similarly, ISM did not show any 
influence to HepG2 apoptosis in the presence of serum neither (Fig. 3.18B). 
With the same concentration of 1 μM, ISM showed different effects on the apoptosis 
of tumor cells, fibroblast cells and ECs. ISM potently induced ECs in the presence of 
serum (Fig. 3.9C). It also induced fibroblast apoptosis in the presence of serum 
although the efficiency of apoptotic induction was much less comparing to EC. In 
contrast, ISM did not show induction of tumor cell apoptosis at all in the presence of 
serum up. These results suggest that the ability of ISM in inducing cell apoptosis is 
cell type-dependent.  
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Fig. 3.18 ISM had no effect on tumor cells apoptosis. A. ISM did not induce B16 
tumor cells apoptosis in the presence of serum up to 1 μM. Serum used was 10% FBS. 
B. ISM did not induce HepG2 tumor cells apoptosis in the presence of serum up to 1 





3.5 ISM but not ISM-C inhibited angiogenesis in vivo 
Although in vitro angiogenesis assays have been verified to be useful for the 
identification of potential molecular targets to alter endothelial cell responses in the 
preliminary screening of novel pharmacologic agents (Yin, et al., 2007), in vitro 
angiogenesis tests are best subjected to confirmation with in vivo assays because of 
the complex nature of in vivo angiogenesis. To further verify ISM’s angiogenesis 
inhibition in vivo, DIVAA was performed.  
DIVAA allows accurate dose-response analysis and identification of effective doses 
of angiogenesis-modulating factors in vivo (Guedez, et al., 2003). This assay consists 
of implantation of semiclosed silicone cylinders (angioreactors) subcutaneously into 
nude mice. In each mouse, a control and experimental angioreactors (filled with 20 μl 
of Matrigel only or Matrigel premixed with angiogenic factors, or Matrigel premixed 
with angiogenic factors as well as ISM protein at different concentrations) was 
implanted subcutaneously into each side of the dorsal flank to reduce variations 
between individual mouse. After 2 weeks implantation, the angioreactors were 
isolated followed by measuring the number of ECs using fluorescently labelled EC-
binding lectin to determine the amount of angiogenesis in each angioreactor.  
In our DIVAA experiment, a mixture of 30 ng/μl of bFGF and 10 ng/μl of VEGF was 
used as angiogenic factors as this combination has been shown to be most effective to 
stimulate angiogenesis in vivo (Guedez, et al., 2003). As shown in Fig 3.19A, 
angiogenic factors (VEGF/bFGF) showed apparent stimulation of angiogenesis in 
angioreactor compared to control (Matrigel alone). When ISM was added together 
with VEGF/bFGF, remarkably less angiogenesis was observed. Consistent with visual 
observation, angiogenesis quantification using EC binding lectin indicated minimal 
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angiogenesis in control and increased angiogenesis in VEGF/bFGF present 
angioreactors. In contrast, ISM significantly suppressed VEGF/bFGF induced 
angiogenesis at 0.5 μM and 1 μM (Fig. 3.19B). It is noted that the concentrations of 
ISM in inhibiting angiogenesis in vivo were also effective in inhibiting multiple 
aspects of angiogenesis in vitro, including capillary network formation, cell 
proliferation and apoptosis induction (Fig. 3.3, 3.8 and 3.9). These results demonstrate 
that ISM functions as an angiogenesis inhibitor in vivo.  
Surprisingly, when ISM-C was tested under similar experimental condition, it did not 
suppress in vivo angiogenesis at 0.5 μM or 1 μM (Fig. 3.19), concentrations where it 
is also effective in inhibiting in vitro capillary network formation and EC proliferation 
(Fig. 3.10 and 3.13).   
In this experiment, both ISM-C and ISM were mixed with Matrigel as a single dose 
before the Matrigel-containing angioreactor was implanted under the mouse skin and 
the angiogenic responses were determined 2 weeks later. The lack of anti-angiogenic 
activity of ISM-C may not reflect the direct effect of ISM-C on in vivo angiogenesis 
but rather reflects the stability of recombinant ISM-C protein in in vivo environment. 
It is not known the relative stability of recombinant ISM-C comparing to ISM under 
this in vivo assay condition. Further investigations are needed to confirm if ISM-C 
could inhibit angiogenesis in vivo.  
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Fig. 3.19 ISM suppresses angiogenesis in vivo. Effect of ISM on in vivo 
angiogenesis was examined using the directed in vivo angiogenesis assay by 
implanting a Matrigel based angioreactor in mice. A. ISM potently suppressed by 
VEGF/bFGF induced angiogenesis in the angioreactor. Control (Matrigel alone) only 
showed minimum angiogenesis. ISM-C failed to suppress VEGF/bFGF induced 
angiogenesis. Representative photographs are presented. B. Quantitative measurement 
of angiogenesis in the angioreactor. ECs inside the angioreactor were quantified using 





Chapter Four: Results Part II 
 
4. ISM inhibited angiogenesis through multiple mechanisms 
Multiple processes are involved during in vitro capillary network formation on 
Matrigel. In addition to EC attachment to matrix, apoptosis, migration, cell-cell 
adhesion as well as EC morphogenesis also play important roles. The fact that ISM 
affects neither EC attachment to Matrigel nor migration suggests that it is most likely 
influencing other aspects of in vitro angiogenesis, such as the assembly into tubular 
networks (morphogenesis).  
ECM-integrin-cytoskeletal signalling axis which has been revealed to play a critical 
role during EC morphogenesis (Davis, et al., 2003,Davis, et al., 2002,Davis, et al., 
2007) is an important factor for investigation. EC morphogenesis requires EC 
interactions with ECM through integrins, and downstream signalling events involving 
cytoskeletal elements that control EC shape for capillary tube assembly. Integrins are 
the major cell surface receptors mediating cell adhesion to matrix and play important 
roles in angiogenesis (Silva, et al., 2008). It is clear that both β1 and αv integrins can 
support vascular morphogenesis, including α2β1, α1β1, α5β1, αvβ3 and αvβ5 (Bloch, 
et al., 1997,Brooks, et al., 1994,Senger, et al., 2002). Many of the molecules 
regulating integrin signalling, such as FAK and paxillin, are associated with the actin 
cytoskeletal dynamics, which controls cell shape and is centrally relevant to capillary 
tubes formation (Schwartz, et al., 2000).  
Integrin is also important for cell-cell interaction and even cell apoptosis (Schwartz, et 
al., 2002). Experimental work demonstrated that integrin-mediated cell death involves 
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recruitment of Caspase -8 to unligated integrins and thereby initiating an apoptotic 
pathway (Stupack, et al., 2001).  
ISM induced EC apoptosis, which might be one of the inhibitory mechanisms of EC 
tube formation. Although ISM inhibited VEGF-stimulated EC proliferation, it is 
unlikely to be the main reason for its suppression of capillary tube formation since 
there is only minimal EC proliferation during the period of EC capillary tube 
formation on the Matrigel (6-8 h) (Sharghi-Namini, et al., 2008).  
Therefore, we focused on studying the molecular mechanisms of ISM’s involvement 
in ECM-integrin-cytoskeletal signalling axis as well as its induction of EC apoptosis.  
 
4.1 Interaction between ISM and integrin αvβ5  
 
4.1.1 ECs bind to immobilized ISM and ISM-C but not ISM-N  
To find out whether ISM directly interacts with integrins, EC binds to ISM-coated 
surface were investigated. This is to understand whether there is any interaction 
between ISM and EC cell surface. Cell were added to different concentrations of ISM, 
ISM-N or ISM-C-coated surface and incubated for 2 hours. Subsequently, unadhered 
cells were washed away and adhered ones were fixed followed by photography under 
microscopy.   
As shown in Fig. 4.1, although ECs did not attach to lower concentration (100 nM) of 
the ISM-coated surface, ECs attached to 500 nM and 1 μM of ISM-coated surface in a 
dose-dependent manner. This data suggests that a critical threshold of ISM is required 
to facilitate EC attachment. ECs also attached to immobilized ISM-C surface while 
ISM-N did not support such ECs adhesion at any concentrations.  
In addition, ISM-C supported EC spreading as efficient as ISM. The adhesion 
between ECs and ISM or ISM-C indicates their direct interaction. This result is 
consistent with the ability of ISM and ISM-C but not ISM-N in inhibiting in vitro 
capillary network formation, suggesting that ISM inhibited capillary tube-structure 



















Fig. 4.1 ECs binds to immobilized ISM and ISM-C but not ISM-N. ECs attached 
and spread on ISM and ISM-C coated surface in a dose-dependent manner. Lower 
concentration (100 nM) of ISM and ISM-C did not support EC adhesion. ECs did not 
attach to ISM-N-coated surface. Representative pictures were taken under phase-





4.1.2 ISM bound to ECs through integrin αvβ5 
To investigate if ISM binds to integrins expressed in ECs, the native plasma 
membrane proteins of cultured ECs are isolated and incubated with recombinant ISM 
in vitro. ECs are known to express vβ3, vβ5 and a series of β1 integrins (Silva, et 
al., 2008). Co-immunoprecipitation experiments using anti-integrin antibody (to 
detect a particular integrin subunit or heterodimer) or either anti-His or anti-ISM 
antibody (to detect recombinant ISM) were carried out. Anti-ISM antibody is a 
polyclonal IgG purified from the crude serum using protein A/G affinity 
chromatography method. The antiserum was produced by immunizing rabbit with 
E.coli produced recombinant full-length ISM by Biogenes GmbH (Germany) using 
standard procedures.  
As shown in Fig. 4.2, only integrin vβ5 but not αvβ3 was co-immunoprecipitated by 
anti-His antibody (Fig. 4.2A and B). On the other hand, only anti-ISM could co-
precipitate with integrin v or β5 but not β1 or β3 (Fig. 4.2C, D, E and F). These 
results suggested that ISM could selectively interact with ECs through vβ5 integrin. 
Furthermore, ISM-C also interacted with vβ5 (Fig. 4.2G), which indicated that ISM 
interacted with vβ5 integrin on EC surface through the ISM-C region.  
To further confirm the interaction between ISM and integrin αvβ5, anti-vβ5 
neutralizing antibody was pre-incubated with ECs before cells were plated onto ISM-
coated surface. As shown in Fig. 4.2 H, anti-vβ5 antibody partially but significantly 
blocked EC attachment to ISM-coated surface. Under the same condition, normal 
mouse IgG or anti-vβ3 antibody did not present significant blocking of EC 
attachment to ISM-coated surfaces. These results demonstrated that ISM interacted 
with ECs lat least partially through vβ5 integrin (Mercurio, 2002).  
Taken together, the interaction of integrin vβ5 with both ISM and ISM-C can 
provide a link on their inhibitory effects on in vitro EC capillary network formation. 
Both ISM and ISM-C may suppress EC tube formation by interacting with integrin 
vβ5 on EC surface. Moreover, the partial but not complete blocking by αvβ5 
integrin neutralizing antibody raises the possibility of the existence of additional high-




A                                                         B 
 











G                                      H 
         





Fig. 4.2 ISM bound to αvβ5 integrin on ECs. Recombinant His-tagged ISM was 
incubated with membrane protein extract of ECs and subjected to 
immunoprecipitation (IP) followed by immunoblot (IB). Panels A and B showed 
results of IP using anti-αvβ5 or control IgG and IB with anti-His and anti-β3 antibody. 
Panels C, D, E and F showed results of IP using anti-ISM antibody followed by IB 
with antibodies against integrin αv and β1, β3, β5 and ISM. Only αv and β5 are co-
immunoprecipated by anti-ISM antibody. Panel G showed the results of IP using anti-
αvβ5 or control IgG and IB with anti-his antibody after incubation of His-tagged ISM-
C with membrane protein extract of ECs. Panel H indicated that Integrin αvβ5 
neutralizing antibody partially but significantly blocked the EC attachment to ISM-








4.2 ISM disrupted EC focal adhesions 
Many studies had highlighted the importance of crosstalk between integrin and 
growth factor receptors during angiogenesis (Carmeliet, 2002,Eliceiri, 2001,Somanath, 
et al., 2009). Initiation of EC morphogenesis is largely dependent on the specificity of 
essential signalling mechanisms that are activated through the association between 
growth factors, their receptors, and their specific extracellular matrix ligands. In 
addition to complex formation between growth factor receptors and integrins, growth 
factors also directly interact with integrins (Avraamides, et al., 2008).  
It has been reported that anti-αvβ3 antibodies blocked angiogenesis induced by bFGF 
whereas antibodies that target αvβ5 blocked angiogenesis induced by VEGF 
(Friedlander, et al., 1995), suggesting the two unique pathways of angiogenesis were 
regulated by two distinct αv integrins.  Integrin αvβ3 preferentially mediates bFGF-
stimulated angiogenesis while αvβ5 preferentially mediates VEGF-promoted 
angiogenesis.  
Since ISM selectively interacted with integrin αvβ5, we concentrated on the analysis 
of ISM’s impact on ECs under VEGF stimulation. One critical event in VEGF-
mediated signalling involved the coupling of FAK to αvβ5 integrin to form focal 
adhesions (Eliceiri, et al., 2002). Focal adhesions mediate the communication 
between ECM and cytoskeleton, providing essential roles for cell migration as well as 
EC tube formation. Therefore, inhibiting focal adhesion remodelling/ maturation is 
one of the working mechanisms of angiogenesis inhibitors.  
 
4.2.1 ISM inhibited VEGF-stimulated FAK phosphorylation 
VEGF promotes focal adhesion (FA) maturation by stimulating FAK phosphorylation 
at Tyr397 and Tyr861 sites (Schaller, 2004). Since Tyr397 is the major site for FAK 
phosphorylation, the effect of ISM on Tyr397 phosphorylation level of FAK is 
examined in the presence of VEGF. Cells were incubated with different 
concentrations of ISM in the presence of VEGF for 30 mins. Proteins were then 
extracted from treated cells and subjected to western blotting using anti-Tyr397 FAK 
antibody.  
As shown in Fig. 4.3, control without VEGF had minimal Tyr397 phosphorylation 
level and VEGF increased the level of Tyr397 phosphorylation of FAK. However, 
addition of ISM dose-dependently inhibited VEGF-stimulated FAK phosphorylation. 
β-actin indicated the same loading amount of samples. 
In addition, when 1 μM of ISM was present, the increased phosphorylation level 
stimulated by VEGF was almost suppressed to the basal level. This entire inhibitory 
of FAK phosphorylation is correlated to ISM’s ability in complete inhibition of 
capillary network formation, suggesting that ISM might inhibit tube formation 












































Fig. 4.3 ISM inhibited VEGF-stimulated FAK phosphorylation does-
dependently. A. ISM inhibited VEGF-induced FAK phosphorylation at Tyr397 in 
ECs. B. Quantification of the FAK phosphorylation level.  
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4.2.2 ISM inhibited paxillin relocation into EC focal adhesions 
Activated FAK triggers other focal adhesion-associated proteins to be recruited into 
focal adhesion complexes including paxillin. The VEGF-induced paxillin recruitment 
into focal adhesions is also an indication of the formation and rearrangement of focal 
adhesions to form mature focal adhesions. To check whether ISM could inhibit 
VEGF-stimulated paxillin recruitment to EC focal adhesions, paxillin localization 
after ISM treatment in the presence of VEGF was examined.  
Inhibitory effect of ISM on paxillin relocation to EC membrane was observed (Fig. 
4.4). Consistent with previously reported results (Digman, et al., 2008), paxillin was 
uniformly distributed normally, and freely diffusing as a monomer, as observed in the 
control samples that had no VEGF added. In the presence of VEGF, paxillin clusters 
into complexes and localized to focal adhesions on the plasma membrane, observed as 
“dots” at the periphery of the cells (indicated by white dashed arrow). However, the 
“dots” was reduced for cells treated with the various concentrations of ISM (indicated 
by white arrow and data not shown). This result demonstrates that ISM inhibits the 
recruitment of paxillin to focal adhesion and hence affects the subsequent focal 















 VEGF + 1 µM ISMVEGFControl
Fig. 4.4 ISM inhibited VEGF-stimulated paxillin clustering and recruitment to 
plasma membrane focal adhesions. Paxillin and cell nuclei were stained by green 
and blue respectively. Paxillin clusters were observed as “dots” at the periphery of the 
cells Images shown are representative. White dashed arrows indicate the increased 
paxillin clustering to plasma membrane while white arrows indicate the reduced 








4.2.3 ISM inhibited VEGF-induced actin stress fiber formation 
The cytoskeleton is a critical component in regulating signalling events during EC 
branching, sprouting and lumen formation (Davis, et al., 2002). It is predominantly 
made up of actin stress fibers, which are associated with new actin polymerization 
that interacts with focal adhesion associated-paxillin after focal adhesion maturation 
(Sulochana, et al., 2005). Since both FAK phosphorylation and paxillin recruitment to 
the plasma membrane focal adhesions were affected by ISM, its effect on actin stress 
fibers formation was a necessary factor for investigation.  
As expected, Fig. 4.5 illustrated the inhibitory effect of ISM on VEGF-induced stress 
fiber formation in ECs. Increasing concentrations of ISM reduced the extent of stress 
fiber formation, with the most significant inhibition observed at 1 μM. Stimulation by 
VEGF increased actin polymerization, which gave rise to the appearance of distinct 
stress fiber bundles spanning across the cytoplasm of the cells (indicated by white 
dashed arrows). However, ISM was observed to significantly suppress VEGF-induced 
stress fibers. This suggests that ISM, by inhibiting the formation of actin stress fibers, 
could possibly affect the cytoskeleton to inhibit angiogenesis.  
The above three experiments correlated well with each other to reveal that inhibition 
of EC tube formation on Matrigel by ISM were linked with its ability to influence the 
architecture of endothelial cells by disrupting actin stress fibers and reducing focal 
adhesion, via suppressing VEGF-induced FAK phosphorylation and paxillin 
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Fig. 4.5 ISM inhibited VEGF-induced stress fiber formation. Actin stress fibers 
were visualized with phalloidin (red) and the cell nucleus with DAPI (blue). Increased 
stress fibers bundles were indicated by white dashed arrows while the reduced stress 
fiber formation was indicated by while arrows. Images shown are representative of 







4.3 ISM induced EC apoptosis through Caspase -dependent pathway 
 
4.3.1 Caspase inhibitor abolished the ability of ISM in inducing EC apoptosis  
Our earlier result indicated that ISM induced EC apoptosis in the presence of VEGF 
(Fig. 3.8A). Apoptosis, characteristic of DNA fragmentation, and disruption of 
cellular and DNA repair processes, are initiated by two distinct pathways: one 
involving the activation of a family of cysteine proteases termed ‘Caspases’ and 
another involving the Caspase-independent release of apoptotic inducing factors from 
mitochondria. However, Caspase  activation plays a central role during the excutation 
of apoptosis (Zhang, et al., 2005). It also has been reported that some molecules can 
induce cell apoptosis through both Caspase-dependent and Caspase-independent 
pathways (Lee, et al., 2006). 
To understand which pathway ISM was involved in inducing EC apoptosis, a pan-
Caspase inhibitor z-VAD-fluoromethylketone (fmk) which specifically blocks the 
Caspase activation (Sharifi, et al., 2009) was added together with ISM in the EC 
apoptosis experiments.   
As shown in Fig. 4.6, consistent with the previous results, ISM at 1 μM potently 
induced EC apoptosis when z-VAD-fmk was not present. However, after adding 
working concentration 50 μM of z-VAD-fmk together with 1 μM ISM, the induction 
of EC apoptosis by ISM was abolished by 90%. This result suggests that ISM induces 




4.3.2 ISM promoted EC Caspase 3 activation 
Caspase s are cysteine proteases that synthesized in the cell as inactive precursors, or 
proCaspase s. They are activated by cleavage at aspartic acids by other Caspase s, 
resulting in an amplifying Caspase activation cascade that eventually lead to cell 
apoptosis. Therefore, Caspase s divided into upstream “initiators” that initiate Caspase  
activation cascade, including Caspase  8, 9, 2 or 10; and downstream “effectors” that 
are activated by initiator Caspase s cleave other protein substrate within cells to triger 
apoptotic process, such as Caspase  6, 7, or 3 (Stefanis, 2005). Although pan-Caspase 
inhibitor can resuce ISM-induced cell apoptosis (Fig. 4.6), activation of the most 
downstream “effector” Caspase 3 was investigated to further confirm that ISM 
induced EC apoptosis via Caspase -dependent pathway.  
As shown in Fig. 4.7, the level of active form of Caspase 3 (p17 subunit) was lower in 
VEGF than control (the basal level), indicating that VEGF prevented EC apoptosis by 
inhibiting Caspase 3 activation. When ISM was present, the level of activated Caspase 
3 was increased gradually even in the presence of VEGF, demonstrating that ISM 
promoted Caspase 3 activation in a dose-dependent manner. This result confirmed 
that ISM induced EC apoptosis in the presence of VEGF through the Caspase-
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Fig. 4.6 ISM induced EC apoptosis in the presence of VEGF through Caspase -
dependent pathway. ISM at 1 μM significantly induced EC apoptosis when z-VAD-
fmk was absent. When 50μM z-VAD-fmk was added with ISM together, it abolished 
the ISM induced- EC apoptosis.  
               
               A 
12 kDa
43 kDa
Active caspase 3 
(p17 subunit)
β- actin
Control VEGF 100 nM 500 nM 1μM 
+ VEGF +ISM
 


























Fig. 4.7 ISM promoted activation of Caspase 3 in the presence of VEGF in a dose 
dependent manner. A. Active form of Caspase 3 (p17 subunit) was detected by 
western blot. The level of activated Caspase 3 was increased dose-dependently in the 





Chapter Five: Results Part III 
 
5. Characterization of the role of ISM in tumor angiogenesis in 
mouse 
 
5.1 ISM expression in human and mouse 
 
5.1.1 Expression analyses of ISM in human tissues and tumors 
To stimulate angiogenesis, tumors upregulate the production of a variety of 
angiogenic stimulating factors, including FGF and VEGF (Kandel, et al., 1991). 
Many malignant tumors, however, also generate inhibitors of angiogenesis, such as 
angiostatin (Gately, et al., 1996,O'Reilly, et al., 1994) and TSP1 (Good, et al., 1990). 
To investigate the relationship between ISM expression and tumor, the expression of 
ISM in several human normal and corresponding tumor tissues were examined by 
Western blot. The anti-ISM antibody used in Western blot was a polyclonal antibody 
that can bind to ISM specifically (Fig. 4.2D and E).  
As shown in Fig. 5.1, one dominant band at the molecular weight of about 55kDa was 
detected, which is consistent with the predicted MW of ISM. These results showed 
that ISM was expressed in all tested adult human tissues and tumors. Although each 
lane was loaded with the same amount of proteins, the varying β-actin indicated that 
the expression level of β-actin is not comparable in human tissues and tumors.  
The comparison of ISM expression were performed between tissues and related 
tumors. ISM was upregulated in the brain, liver, lung and testis tumors when 
compared to corresponding normal tissues. It was more abundant in normal breast and 
stomach tissues as compared with corresponding tumors. Similar ISM levels were 
observed in both normal and tumor of colon tissues. These results suggested that the 






























Fig. 5.1 Expression of ISM in human normal and tumor tissues. Western blot 
detection of ISM protein in different normal (N) and tumor (T) samples extracted 
from adult human tissues. Each lane was loaded with 10 μg of proteins. β-actin is not 





5.1.2 Expression analyses of ISM in mouse tissue 
The tissue expression pattern of Ism in mouse was also analyzed. Total RNA of 
different tissues were extracted from 3 weeks-old mouse and amplified using RT-PCR. 
Semi-quantitative RT-PCR analysis of multiple mouse tissues indicated that Ism was 
expressed in various mouse organs including the spleen, liver, brain, heart, kidney, 
muscle and with the highest expression level in lung. Ism was also expressed at 
relatively high level in the brain while at low level in the spleen, liver, heart, kidney, 
muscle and pancreas (Fig. 5.2A). The housekeeping gene β-actin was used as the 
reference gene for the semi-quantitative RT-PCR and it showed a comparable 
expression level among all mouse tissues analyzed.  
Subsequently, real-time RT-PCR quantification analysis further confirmed the high 
expression level of Ism in lung and brain (Fig. 5.2B). As shown in Fig. 5.2C, the 
threshold cycle number C(T) for lung and brain were much lower than that of other 
tissues, indicating more starting copies of Ism mRNA while β-actin expression was 
similar among these tissues. The copy number of β-actin mRNA was more abundant 
than that of Ism as suggested by the low C(T). Nevertheless, combination analysis of 
the semi-quantitative RT-PCR and real-time RT-PCR results confirmed the high 
expression of Ism in lung and brain of mice compared to other tissues in 3-week old 
mice. 
Comparing Ism expression in mouse and human, some similarities were observed. 
ISM was expressed in a variety of tissues in both human and mouse, including lung, 
brain, and liver (Fig. 5.1 and 5.2). Moreover, the mouse tissues were from 3 weeks-
old fetus while human tissues were from adult, suggesting that ISM expression level 
did not vary in different developmental stages. These results indicated that the tissue 
























































































Fig. 5.2 Tissue expression analyses of ISM mRNA. A. Semi-quantitative RT-PCR 
showed the higher expression of ISM mRNA in lung and brain tissues. B. Real-time 
RT-PCR analyses of ISM in different mouse tissues. Lung had the lowest threshold 
cycle number while muscle and kidney had the highest one. C(T): threshold cycle 
number; Tm: melting temperature. C. Real-time RT-PCR analyses of β-actin in 





5.2 Establishment of stable cell lines overexpressing ISM 
Gain-of-function approach by overexpression is widely used for gene functional 
analysis. Overexpression of gene in tumor cells is an established method to 
investigate gene function in tumor angiogenesis and tumor progression. Various 
endogenous angiogenesis inhibitors, such as TSP1 and TSP2, have been successfully 
identified using this approach (Streit, et al., 1999). To examine the role of ISM in 
tumor angiogenesis, overexpression of ISM in tumor cells was selected to investigate 
ISM function in tumor angiogenesis.  
In order to choose a suitable host to study the effects of ISM overexpression, 
endogenous ISM expression levels were analyzed in several tumor cell lines including 
HepG2 (human Hepatocellular carcinoma cell line), B16 (mouse melanoma cell line), 
MCF7 (Human breast adenocarcinoma cell line) and A549 (Human lung 
adenocarcinoma epithelial cell line). Whole cell lysate were extracted and subjected to 
western blotting using anti-ISM antibody. Human pancreas tissue was also used in 
western blotting for the comparison of ISM expression levels among tumor cell lines 
and tissues.  
The results showed that ISM was expressed at low level for all tumor cells studied, 
compared to the ISM level in pancreas (Fig. 5.3). ISM was undetectable in HepG2, 
B16 and MCF7 cells, indicating that there was minimal or no ISM expression in these 
tumor cells. Compared to ISM expression levels in tumor tissues (Fig. 5.1), ISM is 
expressed at very low level in cultured tumor cells, suggesting that stromal cells but 
not tumor cells might be the main source of ISM in tumors. Alternatively, tumor cells 
may be stimulated to produce high level of ISM in vivo in the tumor environment. 
Although HepG2, B16 and MCF7 are all suitable host due to their low endogenous 
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ISM expression level, we choose to use B16 cells to generate syngeneic mouse tumor 
in C57BL/6 mice, to study the functions of ISM in tumor angiogenesis during tumor 
development.  
In order to obtain the stable mouse ISM-overexpressing B16 cell lines, an expression 
construct named pSecTag2B-ISM was created by subcloning of the mouse ISM 
cDNA into the multiple cloning sites of the mammalian expression vector pSecTag2B 
(Invitrogen, USA). pSecTag2B expression vector was designed for high-level stable 
and transient expression in mammalian hosts. It contains CMV promoter for efficient 
and high-level expression of the protein of interest; Zeocin resistance gene for 
selection of the transfectants; murin Ig κ-chain leader sequence at N-terminal for 
protein secretion; c-myc epitope and polyhistidine-tag at C-terminal for protein 
detection and purification.  
Plasmid pSecTag2B-ISM was transfected into B16 cells by lipid-based transfection. 
Cells that had taken up this plasmid were selected by Zeocin of 400 μg/ml. Multiple 
Zeocin-resistant single colonies were isolated individually. Isolated colonies were 
expanded by subculture and further designated as B16/ISMa, B16/ISMb, B16/ISMc, 
and B16/ISMd. In contrast, vector-transfected B16 colonies were pooled and 
designated as B16/Vec and used as control cells.  
To determine ISM expression, conditioned media from the selected stable cell lines 
were collected and concentrated by centrifugation using centrifugal filter device. ISM 
expression was confirmed with western blotting using anti-his tag antibody. As shown 
in Fig. 5.4A, ISM expressed by stable cell lines could be detected at the molecular 
weight of 68 kDa, which is consistent with the predicted molecular weight of 
recombinant ISM. Two (B16/ISMa and B16/ISMb) out of four stable cell lines were 
ISM-positive. No corresponding signal was detected in B16/Vec cells, indicating the 
specificity and higher expression level of ISM in B16/ISMa and B16/ISMb. The 
expression levels of ISM were also comparable among these stable cell lines.  
To further examine the purity of established stable cell lines, immunostaining of 
B16/ISMa and B16/ISMb cells with anti-c-Myc antibody were performed. Exogenous 
ISM was indicated by red color as the secondary antibody was conjugated with 
Alexafluor 568.  As shown in Fig. 5.4B, nucleus was stained with blue by DAPI. Red 
fluorescence was only observable in B16/ISMa and B16/ISMb cells, indicating that 
B16/ISMa and B16/ISMb but not B16/Vec express exogenous ISM. It is also noted 
that more than 95% of the cells were stained with red fluorescence, demonstrating the 
high purity of B16 stable cell lines that overexpress ISM.  
Taken together, stable transfection of ISM overexpression construct into B16 cells 
resulted in enhanced ISM expression in B16/ISMa and B16/ISMb two stable cell lines 
















Fig. 5.3 Endogenous ISM expression level in various tumor cell lines. ISM was 
expressed at significant lower level in A549 tumor cells compared to pancreas. Under 
the same experimental condition, ISM was not detected in HepG2, B16 and MCF7. 





























Fig. 5.4 Selection of ISM-overexpressing B16 stable cell lines. A. Expression of 
ISM was detected by western blotting using anti-his antibody. ISM was undetectable 
in the conditioned medium by B16/Vec while strong expression of ISM was detected 
in the conditioned medium by B16/ISMa and B16/ISMb but not B16/ISMc and 
B16/ISMd. B. Immunostaing of B16 positive stable cell lines with anti-c-Myc 
antibody. Secondary antibody used was anti-mouse IgG conjugated with Alexa fluor 
568. ISM staining was shown as red fluorescence. Nucleus was stained blue by DAPI. 





5.3 In vitro characteristics of ISM overexpressing B16 cells  
Before inoculating mouse with the transfected stable tumor cell lines that overexpress 
ISM, ISM-overexpressing stable cell lines and the control stable cell line were 
analyzed for cell proliferation and apoptosis in culture. These analyses were done to 
determine if integration of the pSecTag2B-ISM plasmids has altered the 
characteristics of the cells.  
 
5.3.1 Overexpression of ISM did not affect B16 cells proliferation in vitro 
To determine whether cell proliferation is influenced by the transfection process or 
overexpression of ISM, the in vitro growth kinetics of these stable cell lines were 
monitored. B16/Vec, B16/ISMa and B16/ISMb cells were seeded in 6-well plate 
respectively and the cell numbers were counted over 5 consecutive days. In order to 
avoid any possible masking effect caused by undefined components of serum in cell 
culture, the cells were maintained in medium containing 2% FBS. As shown in Fig. 
5.5, there was no significant difference in cellular proliferation of B16 cells between 
control stable cell line and cell lines that overexpress ISM. This result indicated that 
the in vitro growth characteristics of these stable cell lines were not changed by the 
increased expression of ISM or by the transfection process.  
 
5.3.2 Overexpression of ISM did not affect apoptosis of B16 cells in vitro 
The ISM-overexpressing cells appeared indistinguishable in growth rate from vector-
transfected cells (Fig. 5.5). To further exclude the possibility that overexpression of 
ISM was associated with changes in cell viability, apoptosis of cells cultured under 
basal culture conditions were examined using the cell death detection ELISA kit 
measuring DNA fragmentation (Roche, Germany). There was no significant 
difference in apoptosis between ISM-overexpressing and control cells (Fig. 5.6). 
Essentially, there was very little apoptosis of these cells under basal culture condition 
in 2% FBS. 
Taken together, these results suggest that stable transfection of ISM expression 
construct increased the expression of ISM without affecting cell proliferation and 






























Fig. 5.5 Growth kinetics of stable cell lines. In vitro growth rates were not changed 
in ISM-overexpressing B16 stable cell lines (B16/ISMa and B16/ISMb) comparing to 

































5.6 Apoptosis of stable cell lines. Culturing ISM-overexpressing stable cell lines 





5.4 Overexpression of ISM in B16 cells suppressed tumor growth via inhibiting 
tumor angiogenesis  
5.4.1 Tumor growth was reduced in ISM-overexpressing tumors 
To study the roles of ISM in tumor formation and development, 1 million of 
B16/ISMa or B16/ISMb cells were inoculated subcutaneously into the right dorsal 
flank of C57BL mouse. The same number of B16/vec cells was injected into the left 
dorsal flank in the same mouse as control. Subcutaneous tumor became visible around 
5-6 days after tumor cell inoculation and the experiment was terminated about 2 
weeks post tumor cell inoculation before the mice started to die (mouse was observed 
to start dying from 15~16 days after injection of B16 tumor cells). 
Tumor became visible with around 0.5 mm width and 0.5 mm length and tumor 
volume was then measured every two days. As shown in Fig. 5.7 A, a similar tumor 
growth pattern among all tumors was observed during the early growth phase but the 
delayed tumor growth in B16/ISMa or B16/ISM b was observed at all time points after 
the early growth phase. At the end of the experiments (14 days after tumor cell 
inoculation), tumors were harvested and carefully excised and weighed, it was found 
that tumor weight from ISM-overexpressing B16 cells were reduced by 50% 
compared to control (Fig. 5.7B).  
Representative sets of mouse tumors from B16/ISMa and B16/Vec of each individual 
mouse at day 14 were shown in Fig. 5.8. Although the in vitro growth rate of ISM-
overexpressing cells and control cells were identical, in vivo tumor growth were 
significantly reduced in tumors formed from B16/ISMa or B16/ISMb cells. 
Interestingly, overexpression of ISM also led to a reduction of melanin production in 
B16 melanoma cells (Fig. 5.8B). However, further work is required to ascertain if the 
reduction of melanin production is linked to the reduced tumor progression in mice. 
An earlier report (Zhang, et al., 2008) had shown that melanin production is not linked 
to B16 melanoma cell invasiveness in vitro.  
In conclusion, although overexpression of ISM did not influence in vitro tumor cells 
proliferation and apoptosis, it significantly inhibited tumor growth. These results 
suggest that the effects of ISM on tumor growth are indirect. 
 
 















































Fig. 5.7 Overexpression of ISM resulted in reduction of B16 tumor growth in 
mice. A. Tumor growth curve in mice. X axis represents the days after tumor cell 
inoculation. ISM suppressed tumor volume up to 60% at 14 days post inoculation. B. 
Tumor weight at the end of the experiment (14 days post tumor cell inoculation). ISM 
led to tumor weight reduction of more than 50%. Data were presented as mean ± SE. 












Fig. 5.8 Overexpression of ISM inhibited tumor growth in vivo. A. Representative 
tumor-bearing mouse were photographed. Tumor size was reduced in ISM-
overexpressing tumors. B. Each pair of tumor was extracted from the same mouse. 





5.4.2 Microvessel density was reduced in ISM-overexpressing B16 tumors 
Vascularisation is essential to tumor development. The growth of a solid tumor 
beyond the size of 1-2 mm3 will be halted due to the shortage in the supply of oxygen 
and nutrient if there is no angiogenesis (Folkman, 1972). The quantification of 
microvessel density (MVD) is currently the gold standard for neovascularisation 
measurements in solid tumors. The prognostic significance of MVD in tumor 
progression were firstly reported in patients with breast cancer (Weidner, et al., 1991) 
and then MVD has been identified as a powerful prognostic tool in many human 
tumor types (Fox, 1997). Since platelet endothelial cell adhesion molecules (PECAM-
1/CD31) is the most specific and sensitive tumor endothelial marker compared to 
other available antibodies such as CD34 and von Willebrand’s Factor (vWF) (Parums, 
et al., 1990), MVD is usually assessed by immunostaining with antibody to CD31. 
Microvessels in the most active areas of neovascularisation (hot spots) of tumor are 
counted and taken as the MVD of the tumor.  
To investigate whether the decreased tumor growth in B16/ISMa and B16/ISMb was 
attributable to decreased tumor angiogenesis, blood vessel density and morphology of 
tissue sections of various tumors were evaluated. Immunofluorescence staining of 
tumor tissue sections with anti-CD31 antibody revealed a decreased tumor 
vascularization in ISM-overexpressing tumors compared with control tumors (Fig. 
5.9A, tumor vessels in red, indicated by while arrows). The average tumor vascular 
density of each tumor group, which included all lumen and non-lumen CD31+  
structures (cell clusters and spots) was significantly decreased by more than 40% in 
ISM-overexpressing tumors (Fig. 5.9B).  
Two independent ISM-overexpressing cell lines (B16/ISMa and B16/ISMb) showed 
similar and consistent effect in mice (Fig. 5.8 and 5.9), strongly suggests that 
continued presence of high level of ISM in the tumour milieu inhibits tumor 

































Fig. 5.9 B16/ISM tumors show a reduced vascularization compared to controls. 
A. Tumor vessels (indicated by white arrows) were visualized by CD31 staining. 
Representative pictures were shown. Red staining indicates CD31 positive EC while 
blue staining by DAPI indicates cell nucleus. Scale bar presents 50 μM. B. 
Quantification of the degree of microvascularization. Only angiogenesis in hot spot 
areas of a tumor section were selected for vessels analyses. For quantification, the 
average number of vessels per microscopic filed, from three microscopic fields per 
tumor section, three tumor sections per tumor (representing the upper, middle and 
lower portion of the tumor) and four tumors for each experimental group (B16/Vec, 
B16/ISMa or B16/ISMb) were analysed. Data were presented as mean ± SE **: 
P<0.01, n=36.  
154 
 
5.5 Investigating the mechanisms of how ISM inhibited B16 tumor growth and 
angiogenesis 
5.5.1 Tumor cell proliferation was not altered in ISM-overexpressing B16 tumors 
Uncontrolled cellular proliferation is one of the most predominant characteristic of 
tumor growth. To find out whether the decreased growth in ISM-overexpressing 
tumors is a result of reduced tumor cell proliferation, tumor cell proliferation was 
examined by immunostaining with an antibody to the proliferation marker 
proliferating cell nuclear antigen (PCNA) (Kubben, et al., 1994).  
As shown in Fig. 5.10A, PCNA staining in tumor sections was shown in red. 
Consistent with the previous report (Rivero, et al., 2004), the PCNA staining was 
revealed as a granular pattern limited to the cell nucleus. Approximately 70% tumor 
cells were PCNA-positive in both tumors, indicating highly proliferative 
characteristics of B16 tumor. The average number of proliferating cells per 
microscopic field quantified by analysing multiple tumor samples in each tumor 
group showed that there was no significant difference of cell proliferation between 
control and ISM-overexpressing tumors (Fig. 5.10B).  
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Fig. 5.10 There was no significant difference of tumor proliferation between 
control and ISM-overexpressing tumors. A. PCNA immunostaining in tumor 
sections. Red indicated PCNA-positive while blue indicated nucleus. Representative 
pictures were shown. Scale bar represents 50 μM. No significant difference in the 
number of PCNA-positive cells were observed in B16/ISM, B16/ISMa and B16/ISMb 
tumors. B. Quantification of proliferating tumor cells. The average number of vessels 
per microscopic filed, from five microscopic fields per tumor section, three tumor 
sections per tumor (representing the upper, middle and lower portion of the tumor) 
and three tumors for each experimental group (B16/Vec, B16/ISMa or B16/ISMb) 





5.5.2 Tumor cell apoptosis was increased in ISM-overexpressing B16 tumors 
Either up-regulated proliferation or resistance to programmed cell death or both are 
characteristics of tumor development. Since cell proliferation was not changed in 
ISM-overexpressing B16 tumors (Fig. 5.10), it is much likely that the reduced tumor 
growth is resulted from the increased cell apoptosis. This hypothesis is further 
supported by the previous reports that apoptosis rather than proliferation is the 
predominant tumor cell response to anti-angiogenic molecules (O'Reilly, et al., 
1996,Streit, et al., 1999,Volpert, et al., 1998). Terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL), a common used method for detecting DNA 
fragmentation by labeling the terminal end of nucleic acids (Christina, et al., 2006), 
was therefore used to determine  B16 tumor apoptosis.  
As shown in Fig. 5.11A, TUNEL staining results showed a remarkable increase of 
apoptotic tumor cells (green dots) in ISM-overexpressing B16 tumors compared to 
B16/Vec control tumors. Cell nucleus was labelled blue using DAPI staining. The 
average apoptosis index (AI) quantified by assessing the number of positive apoptotic 
cells in 27 microscopic fields (1000 tumor cells serve as one field) in each tumor 
group were shown in Fig. 5.11B. This increased apoptosis of tumor cells may have 
contributed to the delay growth of B16/ISMa and B16/ISMb tumors.  
In conclusion, these results demonstrated that the decreased tumor growth by ISM 
overexpression B16 cells correlated with the increased tumor cell apoptosis but not 
tumor cell proliferation.  
A 
TUNEL TUNEL TUNEL



















Fig. 5.11 Increased apoptotic tumor cells were observed in ISM-overexpressing 
tumors. A. Immunofluorescent TUNEL staining of TUNEL. Green indicated 
apoptotic tumor cell and blue indicated nucleus. There were more apoptotic tumor 
cells in B16/ISMa and B16/ISMb tumors compared to those in B16/Vec tumors. 
Representative images were shown. Scale bar presents 20 μM. B. Quantification of 
apoptosis index. Apoptotic cell per field, three fields per tumor section, three tumor 
sections per tumor and three tumors in each experimental group were counted. Data 
were presented with Mean ± SE. “**”, P<0.01.  
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5.5.3 Infiltration of tumor associated macrophages (TAMs) was reduced in ISM-
overexpressing B16 tumors 
TAMs infiltration into the stromal compartment of malignant tumor plays an 
important role in tumor angiogenesis and tumor progression and hence macrophages 
account for a large percentage of the tumor mass in a number of solid tumours 
(O'Sullivan, et al., 1994). During the development of B16 melanoma, infiltration of 
TAMs is particularly essential as macrophage depletion inhibited melanoma growth 
characterized by scarce vascular structures (Gazzaniga, et al., 2007). To determine 
whether the reduced B16 tumor angiogenesis is due to the decreased TAMs 
infiltration, the amount of macrophages in tumors were assessed. 
Total proteins extracted from tumor were subjected to western blotting using antibody 
that specifically recognises macrophage specific antigen F4/80. The result showed 
lower level of F4/80 protein in B16/ISMa and B16/ISMb that control tumors (Fig. 
5.12), suggesting lower number of macrophages cells and hence reduced TAMs 
infiltration. This finding suggests that modulation of macrophages infiltration is one 
possible mechanism by which ISM may inhibit tumor angiogenesis. Since the TAMs 
is a small population among tumor cell components, flow cytometry or 
immunostaining would be more sensitive than Western blotting to detect the 







Fig. 5.12 TAMs infiltration was decreased in ISM-overexpressing tumors. 
Macrophages cells were detected by western blotting using anti-F4/80 antibody. 
Equal amount of total proteins extracted from tumor were loaded in each lane.  
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 5.5.4 VEGF expression was not affected in tumors that overexpress ISM 
VEGF, an endothelial cell-specific mitogen, has been shown to be overexpressed in 
most tumors and stimulate angiogenesis (Leung, et al., 1989). One of the mechanisms 
of TAMs in inducing tumor angiogenesis is to secrete a range of angiogenic cytokines 
including VEGF and bFGF. To find out whether the reduced macrophages in ISM-
overexpressing tumors is correlated with VEGF expression, western blotting were 
conducted to determine the expression level of VEGF in tumors.  
As shown in Fig. 5.13, there was no significant difference on the expression level of 
major form of VEGF between ISM-overexpressing and control tumors. This result 
excluded the possibility that the observed reduction in tumor size was cause by ISM-
mediated down-regulation of VEGF gene expression, and demonstrated that ISM 
inhibited tumor angiogenesis even in the presence of high tumor cell VEGF 
expression. Furthermore, although less tumor associated macrophages were detected 
in ISM-overexpressing tumors, VEGF expression level had not changed 
correspondingly. This suggested that VEGF mostly likely was not the main cytokine 








Fig. 5.13 Overexpression of ISM did not influence VEGF expression in tumors.  
The western blot analysis of VEGF expression level in control (B16/Vec) and ISM-
overexpressing (B16/ISMa or B16/ISMb) tumors. No significant difference of VEGF 
expression level was detected. Equal amount of total proteins (100 μg) extracted from 





Chapter Six: Results Part IV 
6. Characterization of the role of ISM in embryonic angiogenesis in 
zebrafish 
Angiogenesis occurs not only during the progression of many diseases (e.g. tumor 
angiogenesis), but also during the progression of normal physiological processes (e.g. 
embryonic angiogenesis). To investigate the role of ISM in embryonic angiogenesis, 
transgenic zebrafish Tg (fli1: EGFP) was used. This transgenic zebrafish line is an 
excellent model to study gene function in embryonic angiogenesis due to its genetic 
amenability and GFP expression in vascular endothelium. It is well accepted that the 
sequence and expression pattern of gene is correlated to its function. Therefore, 
analysis of the sequence and expression pattern of ism was conducted first to provide 
fundamental information for investigating ism function. 
 
6.1 Bioinformatic analyses of ISM gene(s) in zebrafish 
6.1.1 Sequence analyses of zebrafish ism, ism2 and LOC100002267 
There are three genes found to be paralogus when blasting ism cDNA sequence 
against the zebrafish genome database: ism1, ism2 and LOC100002267. In zebrafish, 
the cDNA of ism1, ism2 and LOC100002267 encodes a protein of 461, 437 and 460 
amino acids respectively. To examine the possible domains in zebrafish Ism1, Ism2 
and LOC100002267, amino acid sequence of these genes was analyzed using Simple 
Modular Architecture Research Tool (SMART) (http://smart.emblheidelberg.de/) 
program. As shown in Fig. 6.1, zebrafish Ism1, Ism2 shared the same domain 
organization with human ISM. They contain a signal peptide in the N-terminus, TSR 
domain in the center and AMOP in the C-terminus. However, different from Ism and 
Ism2, there was no signal peptide predicted in LOC100002267.  
To identify the similarity in sequences of zebrafish Ism1, Ism2 and LOC100002267, 
the amino acid comparison was conducted by sequence alignment using DANMAN 
software. Zebrafish Ism1 shared amino acid identity of 44% to that of Ism2 and 43% 
to LOC100002267; In contrast, Ism2 shared 59% identity to LOC100002267; 
suggesting that Ism2 and LOC100002267 were more closely related at the amino acid 
level.  
TSR domain and AMOP domain shared significant sequence identity (~90%) among 
Ism1, Ism2 and LOC100002267, indicating that both TSR and AMOP domains were 
highly conserved in zebrafish Ism family (Fig. 6.2). Although N-terminal region in 
ism family members contains around 200 amino acids, no known domain or motifs 
were detected using available protein domain databases. The N-terminal region of 
Ism1, Ism2 and LOC100002267 shared only ~50% amino acid identity.  
Taken together, sequence analyses results indicated that ism2 and LOC100002267 
were more closely related to each other than to ism1. These three genes shared the 








Zebrafish LOC100002267  
Fig. 6.1 Comparison of the domains of zebrafish Ism, Ism2 and LOC100002267 
with human ISM. Domains and signal peptide were predicted by SMART. SP, signal 
peptide; TSR, TSR domain; AMOP, AMOP domain.  
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         hISM    (1) MVRLAAELLLLLGLLLLTLHITVLRG-----------SGAADGPDAAAGNASQAQLQNNL 
        zIsm1    (1) MVRLAAELLLLLGLLLLTLHITVLRS-----------SPLQHGNDTVSLEQDSRVAENNV 
        zIsm2    (1) -MLRARKGLWVLLSVLLAFWIERAIS---------------FPVRHHK------RSRNGV 
zLOC100002267    (1) MLIRSQALRWAVFLTLCALMVKGFPAKRRRANHIKSKSGASLEVRGHGGSKDVKQSLQDI 
                      
         hISM   (50) NVGSDTTSETSFSLSKEAPREHLDHQAAHQPFPRPRFRQETGHPSLQRDFPRSFLLDLPN 
        zIsm1   (50) NADSS----SSVQLGPGDRQTRVAHIPASQPWAQ----SPGTGGSLQRDGPGAFLLDLQN 
        zIsm2   (39) YVENQ-VQNHLADSHPHQRRWLQHHSTGVLPLPEP------------EEESKPFVLDFKN 
zLOC100002267   (61) QGQNQ-LRSELPLPRRHKRRWSRIHSEGVLPKPAP------------EEEEETFILDLKN 
                      
         hISM  (110) FPDLSKADINGQNPNIQVTIEVVDGPD-SEADKDQHPENKPSWSVPSP------D----- 
        zIsm1  (102) FPDLSKADINGQNPNIQVTIEVVDSLEGSEPEKGMRKENKPGWAAPN------------- 
        zIsm2   (86) LPDLANADIGSQNPNIQVTIEVLDDPP-MDVEMDLVKEWSNDWSTSSPSSTVEWLGGKKL 
zLOC100002267  (108) FPDLANADLGSQNPNIQVTIEVVDSPQ-MEIEMDLAKESRNDWSLSSE----EWLGHKKL 
                      
         hISM  (158) -WRAWWQRSLSLAR------ANSGDQDYKYDSTSDDSNFLNPPRGWDHTAPGHRTFETKD 
        zIsm1  (149) -WRNWWQRSSSSSSSSVSTPKGPEEQDYPYESNTEDSNFLKPLGDWERRVKSEAGAGSRT 
        zIsm2  (145) FWPLFWGYTDADSGEDGTGQAEDEEDDYDYDSGEPIPSGLG------------KTDGDWT 
zLOC100002267  (163) FWPLFWEYHDSSQEGPGQGSLEENEEDLIYEGEDSFLSGVGADW-------NSRWKGWDS 
                      
         hISM  (211) QPEYDSTDGEGDWSLWSVCSVTCGNGNQKRTRSCGYACTATESRTCDRPNCPGIEDTFRT 
        zIsm1  (208) QTEYDYIDGEGDWSAWSPCSVSCGNGNQKRTRSCGYACTATESRTCDMPSCPGIEDAFKT 
        zIsm2  (193) HNRYEEKEEE--WSTWSPCSVTCGHGNQTRSRSCGDFCTSTESQSCDLVPCP-------D 
zLOC100002267  (216) TDNYEYEEEE--WSDWSPCSATCGQGNQKRIRSCGYACTATESRTCDLERCP-------D 
                      
         hISM  (271) AATEVSLLAGSEEFNATKLFEVDTDSCERWMSCKSEFLKKYMHKVMNDLPSCPCSYPTEV 
        zIsm1  (268) AATEVSLLAGTEEFNATELFGVDTDSCERWMNCKSEFLKKYMSKVATDLPSCPCFYPTEV 
        zIsm2  (244) DWNSVGHVFPFEMENGTEPYGTDVGSCEKWLNCKSEFLQRYLQQVFTELPNCPCSYPSHV 
zLOC100002267  (267) DIIPVTEPSPHEMANNTELLGTDVDSCEKWLNCKNDFLQKYLHKVLTELPNCPCVYPSEV 
                      
         hISM  (331) AYSTADIFDRIKRKDFRWKDASGPKEKLEIYKPTARYCIRSMLSLESTTLAAQHCCYGDN 
        zIsm1  (328) AYSTADVHDANTKRNFRWKDASGPKEKLEIYKPTARYCIRSMLTLESTTLAAQHCCYDDS 
        zIsm2  (304) SNNIVSLLDVGHERSFQWRDASGPKERLDIYKPSARSCLRSGLSKNGTTLAAQHCCYDDN 
zLOC100002267  (327) VYSAVNVFDRKLQKTYRWRDASGPKERLDIYKPSARFCIRSMLSFDSTTLAAQHCCYDDH 
                      
         hISM  (391) MQLITRGKGAGTPNLISTEFSAELHYKVDVLPWIICKGDWSRYNEARPPNNGQKCTESPS 
        zIsm1  (388) MKLITRGKGAGTPNLISTEFSADLHYKVDILPWIICKGDWSRYNHARPPNNGQKCAENPQ 
        zIsm2  (364) KQLITRGKGAGTPNLISTEFSPELHFKVDVLPWILCKGDWSRFHAVRPPNNGLHCMENPQ 
zLOC100002267  (387) MKLITRGKGAGAPNLISTEFSPELHYKVDVLPWILCKGDWSRFHSVRPPNNGLQCVDNPQ 
                      
         hISM  (451) DEDYIKQFQEAREY 
        zIsm1  (448) DEDYYKQFEEAREF 
        zIsm2  (424) QDIFMNELEEAREY 
zLOC100002267  (447) ENVYMNELEEAREY 
  
Fig. 6.2 Amino acid sequence alignment of the zebrafish Ism with zebrafish Ism2, 
LOC100002267 and human ISM. Identical amino acid residues were highlighted 
either in yellow (identical in all four sequences) or in blue (identical in three or two 
sequences). The signal peptide cleavage site at N-terminus is indicated by arrow. TSR 
domain in the centre is framed by red rectangle and AMOP domain at C-terminus is 
underlined. Dots represented gaps inserted for maximal alignment, and numbers of 





6.1.2 Phylogenetic analyses of zebrafish Ism1, Ism2 and LOC100002267 
Phylogenetics, the comparison of equivalent genes coming from several species for 
reconstructing evolutionary trees, is often used to retrace the origin of a gene and 
distinguish orthologous pairs of genes (Barbazuk, et al., 2000). To understand the 
evolutionary and orthologous gene relationships of Ism1, Ism2 and LOC100002267, 
phylogenetic analyses were performed. Protein sequences of these genes from 
different vertebrate species were analyzed using ClustalW program for phylogenetic 
tree generation. Tail1 genes (distantly related to Ism) from different vertebrate species 
were also included to make pholygenetic analyses more precise.  
As shown in Fig. 6.3, pholygenetic analysis revealed two different groups, which was 
consistent with the previous sequence similarity analysis result (Fig. 6.2). Zebrafish 
Ism2 and LOC100002267 were more closely related to Tail1 in human, mouse and rat 
species while zebrafish Ism1 was more closely related to Ism in fugu, Xenopus, 
chicken, rat, moue and human. Zebrafish Ism1 was most closely related to fugu Ism, 
and the closest non-fish Ism homologoue was Xenopus Ism. These results indicated 
zebrafish Ism1 is the orthology of human ISM.  
Based on our sequence analysis results, we therefore designated ism1 as ism, ism2 as 










Fig. 6.3 Phylogenetic analysis of Ism in vertebrates. Phylogenetic tree were 
generated by amino acid sequence. Genbank accession number: mouse Ism, 
XP_283765; human ISM, XP_097736; rat Ism, XP_001081313; Xenopus Ism, 
AAM13976; zf Ism1, AAW79562; fugu Ism, CAG09521.1; chicken Ism, XP_415036; 
mouse Tail1, XP_138107; human Tail1, CAE47313; rat Tail1, XP_001059035; zf  
Ism2, NP_001018345; zf LOC100002267, XP_001342093.2.  
 
 
6.1.3 Synteny analyses of zebrafish ism, tail1a and tail1b 
Conserved synteny is the phenomenon that two or more genes that are organized on 
the chromosome in one species are also found in similar organization on a 
chromosome in another species. Compared to sequence-based method in determining 
gene orthology, synteny-based approach is an additional predictor with better 
resolution (Barbazuk, et al., 2000). The extensive conserved synteny between human 
and zebrafish genomes can be used in predicting orthologous gene relationships 
(Barbazuk, et al., 2000). To further confirm that ism is the orthology of human ISM, 





In zebrafish, ism and tasp1 located next to each other on chromosome 13 while 
human ISM and TASP1 are located in similar fashion on human chromosome 20 (Fig. 
6.4A), indicating that the region containing ism on zebrafish 13 shared conserved 
synteny with the region containing ISM on human chromosome 20.  This result 
confirms our previous sequence analysis results that zebrafish ism was an orthology of 
human ISM. On the other hand, four other genes (txndc1, trim9, nin, and pygl) from 5’ 
upstream of ism on chromosome 13 were found to have orthologs (NIN, PYGL, 
TRIM9 and TXNDC1) on human chromosome 14, indicating that some chromosomal 
rearrangement and shuffling might have occurred in the vicinity of ism in zebrafish 
chromosome 13 since the teleost-tetrapod divergence. 
Three genes and tail1a were found to be located on chromosome 20 in the following 
sequence from 5’ to 3’: zgc: 63667, zgc: 136808, tail1a and zgc: 175221(Fig. 6.4B). 
However, genes adjacent to human TAIL1 was CRORF133, AHSA1, SPTLC2 and 
none of them were orthologs to the genes adjacent to zebrafish tail1a. This result did 
not support the syntenic relationship between the region containing tail1a on 
zebrafish chromosome 20 and the region containing TAIL on human chromosome 14. 
In contrast, although tail1b and sptlc2 located on zebrafish chromosome 17 had 
orthologs (TAIL1b and SPTLC2) on human chromosome 14 (Fig. 6.4C), the order of 
the genes were inverted, suggesting that the region containing tail1b on zebrafish 17 
might share conserved synteny with the region containing TAIL1b on human 
chromosome 14. 
Therefore, syntenic analyses were consistent with phylogenetic analyses, indicating 
that zebrafish ism was orthologous to human ISM and zebrafish tail1b might be 
orthologous to human TAIL1.  
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Fig. 6.4 Syntenic analysis of zebrafish ism, tail1a and tail1b. A. Orthologues of 
zebrafish and human genes in ism chromosome region was shown in table. Syntenic 
relationship between zebrafish chromosome 13 and human chromosome 14 and 20 
demonstrated the chromosomal rearrangement and shuffling. The gene adjacent to ism 
on chromosome 13 was conserved on chromosome 20 of human. B. Orthologues of 
zebrafish genes in tail1a chromosome region was not found to be adjacent in human 
TAIL1 chromosome region. Syntenic relationship between tail1a and TAIL1 region 
was not indicated. C. The order of the orthologs of zebrafish and human genes in 
tail1b chromosome region was inverted. The orthologs of TAIL1 in human might be 





6.2 Expression analyses of zebrafish ism, tail1a and tail1b 
6.2.1 Temporal and spatial expression analysis 
To better understand the functions of ism, tail1a and tail1b during development, 
temporal expression profile of these genes were investigated. Zebrafish 
embryogenesis lasts for 3 days after fertilization, and the embryos finish hatching and 
enter into the larva stage; therefore, embryos from 0 hpf to 3 dpf stages were studied. 
Time interval for gene expression analysis were selected based on major events taking 
place in terms of gene function as well as cell behaviors (fate, lineage and 
organogenesis). Expression levels of ism, tail1a and tail1b were determined by semi-
quantative RT-PCR. To avoid genomic DNA contamination, gene-specific primers 
were carefully designed so that one half of the primer hybridizes to the 3’end of one 
exon and the other half to the 5’ end of the adjacent exon. -actin was used as the 
internal reference.  
As shown in Fig. 6.5A, ism was detectable at 1-cell and 32-cell stages despite its low 
expression, indicating its maternal expression characteristic. Genes which are 
expressed as maternal transcripts are required for the maintenance of normal rate and 
pattern of early cell divisions. The expression level of ism started increasing at 512-
cell stage when the embryo enters midblastula transition (MHB) and zygotic gene 
transcription is activated.  
The maximum expression level of ism was first detected at shield stage (6 hpf). The 
high expression was maintained from tailbud stage (10 hpf) to 24 hpf, the periods 
where active segmentation and somitogenesis (leading to the formation of skeletal 
muscle, vertebrae, and dermis) and neurogenesis occurred (Stickney, et al., 2000). 
169 
 
Subsequently, the expression level of ism was gradually decreased in pharyngula and 
hatching periods (30 hpf, 48 hpf and 72 hpf).  
Different from ism, tail1a did not show any maternal expression (Fig. 6.5A). The 
expression of tail1a transcripts was not detectable until 24 hpf and the level was 
maintained during 30, 48 and 72 hpf. Tail1b had similar temporal expression pattern 
as tail1a (Fig. 6.5A).   
To evaluate the relative mRNA expression level among ism, tail1a and tail1b, the 
intensity of signal in each lane against β-actin was quantified using Image J 1.42 
software. As shown in Fig. 6.5B, the overall expression level of ism was much higher 
than those of tail1a and tail1b whereas the expression level of tail1a and tail1b were 
similar.  
Therefore, the temporal expression analyses indicated that the expression pattern of 
ism was different from that of tail1a and tail1b.  ism had maternal expression whereas 
neither tail1a nor tail1b had. ism had dynamic expression pattern with the highest 
expression level from shield to segmentation stages, whereas the expression levels of 
tail1a and tail1b was consistently low.  
Next, we investigated the spatial expression of ism during zebrafish embryonic 
development by whole-mount in situ hybridization (WISH). Based on the principle 
that complementary single-stranded nucleic acids can bind to each other, WISH was 
developed by using a digoxigenin (antigen)-labeled complementary RNA strand (as 
probe) to localize a specific RNA sequence in the whole embryo which can be 
detected by immunohistochemistry method.  
170 
 
As shown in Fig. 6.6, ism was expressed in the embryonic shield during shield stage 
(indicated by white arrow), and in the midbrain-hindbrain boundary (MHB) (indicated 
by yellow arrow) as well as the posterior trunk region (indicated by green arrow) 
during the gastrulation stage. Subsequently, its expression was restricted in the MHB, 
notochord (indicated by red arrow) and tailbud regions (indicated by green arrow). At 
22 hpf, high level expression was observed in the notochord and MHB (Fig. 6.6H). 
Cross-sectioning of embryos after WISH showed the typical notochord structure in 
the stained region, further confirmed the notochord expression of ism (Fig. 6.6L). 
Expression in the tail bud declined by 30 hpf (Fig. 6.6I). Notochord expression 
declined at 48 hpf and disappeared by 72 hpf (Fig. 6.6J and K). In contrast, expression 
in the MHB was maintained and persisted in this structure at least until 72 hpf (Fig. 
6.6E to K). By 72 hpf, additional expression domain was observed in the branchial 
arches (indicated by blue arrow).  
Taken together, both temporal and spatial expression analysis results showed that ism 
was expressed dynamically during early embryonic development. Its major expression 
domain includes MHB, posterior trunk region, notochord and tail. The dynamic 
characteristic showing in the spatial expression of ism was consistent with that in the 
temporal expression analyzed by RT-PCR.  
xIsm was reported to be expressed in MHB, notochord and other domains such as  ear 
placode and mesoderm (Pera, et al., 2002), suggesting that ism shared overlapping but 
not identical expression domains with xIsm. Our results in zebrafish indicated the 
conserved expression pattern of ism between zebrafish and Xenopus. 
MHB is an important signalling center in vertebrates and regulates the polarized 
morphological differentiation of the adjacent tectum and cerebellum (Rhinn, et al., 
2001). Notochord is an embryonic midline structure that positioned centrally with 
respect to both the dorsal-ventral and left-right axes and produce secreted factors that 
signal to all surrounding tissues, and therefore is important for specifying ventral fates 
in the central nervous system, controlling aspects of LR asymmetry and the arterial 
versus venous identity of the axial blood vessels , as well as specifying a variety of 
cell types in forming somites (Stemple, 2005). The high level of ism expression in 
notochord and MHB suggests that ism might play a role in neural differentiation, body 




































Fig. 6.5 Temporal expression level of zebrafish ism, tail1a and tail1b in wild-type 
embryos. A. The temporal expression pattern of ism was different from those of 
tail1a or tail1b while tail1a and tail1b had the same temporal expression pattern. -
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Fig. 6.6 Expression pattern of zebrafish ism during embryogenesis detected by 
WISH. Embryos are shown in lateral (A, E, H-I), vegetal (B), dorsal (C, D, F, G) 
view. A-B, shield stage; C-D, tailbud stage; note the apparent expression in the 
posterior trunk region (white arrow). E-G, Embryos at segmentation stage shown 
distinct expression in MHB (yellow arrow) and tailbud (green arrow). H, Embryos at 
22 hpf shown strong expression in MHB, notochord (red arrow) and tailbud. I, 
Embryos at 30 hpf, note the declined expression in notochord and tailbud. J. Embryos 
at 48 hpf shown minimal expression in notochord and no expression detected in 
tailbud. K. Embryos at 72 hpf shown the persisted but declined expression in MHB. 
Note the additional expression in branchial arches (blue arrow). L. Cross-section 





6.2.2 Adult Tissue expression pattern analyses 
The adult zebrafish tissue expression profile of ism, tail1a and tail1b were also 
analyzed. RNA from different tissues of zebrafish was extracted and subjected to 
semi-quantative RT-PCR using gene-specific gene primers.  
Similar to mouse and human ISM (Fig. 5.1 and 5.2), zebrafish ism was expressed in 
various tissues, including brain, eye, spleen, liver, heart, grill and ovary (Fig. 6.7A). 
The expression level of ism among these tissues was comparable (Fig. 6.7B), which 
was slightly different from mouse Ism that had a relatively higher expression in lung 
and brain tissues (Fig. 5.2).   
Human TAIL1 was reported to be expressed in various tissues including pancreas, 
kidney, heart, brain, skeletal muscle and placenta (Rossi, et al., 2004). Consistent to 
human TAIL1, zebrafish tail1b was expressed in brain and heart while tail1a was 
expressed in brain but with minimal level in heart (Fig. 6.7A). tail1a was also 
expressed at similar levels in eye, spleen, grill and ovary (Fig. 6.7B). In addition, 
tail1b expressed higher in grill compared to other tissues in adult zebrafish.  
These results demonstrated that ism, tail1a and tail1b were expressed in various adult 





































Fig. 6.7 Tissue expression pattern of zebrafish ism, tail1a and tail1b. A. ism, tail1a 
and tail1b were expressed in several tissues. β-actin was used as internal control. B. 





6.3 Functional study of ism, tail1a and tail1b in zebrafish embryonic angiogenesis 
Temporal and spatial expression pattern analysis indicated possible diverse roles of 
ism in zebrafish embryonic development. To investigate the role of ism, lose-of-
function experiment was conducted using morpholino modified antisense 
oligonucleotides (MO) since it has been shown to effectively and specifically 
suppress gene expression in zebrafish embryos (Corey, et al., 2001).  
In zebrafish, three members were found in ism family, including ism, tail1a and tail1b. 
To completely understand the function of ism gene family, the role of all three genes 
were studied. In addition, to investigate the functional relationship among these genes, 
double knockdown and triple-knockdown were also conducted. 
 
6.3.1 ism was required for proper embryonic growth, development and survival 
Two types of MOs were used to knockdown ism. One targeted at the ATG start codon 
region to inhibit translation, named as ism ATG MO. Another splicing interference 
MO named ism spl targeted at the junction of the first exon and the first intron leading 
to intron insertion and pre-mature termination of ism translation (Fig. 6.8A). The 
efficacy of ism MO knockdown was first verified before functional analysis.  
Total RNA was extracted from both wild-type embryos and ism spl morphants, and 
subjected to RT-PCR. The efficacy of ism MO knockdown was analyzed using 
primers that were designed to specifically amplify ism splicing-interfered products 
and endogenous ism respectively. As shown in Fig. 6.8B, the endogenous ism mRNA 
was reduced by about 70% in the morphants compared to the wild-type embryos 
when each embryo injected with 0.4 pmol of MO. The splicing interfered product was 
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detected only in morphants. These results indicated that the ism splice MO was 
efficient in suppressing ism mRNA level.  
Embryos injected with ism mismatch control MOs were indistinguishable from wild 
type embryos. In contrast, injection of either ism ATG MO or ism splice MO resulted 
in embryos that were smaller, shorter, and developmentally deformed (Fig. 6.8C). 
Table 6.1 shown the phenotypes of embryos injected with 0.77 pmol ism MO per 
embryo: the prominent abnormalities were presented in 1) severely distorted body LR 
axis (~95% of MOs), 2) no tail or tail with curled shape (~90% of MOs), 3) 
completely missing notochord or notochord with irregular shape (~50% of MOs), 4) 
somite with irregular pattern or reduced number (~40% of MOs). Somite number is a 
reliable indicator of the developmental stage in zebrafish before 24 hpf (Kimmel, et 
al., 1995). Reduced somite number in ism morphants at the same time post 
fertilization indicated growth retardation comparing to control embryos. Other 
phenotypes were also observed in morphants despite low percentage, such as MHB 
with reduced size and ambiguous boundary, decreased heart size and cardiac edema. 
All embryos injected with 0.77 pmol ism MO survived to 48 hpf and ~60% were alive 
at 72 hpf but none beyond 96 hpf.  
To analyze whether ism MO can induce does-dependent phenotypes, quantification 
was done by counting the number of embryos with any of the abnormalities 
mentioned above. As shown in Fig. 6.8D, the percentage of abnormal embryos in ism 
mismatch morphants stayed at the background noise level (similar to wildtype) 
whereas significant dose-dependent effects were shown in ism morphants. It is noted 
that ~80% of embryos showed developmental defects when 0.77 pmol MO was 
injected. In contrast, embryos injected with 0.77 pmol mismatch MOs had no 
significant difference with wild type embryos, excluding the possibility that the 
phenotypes resulted from MO cytotoxicity. Dose-dependent effects by ism ATG MO 
was consistent with ism splice MO, suggesting that both ATG and splice MOs are 
both efficient in knocking down ism expression. 
Taken together, knockdown of ism resulted in embryonic defects in multiple systems, 
such as neuron (MHB), skeleton (somite and notochord), cardiac (heart and edema), 
and blood circulation, and eventually led to embryo lethality. In addition, obvious 
angiogenesis defects were observed in ism morphants which will be described in 
details in the next section. These results indicated the essential role of ism in early 
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Fig. 6.8 ism was required for proper embryonic growth, development and 
survival. A. The scheme of MO designed to target ism. B. Knockdown efficacy 
shown by semi-quantative RT-PCR. Splice MO interfered product was only detected 
in morphants. Endogenous mRNA level of ism was decreased by ~70% in morphants 
compared to wildtype embryos. β-actin was used as internal control. C. Various 
developmental defects observed in ism morphants. Group and individual wildtype 
embryos, mismatch ism morphants and ism morphants were shown. All embryos were 
at 3 dpf. D. Quantification of embryos with abnormal gross morphology in ism 
morphants, ism mismatch morphants and wildtype. N is the total number of ism 
morphants with abnormal gross morphology. 
 
 
Table 6.1 Summary of major phenotypes in embryos injected with 0.77 pmol ism 
ATG MO or ism splice MO 
Phenotypes Percentage
Body axis Distorted and curled shape, reduced length 95%
Tail No tail, curved shape 90%
Notochord Complete missing, degenerating,  irregular shape 50%
somite Irregular patterning, decreased number 40%
MHB Reduced size, ambiguous boundary 20%





6.3.2 Knockdown of ism led to angiogenic defects 
To examine the effects of ism knock-down on blood vessel development, zebrafish Tg 
(fli1: EGFP) embryos that expresses GFP in vascular endothelium were used (Childs, 
et al., 2002). During zebrafish embryogenesis axial vessels including the dorsal aorta 
(DA) and posterior cardinal vein (PCV) are formed via vasculogenesis by 
approximately 24 hpf. A conserved network of secondary intersegmental vessels 
(ISVs) in the trunk then sprout from the DA and PCV through angiogenesis by 
growing dorsally and by 3 dpf, ISVs are connected to the dorsal longitudinal 
anastomotic vessel (DLAV) (Childs, et al., 2002). Another group of vascular complex 
formed via angiogenesis during embryogenesis is the supra-intestinal artery (SIA) and 
the subintestinal veins (SIV), which provides blood supply to the digestive system and 
begin to appear after 3 dpf.  
In both uninjected embryos and ism morphants, DA and PCV (indicated by arrow) 
were patent by 24 hpf, indicative of unperturbed vasculogenesis by ism knockdown 
(Fig. 6.9A). These results demonstrate that ism might not be involved in zebrafish 
vasculogenesis.   
However, as shown in Fig. 6.9B, the development of trunk ISVs was perturbed when 
elongating dorsally to connect to DLAV. Normally, each ISV remains within the 
ventral portion of each somite segment and ISVs develop parallel to each other and 
with regular spacing. However, in ism morphants, some ISVs crossed somite 
boundary to connect to adjacent ISVs (indicated by red arrow), other ISVs extended 
beyond the intersegmental boundary (indicated by yellow arrow). Excessive sprouting 
(indicated by white arrow) and pre-mature termination of the sprout (indicated by blue 
arrow) was also observed during ISVs elongation.  
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Interestingly, the spacing of ISVs in ism morphants appeared most affected dorsally 
where the vessels terminate, as opposed to ventrally where they originate, suggesting 
that ISVs migration and connection rather than sprouting launching were affected in 
ism morphants.  
The formation of SIAs and SIVs (another network of blood vessels formed via 
angiogenesis by 5dpf) were also examined. However, no significant difference was 
observed between wildtype and ism morphants. The different angiogenic effects by 
knocking down ism might be explained by ism spatial expression pattern. ism is 
highly expressed in notochord which is adjacent to ISVs while minimal or no 
expression was observed in the subintestinal complex region (Fig. 6.6). Although ism 
is expressed in brain (Fig. 6.6), there were no obvious defects in head blood vessels 
(data not shown). 
To quantify the effects of ism knockdown on angiogenesis, the number of wildtype 
embryos, embryos injected with ism control MO and ism MO with ISV phenotypes 
were counted. Since ism knockdown led to various embryogenesis defects, to exclude 
the secondary effect on ISV, only ism MOs with minimal discernable difference on 
the gross developmental morphology compared with wildtype were counted. As 
shown in Fig. 6.9C, the percentage of embryos with abnormal ISV was MO dose-
dependent. ISV defects were observed in up to 40% of ism MOs injected with the 
maximum dose at 0.4 pmol per embryo while no angiogenic defects were observed in 
morphants injected with same amount of mismatch MO.  
The lack of effects on DA and PCV formation and the significant patterning defects 
on ISVs development observed in ism morphants indicated that angiogenesis but not 
vasculogenesis was influenced by knockdown of ism. These results suggest a 
physiological role of ism in zebrafish embryonic angiogenesis.   
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Fig. 6.9 ism morphants showed angiogenic defects. A. Knockdown of ism did not 
affect vasculogenesis. Embryos injected with ism MO showed normal DV and PCV. 
B. Representative photographs of ISV at 3 dpf. Embryos injected with 0.4 pmol ism 
MO demonstrated various abnormal ISV phenotypes (indicated by arrows). C. 
Quantification of ISV defects. N indicated the total number of ism morphants with 





6.3.3 Knockdown of tail1a had no obvious effect on gross embryonic morphology 
and vascular development 
To study the role of tail1a in zebrafish embryogenesis, ATG and splice MO were 
designed for tail1a knockdown. ATG MO targeted 5’ sequence around the translation 
start codon to inhibit tail1a translation. Splice MO targeted the junction of the first 
intron and the second extron leading to deletion of the second extron and pre-mature 
termination of tail1a translation (Fig. 6.10A).   
As shown in Fig. 6.10B, when each embryo was injected with 2.3 pmol tail1a splice 
MO, endogenous mRNA level of tail1a was reduced by about 70% and the MO 
knockdown mRNA product was detected specifically in morphants.  
Morphants were carefully examined in the following aspects: the patterning and 
formation of notochord, somite and MHB, size and chamber positioning of heart, 
circulation initiation time, positioning and size of eye and otoliths, morphology of fin 
and tail, and skin pigmentation. There was no obvious abnormal phenotype in 
embryos injected with tail1a MO up to 2.3 pmol/embryo (tail1a mismatch MO and 
tail1a MO at doses above 2.3 pmol/embryo showed toxicity to embryos) (Fig. 6.10C 
and D). Furthermore, neither vasculogenesis nor angiogenesis has any apparent 
defects in tail1a morphants (Fig. 6.11).  
Taken together, these results indicated that the function of tail1a was different from 
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Fig. 6.10 No obvious phenotypes were observed in tail1a morphants. A. The 
scheme of MO designed to target tail1a. B. Knockdown efficacy shown by semi-
quantitative RT-PCR. Almost 70% of transcript level of endogenous tail1a was 
reduced. C. Representative group and individual images showed indiscernible 
difference between 3 dpf wildtype embryos and 3 dpf tail1a morphants. D. 
Quantification of embryos with abnormal gross morphological defects.   
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Fig. 6.11 No obvious morphological defects of ISVs were observed in tail1a 
morphants. A. Knockdown of tail1a did not influence vasculogenesis. DA and PCV 
were indicated by arrows. B. Knockdown of tail1a did not affect ISVs angiogenesis. 
Representative group and individual pictures showed indiscernible difference between 
3 dpf wildtype embryos and 3 dpf tail1a morphants. C. Quantification of embryos 





6.3.4 Knockdown of tail1b had no obvious effect on gross morphology and 
vascular development 
The role of tail1b in the zebrafish embryonic development was evaluated using the 
same MO knockdown method. tail1b splice MO designed was to target the junction of 
the third exon and the second intron leading to deletion of the third extron and frame 
shifting, resulting in none functional Tail1b protein (Fig. 6.12A). The efficacy of MO 
knockdown efficacy analysis showed around 80% reduction of endogenous tail1b 
mRNA after injecting 1.8 pmol MO per embryo ((Fig. 6.12B), indicating the high 
knockdown efficiency. At this MO dose, no obvious developmental retardations were 
observed.  
Similar to tail1a, knockdown of tail1b did not lead to obvious abnormal gross 
morphology (Fig. 6.12C and D). In addition, no abnormal vascular phenotype was 
observed in tail1b morphants (Fig. 6.13). These results demonstrated that knockdown 
of tail1b had no obvious effect on gross morphology and vascular development in 
zebrafish.  
From the above results, it is clear that there are different roles of tail1a, tail1b and ism 
in embryonic development. ism not only is required for proper embryos development 
and survival but also plays a critical role in embryonic angiogenesis. In contrast, 
knockdown of tail1a or tail1b results in neither abnormal gross morphology nor 
vascular development. Although the abnormal gross morphology during zebrafish 
embryonic development was not observed in tail1a or tail1b morphants, whether there 
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Fig. 6.12 No abnormal gross morphology was observed in tail1b morphants. A. 
The scheme of MO designed to target tail1b. B. Knockdown efficacy shown by semi-
quantitative RT-PCR. C. Representative group and individual images showed 
indiscernible difference between 3 dpf wildtype embryos and 3 dpf tail1b morphants. 
D. Quantification of embryos with abnormal gross morphological defects.   
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Fig. 6.13 No abnormal vasculogenesis or angiogenesis was observed in tail1b 
morphants. A. Knockdown of tail1a did not influence vasculogenesis. DA and PCV 
were indicated by arrows. B. Knockdown of tail1a did not affect ISVs angiogenesis. 
Representative group and individual pictures showed indiscernible difference between 
3 dpf wildtype embryos and 3 dpf tail1a morphants. C. Quantification of embryos 





6.3.5 Double knockdown of ism, tail1a or tail1b  
The genomes of most organisms contain multiple genes with similar structure and/or 
overlapping functions. These genes are members of families that have emerged during 
evolution through gene duplication events. After gene duplication, many gene pairs 
will possess overlapping functions (Green, 2004). Therefore, ablation of one gene 
may not result in any abnormal phenotypes due to its functional redundancy. To 
eliminate their possible complementary effect, double knockdown of ism, tail1a or 
tail1b were performed.    
Based on the MO dose used in the previous single knockdown of ism or tail1a 
experiments, different groups of MO doses were examined in the double knockdown 
of ism and tail1a (ism/tail1a), including 0.15/0.23 pmol (ism splice MO was 0.15 
pmol, tail1a splice MO was 0.23 pmol), 0.25/0.77 pmol, 0.4/1.2 pmol and 0.77/2.3 
pmol per embryo. As shown in Fig. 6.14A, in the groups with high doses (0.4/1.2 
pmol and 0.77/2.3 pmol), the mismatch MOs themselves had toxicity to the embryos. 
In contrast, there were no significant gross morphological defects in 0.15/0.23 and 
0.25/0.77 pmol groups as compared to the mismatch morphants. 
The percentage of embryos with angiogenic defects (quantified by division of the 
number of morphants with blood vessels deformities by the total number of 
morphants without gross morphological abnormality) in 0.15/0.23 pmol group (~20%) 
and 0.25/0.77 pmol group (25~30%) were similar to that of embryos injected with 
0.15 pmol (15~20%) and 0.25 pmol (25~30%) ism MO alone (Fig. 6.9C and 6.14B), 
indicating that there was no synergistic effects between ism and tail1a MO. This 
result suggests that ism may have no overlapping functions with tail1a. It was noted 
that although ism MO alone at 0.25 pmol led to significant angiogenic defects in 
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embryos, there was no statistical significance on defective ISVs in the double 
knockdown 0.25/0.77 pmol ism/tail1a group because of the increased percentage of 
embryos with angiogenic defects in the mismatch group. 
Results of double knockdown of ism and tail1b (ism/tail1b) were similar to ism/tail1a. 
The effects of gross morphology and vascular development were similar between 
double knockdown groups (0.15/0.77 and 0.25/0.77 pmol) and single knockdown of 
ism (0.15 and 0.25 pmol) (Fig. 6.8, 6.9 and 6.15), suggesting that there were no 
syngeneic effects between ism and tail1b neither. This result suggests that ism might 
have no overlapping functions with tail1b as well. 
During the double MO knockdown of tail1a and tail1b, as shown in Fig. 6.16, 
maximum dose were 1.15 pmol and 0.58 pmol respectively per embryo since higher 
dose (1.15/1.15) showed toxicity to embryos. However, there were no significant 
abnormalities observed in the embryonic development in 0.76/0.38 and 1.15/0.58 
pmol doses. These results excluded the possibility that the lack of phenotype during 
single tail1a or tail1b knockdown was because of their complementary effect. 
The results that ism had no overlapping functions with tail1a or tail1b are actually 
consistent with the previous results on sequence and expression pattern analyses that 
tail1a and tail1b was more closely related to each other than to ism. Although tail1a 
and tail1b are closely related to each other on their sequence and embryonic temporal 
expression pattern, results from double knockdown of tail1a and tail1b do not seem to 
suggest that they have overlapping function.  
Triple knockdown experiments were also performed. However, no conclusion can be 
drawn as even a very low dose of MOs was toxic to the embryos.  
Theoretically, gene duplication during evolution has three alternative outcomes: 
nonfunctionalization (one copy may become silenced by degenerative mutations), 
neofunctionalization (one copy may acquire a novel, beneficial function) and 
subfunctionalization (both copies may become partially compromised by mutation 
accumulation). However, the fate of most gene duplication appears to be silencing 
rather than preservation (Lynch, et al., 2000). The lack of phenotype after double 
knockdown of tail1a and tail1b suggests that tail1a and tail1b may become silenced 
by degenerative mutations during evolution.  
Nevertheless, we had only analyzed the gross morphology during zebrafish 
development. Whether knockdown of these genes can cause any molecular level or 
cellular level of abnormalities needs further investigation.  
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Fig. 6.14. The effect of double knockdown ism and tail1a in zebrafish embryos. A. 
Double knockdown ism and tail1a did not shown any significant abnormal gross 
morphology. Mismatch MO doses at 0.4/1.2 and 0.77/2.3 pmol per embryo showed 






































































































































































Fig. 6.15. The effect of double knockdown ism and tail1b in zebrafish embryos. A. 
Double knockdown ism and tail1b did not shown any significant abnormal gross 
morphology. Mismatch MO doses at 0.4/1.15 pmol per embryo showed toxicity to 









Fig. 6.16. The effect of double knockdown tail1a and tail1b in zebrafish embryos. 
A. Double knockdown tail1a and tail1b did not shown any significant abnormal gross 
morphology. Mismatch MO doses at 1.5/1.15 pmol per embryo showed toxicity to 







Chapter Seven: Discussion  
Since the pioneering hypothesis of Folkman in 1971 that tumor growth and metastasis 
are angiogenesis dependent (Folkman, 1971), intensive efforts have been undertaken 
to develop therapeutic strategies to inhibit angiogenesis in cancer. To date, there are 
more than 40, 000 scientific papers published on the subject, about a hundred anti-
angiogenic compounds entered into clinical trials, and numerous others in preclinical 
development (Quesada, et al., 2006). However, in spite of the positive results 
obtained in animal experimental models and even complete tumor suppressions in 
preclinical studies, modest or even negative effects emerged from the first generation 
of compounds in clinical trials (Quesada, et al., 2007). Several probable reasons were 
pointed out for this failure, including an oversimplified view of tumor vasculature 
pathophysiology and incomplete insight into the mechanisms of angiogenesis. 
Therefore, the requirement of developing novel and improved anti-angiogenic drugs 
demands a thorough understanding of the genes involved in regulating this process 
and how do they function in vivo.  
Angiogenesis during development and adulthood is likely regulated by a tightly 
controlled balance between endogenous pro-angiogenic and anti-angiogenic factors. 
The physiological status of this balance is of paramount importance as it might 
determine an individual’s predisposition to turn the angiogenic switch on during 
pathological events dependent on angiogenesis. Although extensive knowledge on our 
perceptive of endogenous growth factors (VEGF, bFGF, PDGF, etc) that stimulate 
angiogenesis are known, the activities associated with endogenous inhibitors are 
poorly understood. To understand how systemic angiogenesis balance in the body is 
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regulated by endogenous inhibitors of angiogenesis requires an understanding of how 
many such molecules exist and their role in inhibiting angiogenesis.  
In this study, we revealed a novel endogenous angiogenesis inhibitor ISM that plays a 
role in both physiological and pathological angiogenesis. It inhibits tumor 
angiogenesis in mouse and plays a role in embryonic angiogenesis in zebrafish. In 
addition, partial understandings of the molecular mechanisms of ISM in inhibiting 
angiogenesis were also achieved. It inhibits EC capillary network formation on 
Matrigel through interfering with integrin αvβ5/focal adhesion complex/actin filament 
assembly pathway downstream of VEGF. Structure-functional analysis suggests that 
AMOP but not TSR domain mediates the most anti-angiogenic activities of ISM. Our 
study is expected to shed new light and open novel avenues towards the 
understanding of the regulatory mechanisms of angiogenesis in physiological and 
pathological conditions, and clinically, to provide a novel therapeutic agent for the 
treatment of cancer.  
In the discussion chapter, therefore, I will compare ISM to several known 
angiogenesis inhibitors; analyze the roles of ISM in physiological and pathological 
angiogenesis; discuss the additional physiological roles of ISM besides angiogenesis 
inhibition; explain the possible mechanisms of the inhibitory activity of ISM in 







7.1 The position of ISM in angiogenesis inhibitors known so far 
Most endogenous angiogenesis inhibitors are classified into two major categories: 
gene products such as TSP-1, VEGI and PEDF; and natural proteolytic fragments 
including angiostatin, tumstatin as well as endostatin (Sato, 2006). As a novel 
endogenous inhibitor of angiogenesis firstly identified by us, ISM belongs to gene 
products category. Consistent with most gene angiogenesis inhibitors that their 
expression are not specific in ECs, the expression domains of ISM are shield region, 
notochord, MHB and tailbud but not blood vessels in embryonic zebrafish (Fig. 6.6). 
Although we found that ISM is expressed in various human and mouse tissues (Fig. 
5.1 and 5.2), whether ISM is expressed in blood vessels within these tissues needs 
further investigation. 
TSR domain has been well studied to play important roles in inhibiting angiogenesis 
and is present in several molecules, including TSP-1 and TSP-2 (Tucker, 2004). 
Similar to TSP-1 and TSP-2, ISM is also an endogenous angiogenesis inhibitor that 
contains TSR domain. It has been reported that the region responsible for the anti-
angiogenic properties of TSP-1 are confined to the second and third TSR (Iruela-
Arispe, et al., 1999). However, ISM is different from TSP-1 that TSR of ISM is not 
responsible for ISM’s anti-angiogenic activities (Table 7.1), demonstrating that the 
presence of TSR alone does not render a protein an angiogenic inhibitor. This is 
supported by the evidence that not all TSR family members ( proteins that share TSR 




We have compared ISM to a number of known angiogenesis inhibitors (both gene 
products and natural fragments) in some of the angiogenesis assays, including TSP-1 
(Chen, et al., 2000), PEDF (Dawson, et al., 1999), and angiostatin (O'Reilly, et al., 
1994) as well as endostatin (O'Reilly, et al., 1997). As shown in Table 7.1, ISM 
possesses many characteristics that other known angiogenesis inhibitors display, such 
as inhibition of EC capillary network formation and proliferation, and induction of EC 
apoptosis; it also shows its unique feature that ISM does not influence EC migration.  
The in vivo anti-angiogenic activities of TSP-1, angiostatin as well as endostatin have 
been well documented using several in vivo angiogenesis models, including rat or 
mouse corneal neovascularisation assay, and CAM assay (Lai, et al., 2007,O'Reilly, et 
al., 1997,O'Reilly, et al., 1994). In our work, we examined the inhibitory role of ISM 
in in vivo angiogenesis by implantation of Matrigel in mouse model. It is important to 
confirm the inhibitory role of ISM using other in vivo angiogenesis models. 
Some of the angiogenesis inhibitors have been shown to potently inhibit tumor growth 
by systemic delivery in mouse model such as angiostatin and endostatin (O'Reilly, et 
al., 1997,O'Reilly, et al., 1994), which is an easily adaptable method for anti-cancer 
drug development. The effects of many angiogenesis inhibitors (e.g.TSP-1 and TSP-2) 
in tumor development were investigated by gene delivery methods, such as 
overexpression of the gene of interest (Streit, et al., 1999,Streit, et al., 1999). Gene 
delivery methods are very effective to determine the efficacy of the protein because 
the tumor milieu will contain the highest amount of protein in a continuous fashion. 
However, it is not easily adaptable for further anti-cancer drug development. 
Although the anti-tumor function of ISM has been identified by overexpression of 
ISM in B16 tumor cells, it remains to be further analyzed whether ISM can be 
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developed as an anticancer drug. This would need to be determined by testing the 
effects of systemic administration of ISM (e.g. intraperitoneal or subcutaneous 
injection) to tumor-bearing mice.  
The mechanisms of action of some potent angiogenesis inhibitors have been well 
studied for the past decades. For example, studies have reported that endostatin blocks 
VEGF-mediated signaling via direct interaction with the VEGFR-2/KDR/Flk-1 
receptor tyrosine kinase in HUVECs (Kim, et al., 2002). It also interacts with α5β1 
integrin and inhibits the migration of ECs by blocking pathways via Ras and Raf and 
further downstream via ERK1 or p38 (Sudhakar, et al., 2003). In our study, we found 
that ISM specifically interacts with αvβ5 integrin (Fig. 4.2), and inhibit EC capillary 
network formation via disrupting the formation of focal adhesion as well as actin 
stress fiber (Fig. 4.3, 4.4 and 4.5). However, the more detailed signalling pathways of 
ISM in inhibiting angiogenesis remain to be worked out and are unclear presently.  
In summary, compared to those angiogenesis inhibitors with well-studied functions 
and well-developed mechanisms, ISM is a newly identified endogenous inhibitor of 
angiogenesis with its initial mechanisms of action revealed. The inhibitory role of 
ISM in different angiogenesis models, the anti-tumor role of ISM in tumor 
development using systemic delivery methods, and new insights into the molecular 
mechanisms associated with ISM for inhibition of tumor angiogenesis and growth are 
required to understand the role of ISM in angiogenesis and realize its potential as a 

















ISM  -   -  
ISM-N - -  - - - 
ISM-C  -  - -  
ISM-TSR - - - - - - 
‘-’, no effect; , strong inhibitory effect; , inhibitory effect; , strong stimulatory effect 
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7.2 The role of ISM in physiological angiogenesis 
Most physiological angiogenesis occurs during embryonic development (Carmeliet, 
2005). By live imaging of transgenic zebrafish embryos, Hogan and Lawson have 
shown that the ISVs in the trunk indeed form via angiogenesis that takes place in two 
stages:  primary sprouts form out of the DA to give rise to ISVs from ~22 hpf and 
secondary sprouts form from the PCV to give rise to intersegmental veins and 
lymphatic vascular precursors from ~32 hpf (Hogan, et al., 2009,Lawson, et al., 2002). 
Although another network consisting of SIA and SIV (provides blood supply to the 
digestive system ) was also formed via angiogenesis (Raghunath, et al., 2009), the 
formation of ISVs in zebrafish embryos serves as a paradigm to study physiological 
angiogenesis due to their metameric arrangement and relative anatomical simplicity 
(Blum, et al., 2008). Our study demonstrated that early blood vessel formation 
through vasculogenesis such as DA and axial vein were not affected by ism 
knockdown (Fig. 6.9A). In contrast, knocking down of ism led to various 
abnormalities in ISV formation (Fig. 6.9B and C), suggesting a specific role of ism in 
physiological angiogenesis.  
The universal pattern of angiogenesis in the trunk requires that the launching of each 
sprout and its dorsal growth are precisely oriented and constrained to specific 
pathways. Especially, sprouts do not extend beyond the intersegmental boundaries, 
suggesting that there are strongly repulsive guidance signals (Childs, et al., 2002). 
These guidance cues were disrupted by knocking down ism. In ism morphants, some 
sprouts cross to the adjacent ISV in an irregular fashion; some sprouts even divide 
into two during the elongation toward DLAV (Fig. 6.9B). However, whether the 
aberrant ISVs originate from DA or PCV or both are not clear at this moment. 
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Venous-derived ISVs can be specifically differentiated by staining tie2 using in situ 
hybridization method. Nevertheless, the aberrant path of angiogenesis in ism 
morphants indicates that ism may be involved in vessel patterning in zebrafish 
embryonic angiogenesis.  
Interestingly, the spacing of ISVs in ism morphants appeared most affected dorsally 
rather than ventrally (Fig. 6.9B). It is reported that the ISV sprouting route is different 
at the dorsal and ventral part (Childs, et al., 2002). The ventral portion of ISV runs 
between the somite boundaries but the dorsal portion of ISV courses between the 
somites to the notochord-neural tube interface (Fig. 7.1). Therefore, the pattern of ISV 
growth at the ventral and dorsal portion may be guided by different cues. The 
initiation of the ventrally angiogenic sprout appear to be constrained by somite 
borders, whereas the dorsal part of the migratory path might correlate with different 
guidance generated by the notochord-neural tube interface (Childs, et al., 2002). The 
expression analysis showed that ism was highly expressed in notochord (Fig. 6.6), 
which is located closer to the dorsal portion. This might explain the result that 
knocking down of ism preferentially influences ISVs sprouting at the dorsal but not 
the ventral portion of ISV (Fig. 6.9B). This is further supported by the result that 
knocking down of ism did not affect SIA or SIV as there was no ism expression 
adjacent to subintestin region (data not shown). 
Notochord is known to play an important role in zebrafish development including 
vascular development possibly by secreting various morphogens. Among the signals 
secreted by notochord is the sonic hedgehog (Shh) (Stemple, 2005). Experimental 
work in the mouse indicates that Shh acts as an angiogenic factor, inducing robust 
neovascularisation in hindlimbs damaged by ischemia via upregulation of angiogenic 
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cytokines including VEGF and angiopoietin-1 (Pola, et al., 2001). Since ism is 
expressed at very high level in notochord during the 2nd day of zebrafish 
embryogenesis, it is possible that knocking down of ism interfered with Shh signaling, 
and thus resulted in chaotic ISV angiogenesis.  
Furthermore, signals from the notochord may guide angioblasts in the fashioning of 
the DA (Gansner, et al., 2008). In both floating head (flh) and no tail (ntl) mutants 
that have sever morphological defects in the formation of notochord, DA fails to form 
(Fouquet, et al., 1997). However, knocking down of ism did not appear to affect 
generation of the DA (Fig. 6.9A). Although it has been speculated that a well-formed 
aorta may be the prerequisite for ISV formation (Childs, et al., 2002), it is not clear 
why the ablation of ism expression in notochord did not influence DA. No obvious 
morphological defects of notochord in ism morphants (injected with ism MO below or 
equal 0.4 pmol, the dose where no gross morphological defect of the embryos were 
observed) might explain the lack of phenotype in DA. However, DA was still formed 
even in the ism morphants which had various notochord defects (data not shown). 
Importantly, as a tissue, notochord is most closely related to cartilage and is likely to 
represent a primitive form of cartilage (Stemple, 2005). Cartilage is an avascular 
tissue and known to be an enriched source of endogenous angiogenesis inhibitors 
(Sato, 2006). ChM-I, isolated from cartilage, is a strong angiogenesis inhibitor 
(Yoshioka, et al., 2006). Another example is Troponin, which is present in human 
cartilage, and inhibits angiogenesis specifically (Moses, et al., 1999). The high 
expression pattern of ism in zebrafish notochord is consistent with our conclusion that 
ISM is an endogenous inhibitor of angiogenesis.  
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Normal angiogenesis in the result of a net balance between  stimulatory and inhibitory 
regulators (Carmeliet, 2005). Surprisingly, as an endogenous angiogenesis inhibitor, 
suppression of ism expression did not exhibit excessive blood vessels during 
embryogenesis (Fig. 6.9). Coincidentally, at present, almost none of the known 
angiogenesis inhibitors has been shown to play a role in embryonic angiogenesis 
(Risau, 1998). Mice deficient for TSP-1, ChM-I and plasminogen (of which 
angiostatin is a fragment) display an apparently normal embryonic vasculature 
(Lawler, et al., 1998,Yoshioka, et al., 2006). In contrast, deletion of ChM-I results in 
enhanced angiogenesis in the cardiac valves of aged mice, leading to disease 
associated with valves thickening (Yoshioka, et al., 2006). In the TSP-1 deficient 
mice, increased tumor growth is observed and characterized with elevated vascular 
density (Lawler, et al., 2001). The enhanced angiogenesis in pathological, but not 
physiological conditions indicate that endogenous angiogenesis inhibitors may play a 
role in shaping pathological and postnatal rather than embryonic vascular system 
(Risau, 1998). It is known that adult angiogenesis barely recapitulates embryonic 
angiogenesis due to the significant difference between embryonic vascular 
endothelium and adult vascular endothelium, and pathological but not embryonic 
angiogenesis is accompanied by inflammation (Lee, et al., 1998). Although no 
excessive blood vessels was observed in ism morphants, whether deletion of ISM can 
increase pathological angiogenesis or affect postnatal angiogenesis warrants further 
investigation.  
It is noted that the loss of function analysis was carried out using gene knockdown in 
zebrafish, and therefore the expression of ISM was partially but not completely 
blocked. It is of interest to further confirm the role of ISM in physiological 
angiogenesis using knockout technology in mice. It is noted that neither knocking 
down of tail1a nor taill1b, two other members in ism family, showed significant 
phenotype on vascular morphology (Fig. 6.11 and 6.13), suggesting the different role 
of ism family genes during embryonic angiogenesis in zebrafish.   
In conclusion, although knocking down of ism did not show excessive blood vessels, 
which is consistent with Risau et al’s hypothesis that angiogenesis inhibitors may play 
more important role in pathological than physiological angiogenesis, the deviant path 
of ISVs indicates that ism is involved in the patterning of certain vasculature in 
zebrafish embryos.  
 
 
Fig. 7.1 Model of the construction of a zebrafish ISV. An ISV is composed of three 
types of endothelial cells, distinguished by their morphologies. The dorsal connection 
to the DLAV is a T-shaped cell (blue); the ventral connection to the aorta is an 
inverted “T” (red). The connecting cell (green) courses between the somites ventral to 
the notochord-neural tube interface, and appears not to follow the somite boundary 





7.3 The role of ISM in pathological angiogenesis 
Tumor angiogenesis, a typical pathological angiogenesis, is indispensable for tumor 
progression and metastasis (Kerbel, 2008). To elucidate the biological role of ISM in 
tumor progression, we used mouse melanoma tumor model and identified ISM as a 
potent endogenous inhibitor of tumor growth and angiogenesis.   
ISM overexpression resulted in prominent inhibition of B16 tumor growth (Fig. 5.7 
and 5.8). The effects of ISM on tumor growth are indirect since tumor cell growth 
rates were unchanged in in vitro culturing ISM-overexpressing B16 tumor cells (Fig. 
5.5). These findings are in accordance with previous findings, showing that 
recombinant ISM had no influence on the proliferation and apoptosis of B16 cells in 
vitro (Fig. 3.16A and 3.18A). Together, these data strongly indicate that B16 cell 
growth is not affected by ISM. Although TUNEL analysis demonstrated the increased 
apoptotic tumor cells (Fig. 5.11), tumor cell proliferation in ISM-overexpressing B16 
tumors were indistinguishable from vector transfected control tumors (Fig. 5.10). 
Interestingly, overexpression of TSP-1, endostatin or angiostatin also resulted in 
reduced tumor size without affecting tumor cell proliferation (O'Reilly, et al., 
1996,Streit, et al., 1999,Volpert, et al., 1998), suggesting similar anti-tumor properties 
between ISM and other angiogenesis inhibitors.  
We also provided strong evidence that ISM-induced inhibition of B16 tumor growth 
was mediated by suppression of tumor angiogenesis. In ISM-overexpressing B16 
tumors, there was a dramatic reduction of microvessel density (Fig. 5.9), as measured 
by the average number of CD31-positive tumor vessels in tumor hot spot areas. The 
reduction of vessel densities reflects anti-angiogenic effects of ISM on the formation 
of tumor vasculature, which leads to increased apoptosis of tumor cell.  
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Importantly, the reduced tumor angiogenesis was not caused by ISM-mediated down-
regulation of major tumor angiogenesis stimulator VEGF expression as VEGF was 
maintained at equally levels in ISM overexpressing and control tumors (Fig. 5.13). 
These findings further demonstrate that ISM inhibits tumor angiogenesis even in the 
presence of high tumor cell VEGF expression. They are also in accordance with the 
previous findings that ISM inhibits VEGF-stimulated in vitro and in vivo angiogenesis, 
including inhibition of capillary network formation and EC proliferation as well as 
induction of EC apoptosis (Table 7.1). Recent experimental evidence suggests that 
melanomas also produce additional angiogenic factors such as bFGF (Ugurel, et al., 
2001), and some types of cancers can even acquire the ability to secrete a plethora of 
additional angiogenic factors during tumor progression (Pavlakovic, et al., 2001). 
Whether ISM has the ability to down-regulate other angiogenesis stimulators such as 
bFGF needs to be further clarified.  
ISM was found to be expressed in various human tumors and particularly up-
regulated in brain and liver tumors (Fig. 5.1). Whereas the biological role of 
endogenous inhibitors of angiogenesis in multistage carcinogenesis has remained 
unknown, up-regulation of angiogenesis inhibitors has been proposed to play a 
protective role in controlling tumor growth (Hawighorst, et al., 2001). Interestingly, 
ISM is expressed at very low level in some tumor cell lines but the expression is 
significantly increased in the related tumors (Fig. 5.3 and 5.1). One possible 
explanation is that the main source of ISM in tumors is stromal cells but not tumor 
cells. It is likely that factors produced by tumor cells or invading inflammatory cells 
might induce ISM expression in the tumor stroma. Another possibility is that the 
expression of ISM is up-regulated in activated tumor cells themselves in vivo in the 
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tumor environment, and cellular localization study is helpful to investigate this 
possibility. Together with the decreased tumor growth in ISM-overexpressing B16 
tumors, these findings suggest that ISM might be similar to TSP-2 (Hawighorst, et al., 
2001) acting as a natural antitumor host defense mechanism. Investigation on the 
development of tumors in which endogenous expression of ISM is knockdown or 
knockout may identify the role of ISM in multistage of carcinogenesis.  
However, Roberts and his co-workers reported that expression of TSP-1 inversely 
correlates with malignant progression in melanoma, lung and breast carcinomas 
(Zabrenetzky, et al., 1994). Compared to normal tissues, down-regulation of ISM was 
also detected in several human corresponding tumors, such as breast tumor (Fig. 5.1), 
which leads to a question why the expression of ISM is down-regulated if it is 
supposed to act as a host defense mechanism against tumor development. The varying 
anti-angiogenic microenvironment in different types of tumor might explain why 
there is no uniform expression pattern of ISM in human tissues and tumors. 
Comparison of ISM expression level in normal skin and melanoma is of interest that 
may help understanding the physiological role of ISM as endogenous angiogenesis 
inhibitor in the development of melanoma. Further studies on the correlation between 
human tumor expression of ISM and tumor progression can provide more clues on the 
relevance of ISM to human cancer. Although ISM can be detected in mouse serum 
(data not shown), there is no clinical data for blood ISM levels in cancer patient.  
Whereas overexpression of ISM potently inhibits B16 tumor growth and tumor 
angiogenesis, it remains to be clarified if the inhibitory effect of ISM on tumor 
angiogenesis is also found in the majority of human malignancies. To investigate 
whether ISM has the inhibitory role in other tumor types, similar experimental 
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method can be applied to HepG2 liver tumor and MCF7 breast tumor since ISM 
expression is absent in these tumor cell lines (Fig. 5.3).  
Concomitant tumor resistance refers to the ability of some large primary tumors 
preventing the growth of distant smaller tumors because of a systemic anti-angiogenic 
environment created as a result of higher levels of angiogenesis inhibitors in the 
circulation (Volpert, et al., 1998). It has been reported that many angiogenesis 
inhibitors present in primary tumors are responsible for preventing the growth of 
distant smaller tumors, such as angiostatin, endostatin and TSP-1 (O'Reilly, et al., 
1997,Volpert, et al., 1998). As a novel angiogenesis inhibitor, whether ISM plays the 
same role as such inhibitors for concomitant tumor resistance needs to be examined. 
Whether ISM plays any role in tumor metastasis may be investigated by 
quantification of metastases after removal of primary tumors that overexpress ISM. 
The exact molecular mechanisms of ISM-mediated inhibition of tumor angiogenesis still 
need to be established, whereas our study has identified that ISM inhibited tumor 
angiogenesis through decreasing TAMs infiltration (Fig. 5.12). Since macrophages 
stimulate tumor angiogenesis via releasing various angiogenic growth factors, including 
VEGF, PDGF, IGF-1, bFGF, GM-CSF, IL-1, IL-6, IL-8, and TNF-α (Lewis, et al., 2005), 
it is conceivable that production of other angiogenic growth factors excluding VEGF 
might be affected in ISM-overexpressing tumors. In melanoma, it has been shown that 
MCP-1 expression correlates with macrophages infiltration and tumor vascularity 
(Gazzaniga, et al., 2007), whether the decreased TAM infiltration is resulted from 
reduced level of MCP-1 needs further study. 
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7.4 Possible mechanisms of action of ISM in angiogenesis 
Our findings demonstrated that recombinant ISM inhibited angiogenesis through 
multiple mechanisms, including suppressing growth factors-induced EC capillary 
network formation, EC proliferation as well as induction of EC apoptosis (Table. 7.1). 
Recombinant ISM also inhibited VEGF/bFGF-induced in vivo angiogenesis in 
implanted Matrigel in mice (Fig. 3.19).  
ISM has two recognizable protein domains, a centrally localized TSR and a C-
terminal AMOP. Although TSR has been linked to the anti-angiogenic activity of 
some angiogenesis inhibitors, such as TSP-1 and TSP-2 (Tucker, 2004), structure-
functional studies indicate that TSR domain of ISM has no anti-angiogenic activity 
(Table. 7.1). Previous publications indicate that the anti-angiogenic activity of TSR 
act, at least in part, by binding to CD36 (Dawson, et al., 1997). The experimental EC 
used in our study is HUVEC which has almost no expression of CD36 (McCormick, 
et al., 1997). Therefore, whether TSR domain of ISM does not affect angiogenesis 
because of its limited ability in inhibiting angiogenesis or because of the absence of 
CD36 in HUVECs needs to be further clarified using other types of ECs, including 
human dermal microvascular endothelial cells (HDMECs) which constitutively 
express CD36.  
Inhibition of EC capillary network formation is mainly mediated through the C-
terminal AMOP domain, correlating with the fact that ECs attach and spread to ISM-
coated surface through this domain (Fig. 4.1). Although AMOP domain was 
hypothesized to be involved in cell adhesion based on its presence in MUC4 and other 
adhesion molecules (Ciccarelli, et al., 2002), its function in cell adhesion has not been 
experimentally validated. Our work here provides the first experimental evidence that 
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AMOP domain in ISM functions in mediating EC adhesion to ISM and in inhibition 
of EC capillary network formation (Table. 7.1) 
Interestingly, only full-length ISM induced EC apoptosis while neither ISM-N nor 
ISM-C (AMOP domain) has such activity (Fig. 3.9 and 3.14). On the other hand, both 
ISM-N and ISM-C is able to inhibit VEGF-stimulated EC proliferation although both 
fragments have weaker anti-proliferative activities compared to full-length ISM 
(Table. 7.1). These results suggest that the anti-proliferative and pro-apoptotic activity 
of ISM requires different functional domains with the pro-apoptotic activity requiring 
the context of the full-length ISM protein, possibly via three-dimensional structure.  
However, ISM-C failed to inhibit in vivo angiogenesis in the Matrigel plug assay (Fig. 
3.19). This finding may reflect differences in the stability or protease resistance of 
ISM and ISM-C in vivo, or it may be related with the fact that the lack of pro-
apoptotic activity leads to the failure of ISM-C in inhibiting in vivo angiogenesis. 
Many angiogenesis inhibitors, including TSP-1, PEDF, endostatin and angiostatin 
induced apoptosis in cultured ECs and inhibited angiogenesis in different in vivo 
angiogenesis models; but none of them were able to block in vivo angiogenesis in the 
presence of the broad-spectrum Caspase inhibitor z-VAD-fmk, indicating that this 
apoptotic event is required for them to block neovascularisation in vivo (Volpert, et al., 
2002). These findings are in accordance with our results that ISM-C dose not inhibit 
in vivo angiogenesis might be because it is unable to induce ECs apoptosis. On the 
other hand, lack of the ability of apoptosis induction in ISM-C did not affect its ability 
in inhibiting in vitro EC capillary network formation, which presents the experimental 
evidence that in vivo angiogenesis may require additional mechanisms, such as 
apoptosis induction.  
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In our study, we have showed that EC apoptosis induced by ISM was Caspase -
dependent and Caspase 3 activation was involved (Fig. 4.6 and 4.7). Further studies 
conducted by Dr. Zhang Yong in our laboratory identified that Caspase 8 but not 
Caspase 9 was important in ISM-induced EC apoptosis (data not shown). These 
results indicate that ISM induces EC apoptosis through the extrinsic pathway. 
However, the molecular mechanisms of how ISM influences Caspase activation are 
not clear at the moment. Whether ISM directly stimulates Caspase activation or 
blocks the inhibition of Caspase activation by VEGF needs further studies. ISM’s 
ability to Caspase 8 is a crucial initiator in death cascades originating from the tumor-
necrosis factor (TNF) superfamily receptors, including Fas (Volpert, et al., 2002). 
Whether Fas or FasL is needed in ISM-induced EC apoptosis warrants further 
examination. To confirm that the induced-apoptosis is essential for ISM’s inhibitory 
activity in in vivo angiogenesis, in vivo angiogenesis experiment can be performed in 
the presence of Caspase inhibitor z-VAD-fmk. 
Although integrin αVβ5 has been identified to be a receptor for ISM (Fig. 4.2), it is 
believed that αVβ5 is not the only receptor for ISM as anti-αVβ5 integrin neutralizing 
antibody only partially blocked EC attachment to ISM-coated surface (Fig. 4.2). 
Moreover, according to Dr. Zhang Yong’s results, knocking down integrin αVβ5 did 
not completely abolish interaction between ISM and ECs neither (data not shown), 
suggesting that ISM may have additional cell surface receptors. Identification of other 
receptors that ISM interacts with is important to fully understand the mechanisms of 
the action of ISM in angiogenesis.  
Time course analysis suggests that ISM most likely influences the early stages of in 
vitro capillary network formation. However, ISM does not influence EC migration, 
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attachment and spreading to certain matrix, such as fibronectin, gelatine and diluted 
Matrigel whose major components are laminin and collagen IV (Table. 7.1), which 
occurs during the early stages of tube formation. This is actually consistent with our 
results that ISM selectively interacts with αvβ5 integrin whose ligand is not collagen, 
fibronectin or laminin. Furthermore, the fact that ISM affects neither EC attachment 
to certain matrix molecules nor migration could not exclude the possibility that ISM 
may still influence EC interaction with other matrix molecules that preferentially 
interact with αvβ5 integrin such as vitronectin.  
It therefore seems that the effects of ISM on EC morphogenesis could be important 
for its inhibitory ability in in vitro angiogenesis. This hypothesis is supported by our 
experimental evidence that ISM inhibits VEGF-stimulated FAK phosphorylation, 
paxillin recruitment to focal adhesion complex as well as actin polymerization in ECs 
(Fig. 4.3, 4.4 and 4.5), which leads to disruption of focal adhesion formation and 
stress fiber assembly that are critical for EC morphogenesis (Hamadi, et al., 2005). 
Because signaling pathways of focal adhesion formation are also activated by integrin 
αvβ5 (Alghisi, et al., 2006), it is likely that ISM inhibits FAK phosphorylation and 
paxillin recruitment by interacting with integrin αVβ5 (Fig. 7.2). Only ISM-C but not 
ISM-N or ISM-TSR selectively binds to integrin αVβ5 in a similar fashion as ISM 
(Fig. 4.2 and data not shown). Whether the biological role of ISM-C’s binding to 
integrin αVβ5 is to disrupt the formation of focal adhesion which then results in 
inhibition of in vitro angiogenesis is of interest for further investigation. If yes, it will 
provide evidence that mechanism of the inhibitory ability of ISM and ISM-C in in 
vitro angiogenesis may be, at least partially identical. These results may be able to 
explain why ISM-C but not ISM-N or ISM-TSR has in vitro anti-angiogenic activity. 
It has been reported that integrin αvβ3 preferentially mediates bFGF-stimulated 
angiogenesis while αvβ5 preferentially mediates VEGF-promoted angiogenesis 
(Friedlander, et al., 1995). Although ISM interacts with integrin αvβ5 but not integrin 
αvβ3, ISM is able to inhibit both VEGF and bFGF-induced angiogenesis. This 
suggests the different molecular mechamisms of the actions of ISM in both VEGF 
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Fig. 7.2 Illustration of the anti-angiogenic mechanisms of the action ISM in ECs. 
212 
 
7.5 Other roles of ISM 
All endogenous angiogenesis inhibitors except sVEGFR1, VEGI and vasohibin have 
pleiotropic effects and their expression is not necessarily associated to the regulation 
of angiogenesis (Watanabe, et al., 2004). Given consideration of our experimental 
data on ISM expression and functional characterization, ISM is highly likely to have 
additional physiological functions, apart from angiogenesis inhibition.  
Similar to Xenopus, ISM was found to be highly expressed in MHB where isthmus 
organizer locates in zebrafish. Isthmus organizer is a signalling center regulating 
pattern of the midbrain and hindbrain development (Nakamura, et al., 2005). Fgf8 
secreted from the MHB is required and sufficient to direct the ordered growth and 
regionalization of the midbrain and anterior hindbrain (Nakamura, et al., 2005). Since 
Edgar et al reported that Xenopus ISM belongs to the Fgf-8 synexpression group 
(Pera, et al., 2002), it is expected that ISM is also involved in MHB patterning. 
Although Edgar et al did not detect apparent phenotypic effect after microinjection of 
xIsm mRNA into early Xenopus embryos (Pera, et al., 2002), loss of function analysis 
of ISM demonstrated MHB abnormalities associated with reduced size or ambiguous 
boundary in a small but significant percentage of zebrafish embryos (Table 6.1), 
which indicates the possible role of ISM in zebrafish neuron development.  
Besides abnormalities in neuron and vascular vessels, ism knockdown causes other 
defectives in multiple systems, including skeleton, cardiac and circulation (Table. 6.1). 
However, which phenotype is primary and which is secondary remains unknown. The 
notochord defects (complete missing or irregular shape) are consistent with the high 
expression of ISM in notochord (Table. 6.1), which also indicates the role of ISM in 
notochord formation and differentiation.  
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Our expression analysis indicated that ISM is highly expressed in lung in 3-week-old 
mouse (Fig. 5.2). Interestingly, TSP-1 is expressed at high levels in developing lung 
in mouse as well and studies on TSP-1-deficient mice indicate that TSP-1 is require 
for normal murine pulmonary homeostasis and causes pneumonia when it is absent 
(Lawler, et al., 1998). Whether ISM plays a similar role as TSP-1 in lung 
development warrants further investigation. TSP-1 is specifically localized to the 
columnar epithelium of the forming bronchi (Lawler, et al., 1998); however, cellular 
localization of ISM in mouse lung has not been examined but is important for the 
study of ISM’s function in lung embryogenesis.   
In adult, ISM is expressed in different tissues in human, such as brain, breast, liver, 
lung, stomach and colon (Fig. 5.1). Such universal expression pattern is also detected 
in zebrafish tissues including brain, eye, spleen, liver, heart as well as grill (Fig. 6.7). 
The presence of ISM in a variety of adult tissues suggests that ISM might play a 




7.6 Prospect of ISM as a therapeutic agent in cancer treatment 
Since the adverse effects of anti-angiogenic treatment are a topic of importance, one 
future direction in anti-angiogenic therapy is to identify novel class of therapeutic 
agents that can specifically affect angiogenesis in diseases without affecting quiescent 
vessels that are vital for tissue maintenance. Endogenous angiogenesis inhibitors are 
able to block pathological neovascularisation but have no impact on the established 
ones in healthy organs (Noh, et al., 2003,Volpert, et al., 2002). These proteins provide 
a rich source to design and develop anti-angiogenic drugs with minimal vascular side 
effects. As one of the endogenous inhibitors of angiogenesis, ISM is therefore 
predicted to be a safe alternate anti-angiogenic agent for cancer treatment.  
The ability of ISM in inhibiting multiple growth factors-induced angiogenesis, 
including the most dominant angiogenic factors VEGF and bFGF, provides strong 
evidence that ISM can serve as a prototype for further development of anti-angiogenic 
drugs. Furthemore, it is very important to block multiple targets concurrently to 
inhibit tumor angiogenesis. Clinically proven, targeting VEGF is not sufficient to 
block angiogenesis as emerging evidences show that other angiogenic growth factors 
can be upregulated to replace the role of VEGF in tumor angiogenesis. The inhibitory 
ability of ISM in the presence of board angiogenic growth factors may provide 
beneficial effects when combining ISM with other angiogenesis inhibitors such as 
avastin. 
Similar to TSP-1 and TSP-2, the clinical application of ISM, however, might be 
limited as ISM is speculated to have pleiotropic effects. The other functions of ISM 
may cause side effects on neuron and lung. In addition, recombinant ISM is not as 
potent as other endogenous angiogenesis inhibitors with ED50 at 300 nM in EC 
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proliferation comparing to 0.5 nM and 3 nM in the recombinant form of TSP-1 and 
endostatin (Dawson, et al., 1999).  
Since genetic overexpression appears not be feasible in patients with advanced cancer, 
we generated tumor studies with systemic delivery by intraperitoneal injection that 
can be adopted in human trials. The systemic administration was conducted using 
methods as described before (O'Reilly, et al., 1997). Briefly, mice were injected 
intraperitoneally twice a day with either 10mg/kg/day of recombinant ISM or with 
PBS once tumors grow up to the visible size after inoculation of B16 tumor cells. The 
volume of tumors was measured every two days. The results of this experiment have 
not been conclusive because it was only conducted once with large variations 
observed within both ISM-treated and control groups. The preliminary results 
however showed that there were no significant effects of ISM on tumor growth. 
Further experimentations are required to give a better perspective. The less prominent 
effects of ISM under systemic administration on tumor growth might be explained by 
its low stability of bioactivity in circulation. It is speculated that ISM has been 
degraded by protease before reaching tumor. Monitoring the plasma level of ISM 
after intraperitoneal injection could aid to decipher if ISM entered the blood 
circulation and address the half-life of ISM in vivo. Other tumor types should also be 
tested to investigate ISM’s therapeutic potential because tumors are highly 
heterogeneous and the mechanisms for tumor growth are different in tumors from 
various tissue origins.    
In our work, we had mainly focused on the functional characterization of ISM in 
angiogenesis. The knowledge of ISM’s three-dimensional structure, functional motifs 
and interacting partners are unclear at the moment and is worth pursuing to ascertain 
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the potential of ISM as therapeutic agent in cancer treatment. They are very important 
to the understanding of pharmacological modulation with the purpose of improving 
ISM’s potency and bioactivity stability. Therefore, further studies on the structure and 
molecular mechanisms of ISM are required. In spite of the existing difficulties for the 
development of ISM as an anti-angiogenic drug, it is clear that further studies on ISM 
or its fragments as therapeutic agent in cancer treatment is warranted.  
7.7 Conclusions  
In this work, we report for the first time that ISM is a novel endogenous angiogenesis 
inhibitor that inhibits angiogenesis in vitro and in vivo. It suppresses mouse melanoma 
tumor growth through inhibiting tumor angiogenesis. It also plays a role in 
physiological angiogenesis in zebrafish embryogenesis. 
Recombinant mouse ISM inhibits multiple aspects of angiogenesis in vitro, including 
growth factors-induced EC capillary network formation, proliferation as well as 
induction of apoptosis without affecting EC migration and attachment to matrix. It 
also suppresses angiogenesis in vivo in mouse. Structure-functional study 
demonstrates that the C-terminal domain AMOP plays an important role in the anti-
angiogenic function of ISM, which is the first report of a biological function of the 
hypothetical AMOP domain in proteins. Whereas ISM-N inhibits VEGF-stimulated 
EC proliferation, it does not affect EC capillary network formation. Surprisingly, the 
TSR domain of ISM has no anti-angiogenic activity.  
Mechanism study indicates that ISM inhibits EC tube formation through interfering 
integrin αvβ5/focal adhesion complex/actin skeleton pathway downstream of VEGF. 
ISM disrupts the formation of focal adhesion complex through inhibiting the 
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activation of FAK and its subsequent paxillin recruitment. ISM also induces EC 
apoptosis through Caspase -dependent pathway and promotes Caspase  3 activation.  
The tissue expression study shows that ISM is expressed in various human tissues and 
tumors as well as mouse organs. Overexpression of ISM significantly suppressed B16 
melanoma tumor growth via inhibition of tumor angiogenesis. ISM inhibits tumor 
angiogenesis by inhibiting TAM infiltration without affecting the expression level of 
VEGF in tumors. 
Finally, we analyzed all the genes in zebrafish ism family and designated them as ism, 
tail1a and tail1b mainly based on their gene structure and sequence. Expression 
analysis shows that ism has maternal expression and is expressed continuously by 72 
hpf with dynamic expression pattern. The major expression domains of ism are shield 
region, MHB, posterior trunk, tailbud region and notochord. Different from ism, 
tail1a and tail1b starts to express at 24 hpf and persistently express by 3 dpf with 
similar expression level. Functional study by MO knockdown also reveals distinctive 
role between ism and tail1a as well tail1b. ism is required for the survival and 
development of zebrafish embryos. Furthermore, ism plays an essential role in the 
pattern of ISV formation. However, knocking down of tail1a or tail1b did not result 
in any significant gross morphological phenotypes during zebrafish development. 
Double knockdown of ism and tail1a, ism and tail1b as well as tail1a and tail1b 







7.8 Future perspectives  
Although this work has demonstrated the inhibitory role of ISM in tumor 
angiogenesis in mice as well as its physiological role in zebrafish embryonic 
angiogenesis and identified integrin αvβ5 as its receptor, to establish the foundation 
for further development of ISM as therapeutic agent in cancer treatment, the 
followings need to be investigated:  
 
1. Investigation of the physiological and pathological role of ISM in Ism-/- 
knockout mice model 
Knockout mice are well established model to study gene function in mice. Previously, 
the physiological role of ISM was examined in zebrafish using MO knockdown, it is 
therefore necessary to further characterize the physiological and pathological function 
of ISM in knockout mice.  
Ism knockout mice will be generated using homologous recombination method. 
Phenotypes (especially angiogenic phenotypes) will be examined and compared 
between age-matched wildtype, Ism+/- and Ism-/- mice at different developmental 
stages by histology and CD31 staining, including new born, 4 week-old (puppy) and 8 
week-old (adult) mice. If the knockout mice do not exhibit obvious angiogenesis 
phenotype, wound healing and tumor implantation experiments will be applied to 





2. Characterization of AMOP domain of ISM in tumor angiogenesis 
Our previous results indicated that the AMOP domain of ISM (ISM-C) could inhibit 
in vitro angiogenesis with similar potency as ISM (Fig. 3.10). In addition, ISM-C 
supports ECs adhesion in a similar fashion as ISM and can also interact with integrin 
αvβ5 (Fig. 4.1 and 4.2). These raise possibility that ISM-C might be also sufficient to 
inhibit tumor angiogenesis in mice.  
Characterization of AMOP domain in tumor angiogenesis is of paramount importance 
because 1) the size of ISM is much smaller than ISM and therefore has advantages 
over ISM for future therapeutic applications; 2) AMOP domain is a novel predicted 
domain that may function in cell adhesion due to its exclusive extracellular presence 
(Ciccarelli, et al., 2002). The confirmation of AMOP domain in tumor angiogenesis in 
vivo may indicate the importance of this domain in mediating the functions of other 
proteins that also contain this domain.  
Stable B16 tumor cell lines that overexpress ISM-C can be implanted subcutaneously 
into syngeneic mice to generate mouse tumor model. If overexpression of ISM-C in 
tumor cells could suppress tumor growth similar to ISM, then its potential in 
therapeutic applications will be explored by systemic delivery of ISM-C to tumor-
bearing mice.  
 
3. Determination of the three-dimensional structure of ISM protein 
Determination of the three-dimensional structure of ISM is very important to 
understand its structure-function relationship and develop it for therapeutic 
applications. If AMOP domain of ISM is confirmed to be active in vivo, the structure 
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of this domain will be determined as well using X-Ray crystallography as well as 
Nuclear Magnetic Resonance (NMR). Both E.coli and mammalian produced proteins 
will be used for three-dimensional structure study.  
 
4. Identification of other EC receptors of ISM 
Integrins are known to often act as low-affinity co-receptors for ECM proteins 
(Akimov, et al., 2000,Weigel-Kelley, et al., 2003). Although we have demonstrated 
that ISM can interact with integrin αvβ5 (Fig. 4.2), to fully understand how ISM 
inhibits angiogenesis, it is important to determine if additional EC surface receptors 
for ISM exist.  
One approach is to incubate ISM with ECs membrane extract and proteins interacting 
with His-tagged ISM can be isolated through a pull-down assay. Proteins that bind to 
ISM will then be subjected to SDS-PAGE and protein bands will be analyzed and 
identified by Mass Spectrometry. Identified ISM receptor candidates can be validated 
using co-immunoprecipitation or ELISA experiments. After receptor identification, 
antibody blocking or siRNA approaches will be used to determine the functional 
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